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Abstract 
BMI1 has emerged as a key oncogenic factor in many cancers. BMI1 is best 
characterized as a component of the vertebrate canonical polycomb repression complex 1 
(PRC1). This complex facilitates the mono-ubiquitination of histone H2A and chromatin 
compaction ultimately leading to transcriptional repression of target genes. BMI1 and its 
associated PRC1 proteins negatively regulate transcription of hundreds of genes including key 
tumor suppressor genes. Through these mechanisms BMI1 activity has been linked to 
unregulated cellular proliferation, tumor metastasis and cancer-initiating cell self-renewal. 
Accumulated data suggest that BMI1 may be a potential target for pharmacological intervention. 
Previous work suggested that BMI1 has multiple protein binding partners both within the PRC1 
complex and with non-polycomb proteins, although the molecular details and functional 
significance of these interactions remain poorly characterized. Motivated by the prospects to 
target these protein-protein interactions with small molecule inhibitors, we pursued a multi-
pronged campaign to: 1) characterize BMI1 protein-protein interactions at the molecular level 
and 2) develop novel chemical tools to explore BMI1 function in both normal and cancer 
biology.  
Using a hybrid solution NMR and X-ray crystallography approach, we solved the 3D 
structure of BMI1 in complex with its PRC1 binding partner protein PHC2. In conjunction, we 
performed a detailed biochemical and biophysical characterization of the BMI1 protein-protein 
interaction domain and demonstrated novel mode of self-association of this domain. Mutagenic 
disruption of both BMI1-PHC2 and BMI1-BMI1 interactions blocks cellular proliferation 
demonstrating that multiple protein-protein interactions are critical for BMI1 function. On the 
basis of these findings, we designed two biochemical assays to quantify the BMI1-PHC2 
xvi 
interaction. We employed these assays as a platform for high-throughput screening to discover 
small molecule inhibitors of BMI1. Through this screen, we identified three classes of small 
molecule inhibitors that bind directly to BMI1 to disrupt the BMI1-PHC2 protein-protein 
interaction. Through mechanistic studies by NMR spectroscopy and mass spectrometry we 
determined that these molecules represent three different strategies for BMI1 inhibitor 
development.  
As a complementary approach to inhibit BMI1 we have pursued development of small 
molecule inhibitors of the Ring1B/BMI1 E3 ubiquitin ligase complex. Through extensive 
structural-activity relationship studies a small fragment-like ligand with millimolar affinity was 
optimized to yield a potent and specific inhibitor with low micromolar inhibitory activity in an in 
vitro ubiquitin ligase assay. Through mutagenesis and solution NMR studies, we demonstrated 
that Ring1B/BMI1 inhibitors induce significant protein conformational change and that the 
inhibitor-bound conformation is incompatible with nucleosome binding by Ring1B. In cellular 
experiments, Ring1B/BMI1 inhibitors decrease global levels of ubiquitinated H2A in MCF10A 
cells demonstrating cellular permeability and on-target activity. These molecules represent the 
first direct-binding inhibitors of Ring1B/BMI1 and have a novel mechanism of action through 
inserting into the Ring1B RING domain leading to significant conformational change that 
prevents direct protein-nucleosome interaction. 
Overall, this work contributes to the understanding of BMI1 function through 
characterization of its multiple protein-protein interactions and demonstrates that these 
interactions can be inhibited by small molecules representing novel strategies to target this 
protein for development of new chemical tools or potential therapeutics for cancer.  
  
 
1 
Chapter 1: Introduction 
A. Motivation 
The work in this dissertation is motivated by the goal of attaining a molecular 
understanding of the role of the oncogene BMI1 in cancer. BMI1 (B lymphoma Mo-MLV 
insertion region 1 homolog) has been identified as a critical factor regulating tumor growth and 
aggressiveness in many pathologies. Despite interest in targeting BMI1 for potential 
pharmacological intervention, the molecular mechanisms governing BMI1’s role in normal and 
cancer biology remain elusive. Of particular interest is understanding BMI1 within the context of 
the multi-subunit polycomb repressive complex 1 (PRC1). As a member of this complex, BMI1 
negatively regulates transcription of many genes involved in cell fate. Lacking enzymatic 
activity, BMI1 function is determined by its protein-protein interactions, which are currently 
incompletely characterized. Comprehensive molecular descriptions of these interactions can 
therefore provide opportunities for inhibitor development through targeted disruption of protein-
protein interactions.  
To support these goals, I have focused on developing a structural and biochemical 
understanding of BMI1’s multiple protein-protein interactions to facilitate development of small 
molecules that can serve as chemical tools to explore BMI1 oncogenic function. By applying 
these compounds to modulate BMI1 function in various contexts we expect to be able to design 
new strategies to inhibit this protein in cancer. 
In this chapter I will briefly discuss the mechanisms of BMI1 and polycomb proteins in 
transcriptional silencing and expand on the role of BMI1 in cancer biology. Given the 
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implications of BMI1 as a potential therapeutic target I will also highlight exciting advances in 
drug discovery through small molecule inhibitors of protein-protein interactions.  
B. Transcriptional regulation through chromatin modification 
In eukaryotic cells nuclear DNA is packaged into chromatin fibers through the assembly 
of nucleosomes. Nucleosomes are the repeating unit of chromatin composed of 145-147 base 
pairs of DNA wrapped around a protein octamer of four histone proteins, H2A, H2B, H3 and H4. 
Higher order condensation of nucleosomes into compact particles allows up to six linear feet of 
DNA to be packaged into a single cell.1 While such packaging is an efficient storage mechanism 
for genetic material, access to the underlying DNA is essential for cellular function through gene 
expression and DNA replication. Thus dynamic processes are required to regulate both global 
chromatin organization and the local transcriptional activity of individual genes.  
A key feature of this process is post-translational modification (PTM) of histone proteins. 
These mechanisms have been extensively reviewed2-7 and for brevity I will summarize the 
overall themes. Histone modifying proteins with enzymatic activity catalyze the addition or 
removal of methyl, phospo, acetyl or ubiquitin groups, among others, to histone residues. 
Histone PTMs serve to regulate gene transcription through a number of mechanisms, although a 
consensus understanding of these processes is not yet defined. Modulation of the biochemical 
properties of histone residues through modification alters interactions between histones and 
DNA and between nucleosomes thus changing the local environment of chromatin organization. 
Additionally, histone PTMs can serve as binding sites for effector proteins with “reader” 
domains that bind specifically to modified residues. Through association of these proteins with 
other proteins such as chromatin remodelers or transcription factors the modifications thus serve 
as signals for activated or repressed gene transcription.8 Specific modifications at different 
residues are associated with active or inactive transcription. For example, histone 3 lysine 4 
trimethylation is associated with active transcription whereas histone 3 lysine 27 trimethylation 
is a mark of repressed transcription.1,9 While tempting to interpret these modifications as a 
“code,” the cellular context such as maturity, phase in cell cycle or other epigenetic memory 
mechanisms can further dictate the functional outcome of individual modifications.6,10,11 Recent 
work has defined mechanisms of histone PTM cross talk where the modification of one residue 
predicates or precludes modification of another residue at either a local or distant chromatin 
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domain. Such crosstalk therefore further serves to coordinate transcriptional profiles and 
complicates analysis of individual modifications.6,11,12  
Of particular interest to this work are the polycomb group (PcG) proteins. PcG proteins 
are an evolutionary conserved family of proteins responsible for catalyzing histone modifications 
associated with transcriptional repression. 
C. Polycomb proteins negatively regulate gene transcription  
C.1. Canonical polycomb gene silencing mechanisms 
In the classical understanding of polycomb biology, PcG proteins form two distinct 
multi-subunit complexes with distinct chromatin modifying functions. In mammals, the 
polycomb repressive complex 2 (PRC2) is comprised of EZH2, EED and SUZ1213-16 and the 
polycomb repressive complex 1 (PRC1) is made up by Ring1B, BMI1, PHC2 and CBX7.17,18 
The canonical mammalian polycomb transcriptional repressive mechanism has been reviewed 
extensively.19-25 Briefly, PRC2 is recruited to chromatin where the SET-domain containing 
subunit, EZH2, catalyzes the trimethylation of histone 3 lysine 27 (H3K27me3).13,26 This 
methyllysine is subsequently recognized by a chromo-domain containing subunit of PRC1, 
CBX7,26,27 recruiting the remainder of the complex including the heterodimer of Ring1B/BMI1 
which catalyzes the monoubiquitination of histone H2A at lysine 119 (H2AK119Ub).28,29 The 
canonical polycomb gene silencing mechanism is illustrated in Figure 1.1.  
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Histone ubiquitination is one of the most abundant histone modifications in cells and is 
found on about 10% of endogenous H2A proteins at any given time.30 In mouse embryonic stem 
cells this mark decorates the promoters of over 500 genes31 regulating transcription of genes 
involved in cell fate and development.32  
While the mechanistic function of histone ubiquitination in polycomb gene silencing is 
incompletely characterized it has been demonstrated to be critical in gene regulation in some 
contexts. Cao and co-workers used western blot and gene expression studies to illustrate that 
knockout of Ring1A or BMI1 decreases global H2A ubiquitination levels and that this is 
correlated with increased expression of Hox genes in mouse embryonic fibroblasts.33 In similar 
studies in embryonic stem cells conditional Ring1B knockout abolished global H2A 
ubiquitination which was correlated with de-repression of polycomb target genes such as Gata4 
and HoxA7.34 
 
Figure 1.1. Canonical hierarchical mechanism of polycomb-mediated gene silencing. 
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While H3K27me3, H2AK119Ub and the presence of PcG proteins on chromatin is 
associated with chromatin compaction and repressed transcription, it is still an open question if 
PcG activity is correlative with silent chromatin or an active driver of gene silencing.35 Indeed, 
the Bickmore and Koseki groups identified classes of genes in embryonic stem cells that were 
repressed by even a catalytically inactive PRC1 complex suggesting that histone ubiquitination is 
not required for polycomb silencing mechanisms in all contexts.31,36  
C.2. Non-canonical polycomb gene silencing mechanisms  
Several lines of evidence have emerged challenging the hierarchical mechanism of the 
canonical polycomb pathway. ChIP and fluorescent microscopy studies demonstrated that PRC1 
and PRC2 complexes can occupy distinct genes37-40 and it was observed that PRC1 can be 
recruited to chromatin in the absence of H3K27me3.39,41-43 Recently, it was demonstrated in 
multiple contexts that PRC2 can be recruited to chromatin by non-canonical PRC1 complexes 
through histone ubiquitination.44,45 These results flip the polycomb hierarchy and suggests there 
are intricate regulatory mechanisms involved that remain to be discovered. Finally, in mice and 
cultured hematopoietic stem cells disruption of PRC1 and PRC2 complexes results in different 
phenotypes signifying that different transcriptional networks are regulated by the different 
complexes.46  Together these data suggest that polycomb silencing mechanisms are likely highly 
context-dependent and provide support for the development of chemical tools that can be used to 
interrogate these systems.  
C.3. Architecture of the canonical PRC1 complex 
Initial biochemical characterization of the canonical vertebrate PRC1 complex revealed 
four protein subunits CBX7, Ring1B, PHC2 and BMI1.18 Subsequent structural and biochemical 
studies determined some of the direct protein-protein interactions that coordinate overall PRC1 
organization. In this context the N-terminal RING domains of Ring1B and BMI1 proteins28,29 
heterodimerize to form the E3 ubiquitin ligase core of the complex.  Ring1B binds directly to 
CBX7 via a C-terminal ubiquitin-like domain in Ring1B.47 The CBX7 chromodomain recognizes 
methylated histone lysines contributing to gene targeting for the entire complex.47-49 The PHC2 
subunit has two conserved domains, a homology domain (HD1) and a C-terminal SAM (sterile 
alpha motif) domain. SAM domains can form helical polymers50-52 and it is suggest that PHC2 
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SAM domain polymerization contributes to the clustering of PRC1 complexes associated with 
chromatin condensation and gene silencing.53,54 Prior studies indicated that BMI1 and PHC2 
interact directly and that this interaction is mediated by the BMI1 C-terminus.55,56 The structure 
and biochemical characterization of this interaction is detailed in Chapter 2. The overall domain 
organization of proteins in the canonical PRC1 complex is illustrated in Figure 1.2. 
 
Figure 1.2. Domain organization of proteins in the canonical PRC1 complex. 
Characterized domains for each protein are labeled. Orange lines indicate direct 
protein-protein interactions within the complex that have been structurally characterized prior 
to this work. Known interactions with other factors are also labeled. 
While these subunits represent the best characterized members of the canonical PRC1 
complex, recent reports of variant PRC1 complexes with either different orthologs of the 
canonical PRC1 proteins or with distinct non-polycomb subunits have been identified with non-
conserved functions.42,57,58 In mammals there are multiple orthologs of PRC1 proteins, including 
CBX (CBX 2,4,6,7,8), BMI1/PCGF4 (PCGF 1,2,3,4,5,6), PHC2 (PHC 1,2,3) and Ring proteins 
(Ring1A, Ring1B). Illustrating their distinctive functionalities different CBX orthologs have 
been found to dominate in certain developmental stages and contribute to regulation of distinct 
gene targets. For example, CBX7-containing complexes repress pro-differentiation genes in 
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embryonic stem cells. CBX7 expression decreases with cell differentiation and this is 
complimented by increasing expression of CBX2 and CBX4 which regulate lineage commitment 
genes.43,59 Further, all PCGF orthologs of BMI1 have conserved RING domains and thus 
incorporation of these subunits into PRC1 complexes is believed to be mutually exclusive. These 
PCGF proteins contribute to PRC1 complex heterogeneity through interacting with distinct 
binding partners, although the cellular context and relevance for all complexes have not been 
established.44,60-62 The mechanisms and functions of this heterogeneity is an area of ongoing 
research.  
D. Polycomb function in biology 
D.1. Phenotypes of polycomb deletion suggest complex functional roles 
Polycomb genes were originally identified in Drosophila as regulating body 
segmentation of the insect.63,64 The family name is derived from the “poly-comb” phenotype 
observed when these genes were deleted.63,65,66 The role of PcG proteins in regulation of 
organism development is conserved in vertebrates, as explored with PcG knockout mice.67,68 All 
mice with disrupted PRC1 components have skeletal abnormalities and compromised viability. 
The most extreme phenotype is observed with Ring1B knockout which is embryonic lethal. In 
contrast, Ring1A is less ubiquitously expressed and Ring1A deletion mice which have 
developmental aberrations but survive full term suggesting that although these homologs can 
mechanistically compensate as an E3 ubiquitin ligase, they have different functional roles.69,70 
Phc1 knockout mice display postnatal lethality and have impaired hematopoietic activity in 
conjunction with skeletal and cardiac abnormalities.71-73 Cbx knockout mice also have high 
perinatal mortality, hematopoietic defects and male-to-female sex reversal.74 Similarly to Ring 
protein homologs, Cbx proteins have non-redundant spatial and temporal distributions and do not 
completely compensate for loss of one protein.43  
While loss of Bmi1 is not embryonic lethal, Bmi1 deficient mice are also barely viable 
and surviving animals exhibit severe hematopoietic and immune deficiencies as well as cerebral 
and skeletal deformities.75-79 Through knockout studies BMI1 was identified as an important 
stem cell gene30,80,81 regulating the self-renewal and pluripotency phenotypes of adult 
hematopoietic,77,78,82-84 neuronal79,85 and prostate stem cells.86 While not explored in detail to-
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date, the extreme phenotypes of Bmi1 knockout mice suggest that PCGF homologs do not fully 
compensate for BMI1 function.  Overall, these studies demonstrate a critical link between BMI1 
molecular mechanisms and many important biological processes.  
D.2. Delineating polycomb function through identification of gene targets  
Understanding the gene targets of polycomb proteins is critical to understand their 
function. One approach to target identification is through ChIP analysis of genes modified by 
H2AK119Ub. However, the incomplete characterization of the role of H2A ubiquitination in 
polycomb-mediated gene silencing means that identifying polycomb target genes based on 
analysis of chromatin H2A ubiquitination can lead to both false positives and negatives. First, it 
has been demonstrated that transcriptional repression of some genes is independent of histone 
H2A ubiquitination but dependent on PcG chromatin occupancy, whereas regulation of a 
different group of genes is dependent on histone H2A ubiquitination.31,36 Further, other E3 
ubiquitin ligase enzymes with activity towards H2A have been identified.87,88 Suggesting that not 
all H2A ubiquitination is the result of polycomb activity, complicating target gene identification 
by this method.  
Another approach to identify target genes is through gene expression profiling following 
knockdown of polycomb proteins. However, this analysis can be complicated by epigenetic 
inheritance of chromatin modifications. These mechanisms can contribute to silencing of genes 
through subsequent generations89-91 precluding a complete analysis of the effects of genetic 
inhibition of polycomb proteins. Given these complications evaluation of PRC1 chromatin 
occupancy in addition to histone modification and gene expression change following complex 
disruption may only hint at a description of polycomb target genes. With these caveats in mind, a 
number of recent studies provide insight into the networks and pathways regulated by vertebrate 
polycomb proteins.  
Bracken and coworkers evaluated chromatin occupancy of PRC1, PRC2 and H3K27me3 
through ChIP-on-chip genome wide mapping of from human embryonic fibroblasts.32 This work 
identified 1000s of co-occupied genes of which almost 300 were de-repressed following siRNA 
depletion of BMI1. Through analysis of these occupied genes it is understood that PcG proteins 
regulate many genes involved in cell fate, development and differentiation. For example, 
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members of the Hedgehog, Notch and Retinoic Acid signaling pathways along with some Hox 
genes were identified as target genes.32 The Jaenisch group similarly performed genome-wide 
ChIP-based mapping of PRC1 subunits Ring1B and PHC1 in embryonic stem cells, identifying 
over 1,000 genes with these proteins enriched near the transcription start site.92 Gene ontology 
analysis revealed a bias of occupied genes for factors involved in transcription and 
developmental processes such as organogenesis, neurogenesis, embryonic development and cell 
differentiation. Transcription factors suggested to be regulated by PRC1 include members of the 
Sox, Hox and Fox families which have essential roles in embryonic development and can be 
misregulated in disease.93-95 Finally, Endoh et al examined global H2AK119Ub through ChIP-
on-chip experiments in embryonic stem cells.31 These efforts identified over 500 genes that were 
enriched for this mark and confirmed that many polycomb target genes are regulators of 
transcription or development. Together these data provide mechanistic support for PcG activity 
in regulation of normal organism developmental.  
E. BMI1 is an oncogene implicated in many cancers 
Complimentarily to BMI1’s role in normal biology, many lines of evidence suggest a 
critical role for BMI1 in cancer biology. BMI1 was originally identified as an oncogene 
collaborating with myc in murine lymphomagenesis.  In these models overexpression of Bmi1 
accelerated myc-driven lymphoma96,97 and could induce de novo lymphomas when expressed by 
itself.98 Subsequent investigations into the oncogenic role of BMI1 have established it as an 
important factor in many solid and blood cancers through multiple molecular mechanisms.  
E.1. Clinical implications of BMI1 overexpression  
Many human malignancies have high levels of BMI1 protein. These include solid cancers 
such as colorectal carcinoma,99,100 breast cancer,101,102 prostate cancer,103 head and neck 
cancers,79,104 hepatocellular carcinoma,105-108 non-small cell lung carcinoma109,110 and 
hematopoietic diseases such as lymphoma,111 and acute myeloid leukemia.112 BMI1 has also 
been identified as a prognostic indicator in a number of pathologies. For instance, acute and 
chronic myeloid leukemia patients (AML and CML) with high levels of BMI1 had decreased 
overall survival and decreased disease free survival compared to patients with lower BMI1 
levels.112,113 Similar correlations have been identified for patients with head and neck cancers,114 
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diffuse large B cell lymphoma,115 colorectal cancer, 100,116 lung cancer,110 liver cancer106 and 
tongue cancer.117 Confounding alternative studies have found correlations between low BMI1 
levels and poor patient prognosis in breast cancer118 and glioblastoma.119 These data suggest that 
BMI1 likely is just one oncogenic factor among many that contribute to these various 
pathologies and the dynamic interplay between the factors can dictate patient outcome.  
E.2. Mechanistic insight into BMI1 as an oncogene 
In a concise summary of the biological “hallmarks” of cancer Hanahan and Weinberg 
characterized six cellular capabilities enabling tumor growth and metastatic propagation.120 
These hallmarks include sustained proliferative signaling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis and activating invasion and 
metastasis. Though many mechanistic studies BMI1 has been identified to contribute to a 
number of these hallmarks. A brief summary is presented below and illustrated in Figure 1.3.  
 
 
Figure 1.3. Contributions of BMI1 to the hallmarks of cancer. 
Figure adapted from Hanahan and Weinberg.{Hanahan, 2000 #695} 
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E.2.1. BMI1 contributes to cellular avoidance of growth suppression and cell death 
Early evidence implicating BMI1 as an oncogene was the demonstration that BMI1 
promotes aberrant cellular proliferation through the transcriptional repression of two critical 
tumor suppressor proteins p16 and p14.121 In humans the p16Ink4A and p14Arf genes are encoded 
in the Ink4A/ARF locus through alternate reading frames.122,123 The p16 protein stimulates 
cellular senescence through the retinoblastoma pathway and the p14 protein promotes cellular 
apoptosis through the p53 pathway. Therefore repression of transcription of these genes by BMI1 
and PcG proteins leads to avoidance of normal cellular senescence and apoptosis pathways.  
Many studies have demonstrated the knockdown of BMI1 leads to increased expression of p14 
and p16 in multiple cell lines.78,124-133 
While avoidance of cell cycle arrest and apoptosis mechanisms through the Ink4A/ARF 
pathway is a well-defined mechanism for BMI1 in cancer, there is ample evidence of BMI1 
contributing to cancer by Ink4A/ARF-independent channels. For example, BMI1 induced 
transformation of Ink4A/Arf-/- astrocytes, promoting an extended proliferative capacity.134 In a 
mouse model for glioma, mice injected with Bmi1 wild type Ink4A/Arf-/- cells developed brain 
tumors with rapid morbidity, whereas mice injected with Bmi1-/-; Ink4A/Arf-/- were protected 
from this aggressive disease.134 Similar results have been found in models for pancreatic 
cancer,135 hepatocellular carcinoma,133,136 leukemia,137,138 prostate cancer,139 Ewing sarcoma140 
and breast cancer.141 Together these data support alternative oncogenic mechanisms for BMI1.  
E.2.2. BMI1 contributes to tumor metastasis and aberrant cellular proliferation    
A further mechanism for BMI1 contributing to tumor development and cancer 
progression is through regulation of the epithelial-mesenchymal transition (EMT).101,142-144 EMT 
is a critical pathway promoting cancer metastasis through induction of mesenchymal properties 
such as motility, invasiveness and resistance to apoptosis in epithelial cells.145,146 
Mechanistically, EMT is regulated in vertebrates by the Twist and Snail transcription factors 
which repress expression of E-cadherin, leading to reduction of adherens junctions and increased 
cellular migratory capacity.146 Recent work by Yang and coworkers established that under 
hypoxic conditions TWIST1 overexpression leads to BMI1 upregulation143 which enhances the 
tumor-initiating capacity of head and neck squamous cell carcinoma cells. While not sufficient to 
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reverse EMT on its own, loss of BMI1 in conjunction with loss of TWIST1 led to increased E-
cadherin expression inducing reversion of EMT and decreased migration in vitro indicating that 
BMI1 is a direct molecular driver of these processes. Complementarily, BMI1 was shown to 
suppress transcription of the tumor suppressor PTEN142 leading to activation of the PI3K-AKT 
signaling pathway and stabilization of the other EMT inducer, SNAIL. Other supporting 
evidence includes the demonstration that other factors including ERα and ZEB1 regulate BMI1 
and therefore modulate EMT.144,147 Together these data demonstrate that BMI1 contributes to 
EMT through multiple mechanisms and overall promotes cell migration and tumor metastasis.148 
Inhibition of BMI1 may therefore represent a strategy to repress these mechanisms in aggressive 
pathologies. 
Another cellular mechanism contributing to cancer cell outgrowth and invasion is 
through avoidance of contact inhibition pathways.149,150 Contact inhibition is a cellular property 
which restricts the in vitro growth of cells in confluent conditions.151,152 Mechanistically, contact 
inhibition is regulated in part by the Hippo pathway via phosphorylation and inactivation of the 
downstream effectors YAP and TAZ.153 Aberrant activation of these transcriptional co-activators 
induces expression of proliferation-promoting factors leading to avoidance of contact inhibition. 
Hsu and Lawlor observed that YAP protein, but not transcript, levels were reduced in Ewing 
sarcoma family tumor cells with BMI1 knockdown and this effect was correlated with reduced 
tumorigenic potential.140,154 This data suggest that in this tumor context, BMI1 may contribute to 
irregular cellular proliferation and invasiveness via the Hippo-YAP pathway. The molecular 
mechanisms of this effect are still under investigation, however this work contributes to a 
growing body of evidence supporting Ink4A/ARF-independent mechanisms for BMI1 in cancer 
biology.  
E.2.3. BMI1 protects cells from arrest through stimulating DNA damage repair and 
protection from oxidative stress 
A third way in which BMI1 contributes to aberrant cell proliferation is through activation 
of DNA repair pathways.155,156 Multiple lines of evidence suggest that BMI1 and other PRC1 
components are recruited to DNA double-strand break (DSB) sites where Ring1B/BMI1 
ubiquitinates both histone H2A and phosphorylated H2AX (γH2AX).157-160 This activity serves 
to promote accumulation of other factors in the DSB repair pathway such as BRCA1, RNF168 
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and 53BP1. While the precise timing of BMI1 recruitment in the repair cascade remains an open 
question, knockdown of BMI1 leads to high levels of chromosome breaks158 and cell cycle arrest 
in G2/M.159 Further, loss of BMI1 sensitizes cells to ionizing radiation160,161 and genotoxic 
agents.158,162 Together these data suggest that BMI1 has an important role in genome protection 
allowing cells to avoid DNA-damage induced arrest.163  
BMI1 has also been shown to promote resistance to oxidative stress in a number of cell 
models.156,162 Liu and coworkers demonstrated that hematopoietic stem cell and thymocytes from 
Bmi1-/- mice have increased levels of reactive oxygen species (ROS) which was correlated with 
increased expression of factors related to redox homeostasis.156 Further, mitochondria from 
Bmi1-/- thymocytes had reduced oxygen consumption and oxidative capacity indicating that 
mitochondrial disruption in the absence of BMI1 may be a source of ROS.156 Similar correlations 
between reduced Bmi1 levels and increased ROS were found in embryonic neurons,164  ovarian 
cancer cells162 and hematopoietic cells.158 In these BMI1-depleted cell culture models increased 
ROS levels triggered activation of the DNA damage response leading to caspase cleavage and 
induction of apoptosis.156,162,164   
Together this data supports a complex role for BMI1 in both upstream genome protection 
from oxidative stress and a downstream response to DNA double-strand breaks coordinating 
their repair and avoidance of apoptosis. Further work is required to sort the precise molecular 
mechanisms of BMI1 in these pathways.  
E.2.4. BMI1 enables self-renewal of cancer initiating cells  
The theory of cancer initiating cells (CIC) suggests that there is a subpopulation of tumor 
cells that possess stem-like properties such as self-renewal and pluirpotency.165-167 These cells 
are also associated with EMT168-170 and can sustain tumor growth or establish new tumor 
populations. Given that CICs are generally resistant to chemo and radiation therapies these cell 
populations are therefore implicated in tumor relapse and have been proposed to be an important 
target for novel therapy development.165,171  
BMI1 has been identified as a critical factor regulating cancer initiating cells in a number 
of contexts.30,81,172 This was first revealed in studies by the Sauvageau83,173, Morrison85 and 
Clarke78 groups in models for normal hematopoiesis and leukemogenesis. In these studies fetal 
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liver cells from Bmi1-/- mice had reduced proliferative capacities in vitro and failed to repopulate 
the hematopoietic compartment of recipient mice.78 In contrast, cells derived from Bmi1 wild 
type mice engrafted in irradiated recipient mice,78 demonstrating that BMI1 is critical for normal 
hematopoiesis and the maintenance of hematopoietic stem cells (HSCs). In a murine model for 
acute myeloid leukemia (AML), mice transplanted with fetal liver cells from Bmi1 wild type or -
/- mice transduced with Hoxa9-Meis1 all developed leukemia with a similar latency 
demonstrating that Bmi1 is not essentiall for establishing leukemia in primary recipients.83 
However, subsequent transplantation of Bmi1 -/- bone marrow cells from primary recipients into 
secondary recipients protected mice from AML, suggesting that BMI1 depletion leads to 
progressive loss of leukemia initiating cells (LIC).83 Supporting in vitro evidence demonstrated 
that loss of BMI1 caused LIC cell cycle arrest in G1 phase, differentiation to macrophages, 
increased apoptosis and reduced colony formation in methylcellulose assays.83 Subsequently, 
BMI1 has been implicated in tumorigenesis and the maintenance of CICs in models of prostate 
cancer,86 gliomas,174,175 hepatocellular carcinoma176 and colorectal cancer.177 Mechanistically, 
BMI1 regulation of the Ink4a/Arf gene products p16 and p14,83 some Hox genes and members of 
the Wnt, Hedgehog and Notch32,92 pathways likely contribute to self-renewal and maintenance of 
CICs in a number of contexts.178-181  
The studies outlined above provide detailed mechanistic support for a complicated 
oncogenic role for BMI1 in many tumor types. 
E.3. Genetic inhibition of BMI1 in cancer models supports small molecule inhibitor 
development for this target 
Numerous genetic inhibition studies have demonstrated that many cancer cell types are 
dependent on BMI1 for continued proliferation and tumorigenesis. In a study comparing the 
effect of RNAi BMI1 knockdown in a panel of normal and cancer cells the Tollefsbol group 
established that loss of BMI1 led to acute cell death and growth inhibition of embryonic, breast, 
ovarian and neuroblastoma cancer cell lines.127 In contrast, loss of BMI1 in normal embryonic 
lung and stem cells, mammary epithelial, lung fibroblasts, skeletal muscle cells and brain cortical 
neurons led to only moderate growth inhibition and no significant cell death.127 This suggests 
there may be a therapeutic window to inhibit BMI1 in cancer cells without adverse effects on 
normal cells. 
15 
The anti-proliferative effect of BMI1 knockdown has been further confirmed in culture 
models for many solid and blood cancers. shRNA and siRNA knockdown of BMI1 significantly 
decreased cellular proliferation of gastric carcinoma,182 hepatocellular carcinoma,108,176,183 breast 
cancer140 and colorectal cancer cells.177 Accordingly, BMI1 knockdown significantly reduced 
tumor growth in mouse xenograft models for breast cancer,184,185 liver cancer,108,136,176,183 ovarian 
carcinoma186 and Ewing sarcoma.140 In exciting recent studies, Kreso et al demonstrated that 
reduction of BMI1 transcript levels in colon cancer initiating cells impairs self-renewal and 
significantly reduces tumor formation in mouse xenograft models of human colon cancer.177 
In models for hematological malignancies, loss of BMI1 through RNA knockdown 
reduced colony formation and prevented leukemic transformation by PLZF-RARα,187 and 
decreased multiple myeloma cell proliferation in vitro and tumor formation in vivo.188 Similarly, 
loss of BMI1 prevented leukemic transformation of cells with the oncogenic AML1-ETO 
chimeric transcription factor.189 In a detailed analysis, Rizo and coworkers demonstrated that in 
primary AML CD34+ cells treated with BMI1 RNAi had impaired self-renewal, colony 
formation and long-term growth.82 BMI1 knockdown accordingly increased expression of the 
cell cycle regulator INK4A/ARF genes products.82 The CD34+ cell population has been identified 
as leukemia initiating cells (LIC) in some AMLs190-192 and these results support the previous 
finding that BMI1 knockdown in CD34+ AML cells precluded the formation of AML in 
secondary mouse recipients.83  
Together these studies suggest that inhibiting BMI1 may be a novel therapeutic approach 
in many cancers including through targeting cancer initiating cells. A complicating factor is the 
role of BMI1 in normal processes as observed in the hematopoietic, gastrointestinal and 
neurological abnormalities of BMI1 knockout mice.77,78,82,83 We believe these extreme 
phenotypes may be a result of the total BMI1 knockout approach used in these studies which 
affects both the E3 ligase capacity of the PRC1 complex as well as complex organization. Novel 
approaches are needed to target different functions of BMI1 within the PRC1 complex to 
establish if there is a therapeutic window for therapy development 
It is worth noting that while there are reports in the literature of small molecule inhibitors 
of BMI1 these do not have demonstrated direct binding to BMI1 and likely have other molecular 
targets. The current BMI1 inhibitors either regulate BMI1 transcription through an unknown 
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mechanism177 or inhibit Ring1B/BMI1-mediated H2A ubiquitination likely through covalent 
modification of the E2 enzyme.193,194 This leaves an exciting opportunity for development of 
well-validated small molecule inhibitors of this important oncogene. Given that BMI1 serves as a 
scaffolding protein in the PRC1 complex efforts to develop targeted small molecule inhibitors of 
this protein should therefore focus on the development of inhibitors of its protein-protein 
interactions (PPIs). 
F. Targeting protein-protein interactions with small molecule inhibitors 
Protein-protein interactions are critical for most cellular functions195 and have been 
identified as promising therapeutic targets to treat many pathologies. Developing small molecule 
inhibitors of PPIs has traditionally been regarded as a challenging task, however recent successes 
both in preclinical and clinical studies has increased enthusiasm for these efforts. These topics 
have been reviewed extensively196-204 so here I will briefly describe the molecular features of 
PPIs that present challenges for small molecule inhibition before discussing methods to identify 
such inhibitors and provide examples of exciting PPI inhibitors for chromatin modifying proteins 
with potential therapeutic value.  
F.1. Challenges for small molecule inhibition of protein-protein interactions 
Traditional drug targets are proteins or receptors that have well-defined small molecule 
binding sites such as G-protein coupled receptors, nuclear receptors, ion channels or 
enzymes.205,206 The majority of FDA approved small molecule therapeutics are modulators of 
these proteins via orthosteric or allosteric inhibition of natural ligand binding. Therefore there is 
a bias in experimental methods, small molecule libraries and theoretical understanding to design 
inhibitors of these targets at the exclusion of inhibitors of protein-protein interactions, of which 
there are hundreds of thousands of potential targets.207,208   
A challenging aspect of inhibiting PPIs is the molecular basis of these interfaces. In 
contrast to receptor-ligand or enzyme-cofactor interactions, PPI interfaces generally have large 
contact surfaces, ranging from 1,000-2,000 Å2 of buried surface area.209-211 The topography of 
these interfaces is typically flat, lacking the small molecule binding pockets featured in enzyme 
or receptor ligand binding sites. The affinity of PPIs can be driven by so-called “hot-spot” 
interactions, where binding free energy (ΔG) is concentrated at specific residues.212-214 
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Alternatively, ΔG is dispersed over a larger area or between multiple direct interfaces 
necessitating larger, more complex inhibitor molecules.199 Another feature of some PPI 
interfaces is conformational flexibility and dynamics which allow proteins to attain different 
structures for transient contacts or interactions with many different binding partners.196,199,215  
From an inhibitor-development perspective these features of PPIs have challenged 
traditional drug discovery approaches based on enzymatic turnover. Conversely, creative 
methods have been developed to exploit PPI hot-spots and conformational dynamics yielding 
novel molecules with utility as both chemical tools and clinical candidates.   
F.2. Methods of identifying protein-protein interaction inhibitors 
Identifying inhibitors of PPIs has historically relied on high-throughput screening (HTS) 
using assay platforms systems sensitive to the disruption of the complex.216 In brief, such assays 
include biochemical assays which quantify the PPI through interaction of the minimal interaction 
components,217 “gray-box” assays composed of the reconstituted complete protein complex218 
and cell-based assays monitoring the PPI in the context of the complex cellular environment. 
HTS involves screening large libraries of small molecules.  However, PPI inhibitor identification 
by this method can be challenged by commercial libraries which have been developed for 
traditional pharmacological targets such as GCPRs and enzymes. As such, commercial screening 
libraries can be ill-suited to identify small molecule inhibitors of PPIs which tend to be larger 
and more hydrophobic than enzyme inhibitors and such molecules are underrepresented in 
commercial libraries.199,219,220 While there are many examples of successful applications of HTS 
for PPI drug discovery these platforms can be challenged by protein targets that participate in 
weak or transient interactions or have complicated biochemical assay systems.  
 In these cases, alternative strategies have been developed to identify small molecule 
ligands of interesting protein targets. Such tactics include fragment based screening to identify 
direct-binding ligands based on biophysical methodologies,221-223 ligand-tethering to trap low 
affinity interactions via covalent linkage at a particular protein site224 and in silico screening 
which requires structural information of the PPI interface.225,226 Fragment based screening is 
described in more detail in Chapter 4. Thinking beyond typical small molecules, 
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peptidomimetics, stapled peptides and natural products are promising approaches for developing 
PPI inhibitors. 
F.3. Examples of PPI inhibitors for chromatin modifying proteins  
 Chromatin modifying proteins are very attractive targets for inhibitor development in the 
quest to selectively regulate cellular processes in various pathologies.227 Many small molecules 
have been developed to inhibit the enzymes that catalyze histone modification228,229 through 
competition with substrate, cofactors or through allosteric mechanisms. A more difficult 
challenge is disrupting the protein-protein interactions that drive chromatin recognition and 
enzyme activity. Figure 1.4 illustrates three strategies for small molecule interference to achieve 
these goals: 1) disruption of chromatin PTM recognition by “reader” domains; 2) disruption of 
PPIs in multi-subunit complexes that contribute to catalytic activity of the enzymatic subunit 
and; 3) disruption of direct protein-nucleosome interactions. 
 First, recruitment of many chromatin-associated proteins is achieved through recognition 
of chromatin modifications by reader domains specific for modified residues. Recently exciting 
molecules targeting these interactions have emerged as both tool compounds and clinical 
candidates. Some of the most famous examples of these inhibitors are JQ1 and I-BET762 which 
inhibit acetyl lysine binding by BET-family bromo-domain proteins.230,231 JQ1 displaces the BET 
 
Figure 1.4. Strategies for inhibiting protein-protein interactions in chromatin 
modification. 
Potential targets for inhibition by small molecules are indicated with red bars. 
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family member BRD4 from chromatin leading to reduced in vitro cellular proliferation and 
delayed tumor growth in xenograft models of the BRD4-requiring NUT midline carcinoma. I-
BET762 also inhibits bromo-domain proteins and has advanced to phase 1 clinical trials for 
hematological malignancies.232 Complementarily, the Frye group has developed UNC1215 
which is an inhibitor of methyllysine recognition by the L3MBTL3 protein.233 This molecule has 
been used as a chemical tool to probe the role of lysine methylation in the protein-protein 
interactions of L3MBTL3.234 Given the diversity of methyl- and actyllysine binding domains, the 
number and scope of chemical tools for this class of proteins will likely expand rapidly.235 
Second, many chromatin modifying enzymes are components of large multi-subunit 
complexes and protein-protein interactions within the complex can modulate enzymatic activity. 
As such, an alternative approach to regulate chromatin modification is through disruption of 
these regulatory protein-protein interactions. A recent example of this is the discovery of 
inhibitors of the EZH2/EED protein-protein interaction which is required for EZH2-mediated 
H3K27 methylation.236,237 Disruption of this interaction by natural products prevents chromatin 
modification, relieves PRC2-mediated transcriptional repression and arrests proliferation of 
EZH2-driven lymphoma cells.236 Similarly, small molecule inhibition of the menin-MLL 
interaction prevents chromatin targeting of MLL-fusion proteins with histone methyltransferase 
activity and reduces transcription of MLL target genes.238-240 In turn, pharmacologic disruption 
of this interaction suppress in vitro proliferation of leukemia cells, reduces tumor growth and 
prevents leukemia progression in mouse models of MLL leukemia.238  
Lastly, an unmet opportunity in regulating chromatin modification is inhibiting direct 
interactions between unmodified chromatin and chromatin-binding proteins.  This a relatively 
new area of research due to difficulties determining which proteins within a multi-subunit 
complex have direct interactions with the nucleosome. Contributions by the Tan group241,242 have 
provided detailed structural and mechanistic insight into these interactions, yet there is a general 
dearth of such data complicating inhibitor development projects. I expect that as identification 
and characterization of these interactions are expanded efforts to develop strategies to inhibit 
them will advance in parallel.  
 The ever-expanding appreciation for the role of chromatin modification in many 
pathologies suggest that this areas of research will provide ample opportunity to develop small 
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molecule inhibitors as tool compounds to illuminate these complicated biological processes and 
as potential therapeutics.  
G. Thesis summary 
In this dissertation I describe structural and functional insights into the multiple protein-
protein interactions of the PRC1 protein BMI1 and demonstrate different approaches to inhibit 
these interactions with small molecules. In Chapter 2, I provide a detailed biochemical and 
biophysical characterization of the BMI1 protein-protein interaction domain and demonstrate 
through mutagenesis that multiple protein-protein interactions are important for BMI1 regulation 
of cellular proliferation. In Chapter 3, I report my efforts to identify small molecule inhibitors of 
the BMI1-PHC2 interaction through a high-throughput screening campaign. In Chapter 4, I detail 
the development of a novel small molecule inhibitor of the Ring1B/BMI1 E3 ubiquitin ligase 
through the optimization of a fragment ligand into a potent, specific, and cell-permeable inhibitor 
of nucleosome ubiquitination through disruption of the interaction between the E3 ligase 
complex and the nucleosome substrate. Finally, in Appendix A I present an efficient NMR-based 
method to characterize disordered regions in proteins for structural and functional studies of 
these proteins.  
In summary, this dissertation provides critical insight into BMI1 as a core architectural 
organizer of the canonical PRC1 complex and demonstrates multiple approaches to modulate 
BMI1’s protein-protein interactions through small molecule inhibitors. These results support 
efforts to understand BMI1’s role outside of the polycomb complex and suggest further 
promising strategies to target BMI1 with chemical probes or potential therapeutics.  
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Chapter 2: Structural Characterization of BMI1 Protein-Protein 
Interaction Domain 
 
A. Abstract 
BMI1 is a subunit of the canonical polycomb repressive 1 (PRC1) complex which 
covalently modifies histones to repress transcription. To date the structural and mechanistic role 
of BMI1 in the PRC1 complex remains incompletely characterized. In this study we 
characterized the BMI1 interaction with PHC2 using biochemical and biophysical methods. 
Furthermore, we determined the high resolution structure of BMI1 in complex with its polycomb 
binding partner PHC2 using a hybrid approach involving X-ray crystallography and solution 
NMR. Structural details reveal that the protein-protein interaction domain of BMI1 adapts an 
ubiquitin-like fold. PHC2 adopts a β-hairpin conformation when in complex with BMI1 to form 
an intermolecular β-sheet. This BMI1 domain binds a short fragment of PHC2 with nanomolar 
affinity. Mutations at the BMI1-PHC2 interface disrupt this interaction in vitro and in cells 
leading to reduced U2OS cell proliferation. Additionally, we found that BMI1 can weakly self-
associate in vitro and disruption of these oligomerization interfaces through mutagenesis impairs 
cellular proliferation. Together this data suggest a model of BMI1 as a central architectural 
protein of the PRC1 complex mediating multiple protein-protein interactions that contribute to 
regulation of cellular proliferation.  
B. Background 
BMI1 belongs to the polycomb group (PcG) family of proteins, an evolutionally 
conserved family of negative transcriptional regulators. In mammals PcG complexes target 
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hundreds of genes associated with cell fate and development.1-3As a component of polycomb 
repressive complex 1 BMI1 interacts directly with the Ring1B protein through a heterodimer 
involving N-terminal RING domains. Additionally, BMI1 has a C-terminal domain which 
previous studies suggested was critical for direct interactions with the polyhomeotic (PHC) 
proteins in the PRC1 complex.4-6 PHC proteins have two conserved domain, a C-terminal SAM 
domain that can form helical polymers7-9 and a homology domain 1 (HD1) which is suspected of 
mediating protein-protein interactions.4,10 
Other work demonstrated that the BMI1 C-terminus is critical for BMI1 function, 
suggesting an important role for these protein-protein interactions. The van Lohuizen group 
generated transgenic BMI1 domain deletion mice and observed that mice lacking the BMI1 C-
terminus had skeletal deformations suggesting that the protein-protein interaction domain 
(“second domain”) is important for Hox gene regulation in mouse development.4 This domain 
was shown to be important for transcriptional silencing in in vitro luciferase assays.11 This 
domain is critical in BMI1-mediated oncogenesis as deletion of the second domain of BMI1 
reduces spontaneous lymphomagenesis in a mouse model for c-Myc mediated lymphoma.12 
Further, data suggest that this domain is critical for cell cycle regulation and a tumorigenic 
transcriptional program as deletion of the domain impairs human fibroblast and mammary 
epithelial cell immortalization.13,14 These studies demonstrate a critical role for this domain in 
BMI1 function, yet a complete a structural characterization of this domain is missing. We were 
motivated to understand the molecular details of interactions mediated by the second domain to 
gain insight into the role of BMI1 in normal and cancer biology. Additionally, structural and 
biochemical characterization can support drug discovery efforts targeting activity of BMI1 in 
cancer.  
C. Results 
C.1. The second domain of BMI1 interacts directly with PHC2 
Previous studies demonstrated that the C-terminus of BMI1 is required for binding PHC 
proteins.4,5 To confirm this we developed a cellular pull-down assay using the Avi-tag system. In 
this system coexpression of the BirA biotin ligase and Avi-tagged BMI1 results in biotinylation 
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of the Avi tag for pull-down with streptavidin beads (Figure 2.1.A).15 We used a construct of 
BMI1 lacking the N-terminal RING domain (Avi-BMI1ΔRing) allowing for detection of protein-
protein interactions mediated by the C-terminus of BMI1, at the exclusion of non-direct 
interactions mediated by the RING domain. In this assay, myc-tagged PHC2 is pulled-down by 
wild type Avi-BMI1ΔRing from HEK293T cells (Figure 2.1.B). This demonstrates that the 
interaction between these proteins is mediated by the C-terminal fragment of BMI1 but not 
through the N-terminal RING domain. The constructs of BMI1 and PHC2 proteins used in this 
experiment are illustrated in Figure 2.1.C.  
 
Figure 2.1. BMI1 C-terminus interacts directly with PHC2_B. 
A. Schematic of streptavidin pull-down of Avi-tagged BMI1 from cell lysate from HEK293T 
cells co-expressing Avi-BMI1ΔRing and BirA. B. Pull-down of myc-PHC2_B from 
HEK293T cells using biotinyated-BMI1ΔRing. Western blots are probed as indicated and 
molecular weight marker is indicated on the left. C. Outline of constructs used in pull-down 
experiments; primary sequence numbers are provided for clarity. 
C.2. Optimization of BMI1 second domain construct for structural studies 
We next pursued in vitro characterization of the BMI1 second domain for detailed 
structural and functional characterization. To define the BMI1 protein-protein interaction domain 
and obtain soluble, folded protein we tested a construct of BMI1 encompassing residues 106-
240. We measured 1H-15N HSQC NMR spectra and found that this protein was folded in 
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solution. However, significant peak broadening for resonances with dispersed downfield and 
upfield chemical shifts and a large number of intense, sharp peaks in the random coil chemical 
shift region of the NMR spectrum indicated that this construct aggregated in solution, likely due 
to the presence of significant number of disordered residues (Figure 2.2.A). To improve this 
construct by removing such flexible regions we employed NMR spectroscopy. As described in 
Appendix A we developed a 13C-detected NMR approach to detect disordered regions in 
globular proteins.16 2D CACO spectrum for BMI1106-240 showed ~34 peaks, and through 
sequential assignment process with CANCO and CBCACO experiments we identified BMI1 N- 
and C- terminal residues 106-120 and 236-240 as being highly flexible in solution (Figure 
2.2.B). Deletion of these residues significantly improved the 1H-15N HSQC spectrum (Figure 
2.2.C), demonstrating that this is a well folded domain that behaves well in solution. Based on 
these studies we defined residues 121-235 as the BMI1 second domain and this construct is used 
for all subsequent studies.  
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Figure 2.2. Optimization of BMI1 second domain construct using NMR 
A. 1H-15N HSQC spectrum of BMI1106-240. B. 13C-detected CBCACO spectrum for BMI1 106-
240 with assignment for flexible regions. Residues remaining from tag cleavage during 
purification are colored in red.  C. 1H-15N HSQC spectrum of BMI1121-235. 
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C.3. Characterization of BMI1-binding domain in PHC2 
We next wanted to define the region of PHC2 that interacts directly with BMI1. It has 
been previously suggested that the N-terminal HD1 domain of PHC2 is involved in the BMI1 
interaction but this interaction was not characterized before using in vitro methods.5 In order to 
confirm that the HD1 mediates the interaction with BMI1 we expressed a fragment of PHC2 
including residues 1-79. To measure binding affinity between BMI1121-235 and PHC21-79 we used 
isothermal titration calorimetry (ITC) which demonstrated mid-nanomolar affinity (KD = 398 
nM) with 1:1 stoichiometric ratio for this interaction (Figure 2.3).  
 
Figure 2.3. ITC determination of BMI1-PHC2 binding stoichiometry and affinity.  
Isothermal titration calorimetry experiment of BMI1121-235 titrated with unlabeled PHC21-79.  
To further characterize this interaction we turned to NMR spectroscopy. Poor peak 
dispersion on the 1H-15N HSQC spectrum of PHC21-79 indicate that this protein is unstructured in 
solution (Figure 2.4.A). This heavy spectral overlap precluded backbone assignment using 1H-
detected triple resonance experiments, and thus to obtain a detailed characterization of this 
interaction we again applied carbon-detected NMR methodology. Using 2D CACO, CBCACO, 
CANCO experiments we assigned 90% of the unstructured PHC21-79. To identify the residues 
involved in BMI1 binding we recorded the same experiments for PHC21-79 saturated with BMI1. 
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Binding of BMI1 to PHC21-79 should result in significant peak broadening for involved residues 
due to the formation of a high molecular weight complex.17 Indeed, addition of BMI1 to PHC21-
79 led to complete broadening of resonances on NMR spectra corresponding to residues 33-58 
(Figure 2.4.B). These data confirm a structural transition from disordered to ordered for this 
motif and indicates that this region represents BMI1-binding motif.  
 
Figure 2.4. Mapping of BMI1-binding motif of PHC2 using 13C-detected NMR. 
A. Selection of 1H-15N HSQC spectrum for PHC21-79 showing poor dispersion of backbone 
amide resonances. Region of spectrum with sidechains is omitted for clarity. B. BMI1-binding 
motif mapping through carbon detected experiments. 13C-detected CACO spectrum for apo 
PHC21-79 (red) is overlaid with spectrum for PHC21-79 with equimolar unlabeled BMI1121-235 
(black). Residues broadened in the presence of BMI1121-235 are labeled. 
To test the role of this motif in mediating the direct BMI1-PHC2 interaction in cells we 
performed pull-down experiments from HEK293T cells overexpressing a construct of PHC2 
lacking this fragment (PHC2Δ30-51) (Figure 2.5.A). The lack of observed interaction between 
BMI1 and PHC2Δ30-51 confirmed that in cells this section of PHC2 forms the critical 
interactions with BMI1. This region of PHC2 represents 52% of the conserved residues in the 
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HD1 domain (Figure 2.5.B). Isothermal titration calorimetry experiments with a synthetic 
PHC233-56 peptide showed similar affinity as the full length domain (PHC233-56 KD= 413 nM) 
(Figure 2.5.C) suggesting that there are likely very few contacts outside of this motif. 
 
Figure 2.5. PHC2 interacts with BMI1 in cells through a conserved fragment. 
A. Streptavidin pull-down of myc-tagged PHC2_B constructs from HEK293T cells transfected 
with Avi-BMI1ΔRing and BirA. Western blots are probed as indicated, molecular weight 
marker is labeled on the left side.  B. Sequence alignment of the three human PHC proteins. 
Conserved residues are highlighted in yellow and residues of PHC2_B that are broadened in 
13C-detected experiments upon BMI1 addition are colored in red. Numbering for PHC2_B 
sequence is provided for clarity. C. Characterization of the BMI1 – PHC233-56 interaction 
through isothermal titration calorimetry with BMI1 titrated with PHC233-56.  
C.4. Structure determination of BMI1-PHC2 complex 
Following mapping of the minimal interaction interfaces between BMI1 and PHC2 we 
pursued structural studies to determine the molecular basis of the complex. We have performed 
crystallization screens using both apo BMI1 and BMI1 in complex with different fragments of 
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PHC2. We obtained crystals of BMI1 co-crystalized in the presence of the PHC233-56 fragment in 
100 mM MES, pH 6.5, 50 mM MgCl2, 7% isopropanol, 6% PEG 4000 which diffracted to 2.5 Å. 
In order to determine the structure of the BMI1 second domain we purified seleno-methionine 
(Se-Met) labeled protein, however we were not able to reproduce the crystals obtained for the 
native protein. As an alternative approach, we performed bioinformatics analysis and found 
sequence similarity to the BMI1 ortholog, PCGF1 which has 29% identity to BMI1 second 
domain. Despite relatively low sequence similarity, we used a model derived from the PCGF1-
BCOR structure18 and determined the crystal structure of the second domain of BMI1 using 
molecular replacement  (Figure 2.6.A; Table 2.1- see Experimental Methods). As expected from 
sequence analysis, the structure of the BMI1 second domain has an ubiquitin-like fold and we 
named it the ubiquitin-like domain (ULD). There is one molecule per asymmetric unit and while 
we could refine the structure of BMI1 ULD, we were not able to model the PHC2 fragment into 
the remaining electron density which was found between two symmetry-related molecules of 
BMI1 ULD. The unmodeled electron density is found in a wide opening between the β1 and α1 
elements, which has been previously found to be involved in protein-protein interactions for 
polycomb ubiquitin-like domains (Figure 2.6.B).18-20 
 
Figure 2.6. Crystal structure of BMI1 ULD. 
A. Structure of BMI1 ULD as determined by X-ray crystallography from crystals obtained for 
BMI1 with PHC233-56 fragment. Secondary structure elements are labeled. B. 2Fo-Fc electron 
density map of PHC2 density (gray) with cartoon images of BMI1 ULD shows electron 
density found at crystallographic interface between two symmetry related BMI1 molecules 
(green). 
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While the structure of BMI1 ULD determined by X-ray crystallography provides insight 
into BMI1 structure when in complex with PHC2, the structure lacks the molecular details of the 
interaction. Therefore, to complete the structure of the BMI1-PHC2 complex, we turned to 
solution NMR. Because of limited stability of the BMI1-PHC2 complex we designed a fusion 
protein with PHC2 residues 30-63 fused to the N-terminal of BMI1. This construct was designed 
to include the intact BMI1 interacting motif in PHC2 as well as a short linker to insure proper 
folding of the complex. The 1H-15N HSQC spectrum for this fusion protein is similar to that of 
15N BMI1 saturated with unlabeled PHC2 (Figure 2.7.A) demonstrating that the fusion protein 
accurately recapitulates the protein complex. We performed chemical shift assignment for the 
BMI1-PHC2 fusion protein based on triple resonance NMR spectra (Table 2.2- see Experimental 
Methods). We found that all BMI1 constructs with or without PHC2 fragments had a tendency to 
aggregate in solution. This resulted in the relatively poor quality of NMR spectra and prevented 
 
Figure 2.7. Hybrid solution NMR- x-ray crystal structure of BMI1-PHC2 complex. 
A. Selection of 1H-15N HSQC spectra for BMI1 ULD saturated with PHC232-61- fragment (red) 
and for PHC230-63-BMI1 fusion protein (black). Resonance assignments are shown and 
resonances coming from the PHC2 portion of BMI1 fusion are indicated with asterisk. B. 
Hybrid X-ray crystal and solution NMR structure of the BMI1-PHC2 complex. The 10 lowest 
energy solution structures for PHC2 are shown in blue and the crystal structure of BMI1 is 
shown in gray. 
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structural determination of the BMI1-PHC2 complex solely based on NMR experiments. 
However, analysis of 3D 13C-edited and 3D 15N-edited NOESY spectra for the BMI1-PHC2 
fusion protein allowed assignment of a large number of intra-PHC2 and inter-PHC2-BMI1 NOEs. 
To circumvent the challenges in determining the structure of the complex solely using 
either X-ray crystallography or solution NMR methods we used a hybrid refinement method. In 
this approach we used the crystal structure of BMI1 and NMR restraints to define PHC2 
structure and determine PHC2-BMI1 contacts. The initial structure was calculated in CYANA.21 
Subsequently, we refined the structure using Rosetta22-24 employing coordinates for BMI1 
derived from the crystal structure and NMR restraints (Table 2.2). The structure of the complex 
shows an antiparallel intermolecular β-sheet formed between the β-hairpin formed by PHC2 
residues 33-47 and the β1 strand of BMI1 (Figure 2.7.B). The hydrophobic core of the complex 
is made up of BMI1 Leu164, Leu175 and Phe178 packing with PHC2 Ala47, Ile43 and Ile38 
Figure 2.8. Structural details of the BMI1-PHC2 interaction. 
A. Close-up view of the hydrophobic core of the BMI1-PHC2 interaction. Hydrophobic 
residues from BMI1 and PHC2 are shown in pink. Structure is rotated 90° relative to part B. B. 
Highlighted polar interactions in the BMI1-PHC2 interface. Key polar residues involved in the 
interaction are show in green. 
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(Figure 2.8.A). PHC2 Phe41 is sandwiched between BMI1 Pro167, Ala169 and Met170 at the 
top of the hairpin. One side of the PHC2 β-hairpin packs against the α1 helix of BMI1 ULD with 
the sidechain of BMI1 His174 hydrogen bonding with the backbone carbonyl of PHC2 Glu39 in 
the β turn and PHC2 His36 forming polar contacts with BMI1 Ser181 (Figure 2.8.B). Polar 
contacts between the sidechains of BMI1 Arg165 and PHC2 Gln44 contribute to the affinity on 
the other side of the interface. Interestingly, we observed that PHC2 Glu45 is buried in the 
structure, extending towards BMI1 Lys182 which is also buried in the interface. Residues 47-63 
of PHC2 are disordered in the structure, as supported by random coil chemical shifts and very 
few NOEs.  
Re-examination of the crystal structure reveals that unmodeled electron density 
corresponds to PHC2 in the structure of a complex (Figure 2.9). PHC2 binds at the 
crystallographic interface between two BMI1 molecules. We concluded that in this crystal 
structure, PHC2 has to be bound in two different orientations with 50% occupancy for each 
PHC2 molecule. We cannot model the complex solely based on crystallographic data likely due 
to limited resolution (2.5 Å) and only partial occupancy of the PHC2 molecules.  
 
 
Figure 2.9. PHC2 electron density is at crystallographic interface in crystal structure. 
Overlay of the hybrid BMI1-PHC2 structure with the 2Fo-Fc electron density map from the 
BMI1 PHC233-56 crystal structure showing density identified for PHC2 peptide. The solution 
structure of PHC2 is colored from blue at the N-terminus to red at the C-terminus. 
49 
 
C.5. Design of mutations in BMI1 to disrupt BMI1-PHC2 interaction 
We next wanted to probe the BMI1-PHC2 interaction through mutagenesis. Based on the 
structure of the complex we rationalized that mutation of Arg165 and His174 in BMI1 to 
glutamic acid would introduce significant electrostatic repulsion with PHC2 Glu45 and Glu39, 
respectively (Figure 2.8.A). We expressed these two BMI1 mutants (R165E and H174E) and 
verified that the proteins retained their secondary fold by NMR spectroscopy (data not shown). 
We tested these mutants in a fluorescence polarization assay with fluorescein-tagged PHC232-61 
(FITC-PHC2) (Figure 2.10.A). In this assay wild type BMI1 binds PHC232-61 with KD= 0.215 ± 
0.016 µM. The R165E mutation reduces the binding affinity by 30 fold (KD= 5.9 ± 0.9 µM) and 
H174E mutation results in a 100-fold loss in binding affinity (KD= 20.13 ± 2.8 µM). Introduction 
of the double R165E/H174E mutation into BMI1 completely abolished the interaction (KD > 50 
µM). In pull-down experiments from HEK293T cells, Avi-BMI1ΔRing R165E/H174E fails to 
pull-down myc-PHC2 demonstrating that disruption of this interaction through these point 
mutants is sufficient to disrupt the complex in cells (Figure 2.10.B).  
 
Figure 2.10. BMI1 mutations disrupt PHC2 interaction in vitro and in cells. 
A. Fluorescence polarization experiments titrating FITC-PHC2 with wild type or mutant BMI1 
ULD constructs. Experiments were performed in duplicates and error bars represent the 
standard deviation from three independent experiments; KD is reported as average and standard 
deviation from three independent experiments. B. BMI1 ULD R165E/H174E cannot pull-down 
myc-PHC2_B from HEK293T cells. Western blots are probed as indicated and the molecular 
weight marker is shown on left.  
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C.6. BMI1 ULD can form higher order oligomers 
Throughout the characterization of the BMI1-PHC2 interaction we made several 
observations that suggested that BMI1 may self-associate in solution. We observed that many 
resonances in the NMR spectra of BMI1 constructs showed various degrees of concentration-
dependent peak broadening consistent with protein self-association in solution (Figure 2.11.A). 
Importantly, BMI1 self-association was not affected by the interaction with PHC2, as 
demonstrated by performing NMR binding experiments between BMI1 ULD and the PHC2-
BMI1 fusion protein. This suggests that oligomerization may represent an intrinsic property of 
BMI1 ULD. To characterize BMI1 ULD self-association we employed analytical 
ultracentrifugation (AUC) experiments.25 AUC is a biophysical method that measures the rate of 
particle sedimentation in solution in a gravitational field.26 This allows determination of 
sedimentation coefficient which contains information on both size and shape of macromolecules 
in the experiment and is sensitive to heterogeneous distributions of species. Thus, from these 
experiments it is possible to assess if a protein or protein complex from multiple species in 
solution.   
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Figure 2.11. BMI1 self-associates in solution. 
A. Portion of 1H-15N HSQC spectrum for BMI1 ULD in the presence of 1 equivalent (blue) or 
2 equivalents (red) of PHC230-79-BMI1 fusion protein. Inset shows relative peak intensity of 
select residues demonstrating broadening of signals with increased protein concentration from 
the formation of larger molecular species in solution. Residues at the second interface 
identified through X-ray crystallography are indicated. B. Van Holde-Weischet [G(s)] plots of 
sedimentation distributions for BMI1 ULD wild type-PHC2 complex at various concentrations 
shows concentration-dependent increase in particle size in solution 
We first wanted to test solution sedimentation behavior of wild type BMI1 ULD. Because 
of limited solubility of BMI1 ULD, we measured sedimentation coefficients for the BMI1-PHC2 
complex which has better solubility. AUC sedimentation velocity experiments were conducted at 
three concentrations of the complex and a concentration-dependent increase in sedimentation 
coefficient was determined with 10 µM, 50 µM and 250 µM samples having coefficients of 1.5, 
1.8 and 2.0, respectively. This indicates a weak, yet significant formation of larger complexes at 
higher concentrations (Figure 2.11.B). 
Inspection of the crystal packing in the structure of BMI1 with PHC2 shows two potential 
head-to-head homo-dimerization interfaces between BMI1 molecules (Figure 2.12.A). The first 
interface is predominantly hydrophobic and comprises residues Asp184-Phe189 and Tyr225-
Thr230. The second interface is made up of polar interactions involving a hydrogen bonding 
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network between the sidechains of Tyr202, Tyr 203, Tyr 211 and Tyr 213 and backbone 
carbonyl groups.  Ile212 is buried between two monomers at this interface. We observed that 
residues Leu200, Leu206 and Ile212 at this interface are particularly broadened at high 
concentrations of protein in solution NMR experiments (Figure 2.11.A). Examination of the 
interactions between symmetry-related BMI1 molecules in the crystal lattice reveal that through 
these head-to-head interactions BMI1 forms a hexamer in the crystal form (Figure 2.12.B).  
 
Figure 2.12. Crystal structure of BMI1 suggests two homodimer interfaces. 
A. Crystal structure of BMI1 ULD shows two head-to-head interfaces colored in gray. Residues 
mutated in functional studies are colored red. B. Hexameric structure of BMI1 ULD formed 
through crystal contacts. 
To test if interface mutants would disrupt BMI1 ULD oligomerization we designed point 
mutations F189Q and I212E to introduce polar groups in place of hydrophobic residues at these 
interfaces. Fluorescence polarization data indicate that these mutations do not very significantly 
affect binding of PHC2 in vitro (F189Q KD = 0.409 ± 0.16 µM and I212E KD=1.2 ± 0.25 µM) 
(Figure 2.13.A). Furthermore, NMR experiments show that both mutant proteins are folded in 
solution and bind PHC2 in a similar manner to wild type protein (data not shown). To assess 
whether these point mutations affect the propensity of BMI1 to self-associate we employed AUC 
(Figure 2.13.B). Sedimentation velocity experiments showed that the BMI1 F189Q –PHC2 
complex has similar concentration dependent sedimentation behavior as wild type BMI1-PHC2 
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complex indicating that this mutant is still able to form higher order species. Interestingly, the 
I212E interface 2 mutant does not show concentration dependent effects, and sedimentation 
coefficients of 1.8 were calculated for I212E samples at both 10 µM and at 50 µM, indicating 
that this mutant has reduced tendency for oligomerization. These data support the conclusion that 
BMI1 self-associates through at least one interface identified through crystallographic studies. 
 
Figure 2.13. BMI1-BMI1 interface mutants disrupt self-association but not interaction 
with PHC2. 
A. Fluorescence polarization experiments titrating FITC-PHC2 with wild type or mutant 
BMI1 ULD constructs. Experiments were performed in duplicates, error bars and KD are 
standard deviation from three independent experiments; B.  Van Holde-Weischet [G(s)] plots 
of sedimentation distributions for wild type or mutant BMI1 -PHC2 complexes at various 
concentrations. 
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C.7. Multiple BMI1 protein-protein interactions regulate cellular proliferation 
We hypothesized that BMI1’s multiple protein-protein interactions are critical to BMI1 
function. To test this we developed a cellular proliferation assay in osteosarcoma U2OS cells, 
which express high levels of BMI1. We found that knockdown of BMI1 in U2OS using siRNA 
reduced proliferative capacity relative to cells transfected with non-targeting siRNA (Figure 
2.14.A, black and blue curves). Following knockdown of endogenous BMI1 by siRNA, cellular 
proliferation could be rescued with overexpression of BMI1 wild type protein (Figure 2.13.A, 
green curve). However, overexpression of BMI1 mutants that disrupted either BMI1-PHC2 or 
BMI1-BMI1 interaction (BMI1 R165E/H174E or I212E mutants, respectively) failed to rescue 
cellular proliferation (Figure 2.14.A, purple and orange curves). This is further demonstrated by 
comparing cell numbers at the end of the five day experiment (Figure 2.14.B), demonstrating 
that both BMI1-PHC2 and BMI1-BMI1 interactions are critical for BMI1 function in regulating 
cellular proliferation. Expression of wild type or mutant BMI1 was analyzed by western blot 
showing complete loss of endogenous BMI1 by siRNA treatment and expression of all BMI1 
constructs (Figure 2.14.C). 
55 
 
 
Figure 2.14. Multiple BMI1 protein-protein interactions regulate cellular proliferation. 
A. Growth curve for U2OS cells that were transfected with either non-targeting (N.T) siRNA 
or BMI1 siRNA and transfected with vectors encoding for BMI1 wild type (WT) or mutant 
constructs. B. Quantification of cell number at end of proliferation experiment, t=120 hours. 
Mean and standard deviation of two technical replicates are shown and analyzed by the 
student’s t-test. *p<0.05. C. Western blot of cell lysate for cells quantified in part B. 
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D. Discussion and Conclusion 
In the present study we have characterized the BMI1-PHC2 interaction using biophysical 
and structural biology methods. We found that the BMI1 protein-protein interaction domain 
forms a moderate affinity complex with the HD1 domain of PHC2 (KD= 398 nM). Structural 
studies reveal that the BMI1 PPI domain has an ubiquitin-like fold, classifying this domain as an 
ubiquitin-like domain (ULD). The PHC2 HD1 domain is disordered in solution and forms an 
intermolecular β sheet upon binding to BMI1 ULD. Disruption of this interaction through 
mutagenesis impairs cellular proliferation of U2OS cells suggesting that the BMI1-PHC2 
interaction plays a role in regulating cell proliferation. Additionally, we demonstrate through 
multiple approaches that BMI1 weakly self-associates in vitro potentially through two interfaces 
and that disruption of this homo-oligomerization through mutagenesis similarly reduces cellular 
proliferation. Together this data suggest a model of BMI1 function as a scaffold protein which 
participates in multiple protein-protein interactions to coordinate subunit organization within the 
canonical PRC1 complex.  
D.1. Need for using multiple methodologies to determine structure of BMI1-PHC2 
complex  
In order to determine the structure of BMI1-PHC2 complex we needed to overcome 
multiple difficulties. We found that 13C-detected NMR spectra (see Appendix A) were very 
helpful in designing BMI1 ULD and PHC2 constructs for structural studies. Previous attempts at 
structural studies of the BMI1 ULD were hampered by protein instability18 highlighting the 
utility of this methodology in designing constructs for structural biology.16 In the present studies 
we also used this methodology for the experimental determination of the minimal BMI1-binding 
motif in PHC proteins which corresponds to only a fraction of conserved residues in the natively 
unstructured HD1 domain. Identification of this motif through bioinformatics or sequential 
deletion studies would be time consuming. Additionally, as structural studies with larger 
fragments of unstructured proteins are challenging, this work reinforces the value of the 13C-
detected NMR methods in defining protein-protein interaction interfaces in natively unstructured 
proteins.17  
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We employed a hybrid X-ray crystallography and solution NMR approach to determine 
the structure of the BMI1-PHC2 complex. This approach incorporated data from both techniques 
to circumvent challenges encountered in structural studies with individual methods. Overall this 
tactic enabled solution of the 3D structure for a complete description of the BMI1-PHC2 
complex. Hybrid structural biology approaches integrating multiple methodologies have been 
used to generate structures of individual proteins or protein complexes that may not be available 
through application of a single method. For example, combined use of solution NMR and cryo-
EM revealed the structural details of regulation of the APC/C E3 ligase complex by the multi-
domain protein EMI1.27 Similarly, integration of solution NMR and small angle x-ray scattering 
(SAXS) have been used for a complete molecular depiction of multi-domain proteins or protein 
complexes.28 These studies demonstrate the complementarity of structural biology methods with 
different resolutions to define both detailed molecular details as well as global architecture of 
macromolecular complexes. In contrast, the approach demonstrated here is novel in that it 
integrates data from two methods which were both challenged by the intrinsic behavior of the 
protein. 
D.2. Structural studies of BMI1-PHC2 reveal basis for polycomb ULD specificity 
In these studies we determined the structure of the BMI1-PHC2 complex, which was 
previously unknown. This structure demonstrates that a short fragment of PHC2 adopts a β 
hairpin structure when in complex with the BMI1 ubiquitin-like domain, which is a common 
architecture in other structures of polycomb protein complexes.18,19 The PPI domains of PCGF1 
and Ring1B adopt an ubiquitin–like fold and interact with a short motifs of their respective 
binding partners, BCOR and CBX7 or RYBP through intermolecular β sheets (Figure 2.15.A). 
The stabilizing polar contacts between the sidechains of BMI1 Arg164 and PHC2 Gln44 are 
conserved between PCGF1 Arg193 and BCOR Glu1640 in the PCGF1-BCOR structure and 
mutation of PCGF1 Arg193 to Ala abolished the interaction in bacterial two-hybrid 
experiments.18 In the Ring1B-CBX7 complex Ring1B Arg246 and CBX7 Glu236 are the 
equivalent residues. Likewise, the critical histidine-backbone carbonyl hydrogen bond is 
conserved in all three structures, with PCGF1 His202 hydrogen bonding with the backbone 
carbonyl of BCOR Pro1746 and Ring1B His258 interacting with the backbone of both CBX7 
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Ala227 and Ile230 (Figure 2.14.A). The buried acidic residue observed in the BMI1-PHC2 
structure is also conserved in the Ring1B-CBX7 or RYBP structures with CBX7 Glu236 and 
RYBP Asp172 extending towards Ring1B Arg266 through the core of the interface. This 
interaction is not conserved in the PCGF1-BCOR structure. The other PCGF orthologs (PCGF 2, 
3, 5 and 6) are also predicted to have the same ubiquitin-like domain.29 PCGF proteins have low 
overall sequence identity (average 36% between BMI1 and PCGF1,3,5,6; 62% between BMI1 
and Mel-18/PCGF2) however the protein-protein interface identified by this study and previous 
structures is highly conserved among all polycomb proteins with this fold (Figure 2.15.B).18-20 
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Figure 2.15. Basis for binding partner selectivity in ULD-domain polycomb proteins. 
A. Structures of polycomb ULD complexes showing a conserved structure and similar 
biochemical contacts. Top: BMI1-PHC2 structure. Bottom Left: PCGF1-BCOR structure 
(PDB: 4HPL); center: Ring1B-RYBP structure (PDB: 3IXS); right: Ring1B-CBX7 structure 
(PDB: 3GS2). Critical interface residues are labeled. B. Sequence alignment of polycomb 
ULD domains. Conserved basic residues are show in green, residues making up the 
hydrophobic core are in teal, the conserved His is shown in red and bulky residues are shown 
in yellow. Non-conserved residues are shown in gray. Secondary structure elements are 
illustrated below the sequence. 
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Despite such conserved structural and biochemical similarity there is no evidence for 
promiscuous binding among polycomb ULD-containing proteins. In bacterial- or yeast-two-
hybrid experiments BMI1 does not interact with BCOR or CBX proteins,4,5 Ring1B does not 
interact with BCOR or PHC2 and similarly PCGF1 does not interact with PHC1 or CBX7. 4,5,18 
4,5,17 This lack of cross-interactions can be rationalized through residue mismatch at key 
positions. In the BMI1-PHC2 structure presented in this chapter, hydrophobic contacts between 
BMI1 Phe178 and PHC2 Ile43 contribute to the hydrophobic core of the structure. In the 
PCGF1-BCOR structure these residues are equivalent to the PCGF1 Val206 and BCOR 
Phe1641, respectively, and a likely steric clash between BMI1 Phe178 and BCOR Phe1641 
would prevent this interaction. Binding selectivity between BMI1 and the Ring1B binding 
partners CBX7 or RYBP is likely due to the substitution of the key basic residue in PHC2 Gln44 
with hydrophobic groups in the Ring1B binding partners (CBX7 Val238 and RYBP Leu165) 
thereby eliminating the sidechain polar interactions at this position that stabilize the BMI1-PHC2 
interaction. This analysis demonstrates the molecular basis for polycomb complex heterogeneity 
through interactions of different ULD-containing subunits with distinct binding partners.  
D.3. Implications of BMI1 protein-protein interactions on PRC1 architecture 
Together, our studies suggest a central role for BMI1 in coordinating the architecture of 
the canonical PRC1 complex. Through interactions with Ring1B and PHC2 proteins BMI1 links 
the ubiquitin ligase Ring1B to the polymerizing PHC subunit (Figure 2.16.A). To our knowledge 
this model is the first of the overall complex based on structural data of all subunits and 
interactions. Further, we have identified that BMI1 ULD self-associates by two potential head-
to-head interfaces. While these interactions are weak in vitro (mid-micromolar affinity), we can 
imagine that in a cellular context this interaction is enhanced by the high affinity interaction 
between the BMI1 ULD and the PHC HD1 domains and the polymerization of the PHC SAM 
domains (Figure 2.16.B). Complementary to PHC oligomerization, BMI1 ULD oligomerization 
may contribute to overall stability of PRC1 complex in cells. Together these studies provide 
detailed insight into BMI1’s protein-protein interactions and set the stage for future work 
identifying other BMI1 potential binding partners and assessing the role of BMI1 self-association 
in PcG complex assembly and gene silencing mechanisms. 
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Figure 2.16. Models for PRC1 organization and oligomerization. 
A. Model of canonical PRC1 complex based on structurally characterized protein-protein 
interactions. B. Model of PRC1 “oligomerization unit” showing affinities for different protein-
protein interactions. Affinities for BMI1 ULD homo-oligomerization and BMI1-PHC2 HD1 
heterodimerization are estimated or determined in this paper and SAM domain homo-
oligomerization affinity is from previously published studies.7,8  
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E. Experimental methods 
Plasmid construction 
cDNA encoding full-length BMI1 and full-length PHC2_B was obtained from the Raul Lab 
(Department of Pathology, University of Michigan) and the desired constructs were subcloned 
into the pET32p bacterial expression vector. The pET32p vector is a modified pET32a vector 
(Novagen) that contains a Precision Protease recognition sequence between a thioredoxin (trx) 
solubility tag and the target protein. Linear DNA sequence for Avi-BMI1ΔRing and for the E. 
Coli BirA biotin ligase were ordered from Genscript. Plasmid encoding the synthetic gene for 
PHC230-63-BMI1 was ordered from Life Technologies and the gene coding sequence was 
subcloned into the pET32p vector. Mammalian expression plasmids were constructed using 
standard molecular biology techniques using the templates described above.  Plasmids for mutant 
constructs were made using standard QuikChange mutagenesis protocol (Stratagene) and verified 
by Sanger sequencing.  
Protein expression and purification 
BMI1 constructs:  All BMI1 proteins were expressed in Codon+ BL21 (DE3) E. coli cells 
(Sigma) with an N-terminal His6- thioredoxin tag (trx). Cells subjected to ampicillin (100 
µg/mL) selection were grown in Luria broth (Fisher) or labeled M9 medium at 37°C (220 rpm) 
until OD600 reached 0.6-0.8. Incubation temperature was lowered to 18°C for 1 hour then protein 
over-expression was induced with 0.5 mM (final concentration) Isopropyl β-D-1-
thiogalactopyranoside (IPTG; Gold Bio) for 16-18 hours at 18°C. Cells were lysed in a buffer 
containing 50 mM Tris, pH 7.5 at 25°C, 250 mM NaCl, 20 mM Imidazole, 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM β-mercaptoethanol (β-ME) using a French Press. 
Clarified lysate was applied to a HisTrap HP (GE Healthcare) column using Äkta Prime FPLC 
and eluted with lysis buffer containing 0.5 M imidazole. To remove the His6- thioredoxin tag, the 
protein was cleaved with Precision protease and BMI1 ULD constructs were further purified 
using cation exchange chromatography. Purified protein solution was buffer exchanged into 
storage buffer (100 mM Bis-Tris, pH 6.5, 50 mM NaCl, 1 mM Tris(2-carboxyethyl)phosphine 
hydrocholoride (TCEP-HCl)) using HiPrep Desalting Column (GE Healthcare). The PHC230-63-
BMI1 fusion protein was expressed and purified as described above. 
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If the protein was to be used for crystallization, ion-exchange purified BMI1 ULD was saturated 
with PHC233-56 peptide (Genscript) and applied to a Superdex S75 gel filtration column (GE 
Healthcare) pre-equilibrated with storage buffer (100 mM Bis-Tris, pH 6.5, 50 mM NaCl, 1 mM 
TCEP). Protein concentration was measured using absorbance at 280 nm. Protein identity and 
purity was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Protein was flash frozen and stored at -80°C.   
PHC21-79. PHC21-79 protein was expressed in BL21 (DE3) E. coli cells (Sigma) with an N-
terminal His6- thioredoxin tag. Cells were subjected to ampicillin (100 µg/mL) selection and 
grown in Luria broth (Fisher) or labeled M9 medium (Marley 2001) at 37°C (220 rpm) until 
OD600 reached 0.6-0.8. Incubation temperature was lowered to 18°C for 1 hour then protein over 
expression was induced with 0.5 mM (final concentration) Isopropyl β-D-1-
thiogalactopyranoside (IPTG; Gold Bio) for 16-18 hours at 18°C. Cells were lysed in a buffer 
containing 50 mM Tris, pH 7.5 at 25°C, 250 mM NaCl, 20 mM imidazole, 0.5 mM PMSF, 1 
mM β-ME using a French Press. Clarified lysate was applied to a HisTrap HP (GE Healthcare) 
column using Äkta Prime FPLC and eluted with lysis buffer containing 0.5 mM imidazole.  Trx- 
PHC21-79 protein was further purified by gel filtration on a Superdex S-75 column in buffer 50 
mM phosphate, pH 6.5, 50 mM NaCl, 1 mM TCEP-HCl. To obtain untagged PHC21-79 protein, 
the thioredoxin tag was cleaved with Precision protease during dialysis against 100-fold excess 
dialysis buffer A (50 mM Tris, 50 mM NaCl, 1 mM TCEP-HCl, pH 7.5 at 25°C). The 
thioredoxin tag was separated from HD1 using a nickel affinity column to bind the thioredoxin 
protein. PHC21-79 was further purified by Superdex S75 gel filtration (GE Healthcare) pre-
equilibrated with storage buffer (50 mM phosphate, pH 6.5, 50 mM NaCl, 1 mM TCEP)  Protein 
concentration was measured using absorbance at 280 nm. Protein identity and purity was verified 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein was flash 
frozen and stored at -80°C.  
Isothermal Titration Calorimetry 
BMI1 and trx- PHC21-79 were dialyzed extensively against ITC buffer (50 mM potassium 
phosphate, pH 6.5, 50 mM NaCl, 1 mM TCEP) and degassed prior to measurement. The 
titrations were performed using a VP-TIC titration calorimetric system (MicroCal) at 25°C. The 
calorimetric cell, containing BMI1 ULD (22 µM), was titrated with trx- PHC21-79 (164 µM) 
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injected in 10 µL aliquots. Data were analyzed using Origin 7.0 (OriginLab) to obtain KD and 
stoichiometry. 
NMR Spectroscopy 
Samples for BMI1 ULD- PHC21-79 interaction studies were made with 15N-labeled BMI1 ULD at 
50 µM in a buffer containing 50 mM Bis-Tris, pH 6.5, 50 mM NaCl, 1 mM TCEP and 5% D2O. 
For PHC21-79 binding studies, samples were prepared with unlabeled PHC21-79 at 25 µM, 50 µM 
or 100 µM, final concentration.  
Samples for PHC21-79 backbone carbon assignment were made with 60 µM 13C15N labeled 
protein prepared in a buffer containing 100 mM Bis-Tris, pH 6.5, 100 mM NaCl, 1 mM TCEP 
and 5% D2O. 13C-detected CACO, CBCACO and CANCO experiments were used for carbon 
assignment 30,31. For BMI1 binding studies, equimolar concentrations of unlabeled BMI1 ULD 
was added to the labeled PHC21-79 and the same experiments were recorded. 
All spectra were acquired at 30°C on a 600 MHz Bruker Advance III spectrometer equipped with 
cryoprobe, running Topspin version 2.1. Processing and spectral visualization was performed 
using NMRPipe32 and Sparky.33  
Crystallization and Crystal Structure Determination 
Initial crystals were obtained through sitting drop screening of gel-filtration purified BMI1 ULD-
PHC233-56 complex. Crystals were further optimized by hanging-drop vapor diffusion with equal 
volumes (1 µL) of protein (9 mg/mL in 50 mM Bis-Tris, pH 6.5, 50 mM NaCl, 1 mM TCEP) 
and the precipitant solution (100 mM MES, pH 6.5, 50 mM MgCl2, 7% isopropanol, 6% PEG 
4000). Crystals formed within 7 days at 39°F. Crystals were cryoprotected using the precipitant 
solution containing 20% glycerol and flash frozen in liquid nitrogen. X-ray diffraction data of 
crystals were collected at a resolution of 2.5 Å at the Advanced Photon Source at LS-CAT beam 
line 21-ID-F. The data were then indexed, integrated, and scaled using the HKL2000 suite.34 The 
crystals belonged to the space group P3212, with the unit cell parameters a=b=78.275, c=43.119 
Å, α=β=90, γ=120°. With 1 molecule in the asymmetric unit, the crystal volume per unit of 
protein mass was 3.77 Å3 Da-1, corresponding to a solvent content of 67.43%.35 The structure 
was determined by molecular replacement method with the CCP4 version of MOLREP 36 using 
the polycomb group Ring finger protein complex structure (PDB code 4HPM B chain) as a 
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search model.19 Model building was performed manually using the program WinCoot37 and the 
refinement was performed with CCP4 refmac5.38 The data statistics are summarized in Table 2.1. 
Table 2.1. Statistics of crystal structure of BMI1 ULD 
Data Set 
 
Experimental Data 
X-ray source 
Wavelength (Å) 
Space group 
Unit cell parameters (Å) 
Resolution limit (Å) 
Total reflections 
Unique reflections 
Redundancy 
Completeness (%) 
Rsymmb 
Average I/σ (I) 
 
Refinement Details 
Resolutions (Å) 
Reflections (working) 
Reflections (test) 
Rwork /Rfree (%)c 
Number of water molecules 
RMS deviation from ideal geometry 
bond length (Å) 
bond angle (o) 
Average B factors (Å) 
BMI1-PHC2 
 
 
APS 21_ID-F 
0.97872 
P3212 
a=b=78.28, c=43.12, α=β=90˚, γ=120˚ 
50 – 2.5 (2.54 – 2.50)a 
52,849 
5,292 
10.0 (8.3) 
99.8 (99.6) 
0.087 (0.477) 
33.93 (3.28) 
 
 
50 – 2.51 
5,018 
268 
24.01/33.38 
20 
 
0.012 
1.737 
57.91 
aThe numbers in parentheses describe the relevant value for the last resolution shell. 
bRsym = Σ|Ii-<I>|/ ΣI where Ii is the intensity of the i-th observation and <I> is the mean 
intensity of the reflections. 
cRwork = Σ||Fobs|-|Fcalc||/ Σ |Fobs|, crystallographic R factor, and Rfree = Σ||Fobs|-|Fcalc||/Σ|Fobs| when 
all reflections belong to a test set of randomly selected data. The high Rfree is due to the 
inability to model part of the density corresponding to PHC2, illustrated in Figure 2.9. 
 
Measurement of BMI1-PHC2 distances using NMR  
Protein samples for NMR structure determination contained 200 µM PHC230-63-BMI1 ULD 
fusion protein. Backbone and methyl sidechain assignment were made with 13C15N-labeled 
PHC230-63-BMI1 prepared in a buffer containing 50 mM Bis-Tris, pH 6.5, 50 mM NaCl, 1 mM 
TCEP and 5% D2O. Backbone assignment was done using a series of triple-resonance 
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experiments including HNCACB, CBCA(CO)NH, HNCA, HN(CO)CA, HNCO and 
HN(CA)CO. Methyl side chain resonances were assigned using 3D 13C-1H-1H HCCH-TOSCY. 
Nuclear Overhauser Effect (NOE) cross-peaks were identified using 15N-separated NOESY-
HSQC and 13C-separated NOESY-HSQC spectra. Distance restraints were calculated with 
CYANA21 from 1HN and methyl 1H NOEs within PHC2 residues and between PHC2 and BMI1 
ULD. The hybrid NMR- X-ray crystal structure of the BMI1 ULD-PHC2 complex was refined 
using Rosetta22-24 constrained with these distance restraints, PHC2 dihedral angles calculated by 
TALOS+39 and BMI1 ULD coordinates from the crystal structure. The data statistics are 
summarized in table 2.2. 
Table 2.2. Statistics for NMR Structure Determination. 
 
PHC230-63-BMI1 NMR assignment statistics 
 
Assigned backbone amide resonances 91% (91% total BB amides) 
Assigned methyl resonances 
 
79% (57% of total methyl) 
NMR distance and dihedral constraints 
Distance restraints  
Total number of NOE restraints 162 
Intra-residue restraints (I=J) 46 
Sequential restraints (I-J=1) 45 
Backbone-backbone 24 
Backbone-sidechain 8 
Sidechain-sidechain 13 
Medium-range restraints 1<(I-J)<5 10 
Backbone-backbone 3 
Backbone-sidechain 1 
Sidechain-sidechain 6 
Long-range restraints (I-J)>=5 61 
Total Dihedral angle restraints 30 
Phi 15 
Psi 15 
 
Fluorescence polarization assay 
For binding experiments (KD measurements) fluorescein-labeled PHC232-61 (FITC-PHC2; 
Genscript) at 20 nM was titrated with a range of BMI1 ULD concentrations in the FP buffer (50 
mM Bis-Tris, pH 7.5, 50 mM NaCl, 1 mM TCEP, 0.01% BSA, 0.25% tween-20). After a 1 hour 
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incubation of the protein-peptide complexes, changes in fluorescence polarization and anisotropy 
were measured at 525 nm after excitation at 495 nm using PHERAstar microplate reader (BMG). 
Data fit with a sigmoidal dose response equation were used to assess BMI1 ULD construct 
binding with the Prism 4.0 (GraphPad) program.  
Analytical Ultracentrifugation  
Sedimentation velocity experiments were performed on a Beckman Optima XL-I at the Center 
for Analytical Ultracentrifugation of Macromolecular Assemblies (CAUMA) at the University of 
Texas Health Center at San Antonio. Calculations were performed with the UltraScan 
software40at the Texas Advanced Computing Center at the University of Texas at Austin and at 
the Bioinformatics Core Facility at the University of Texas Health Science Center at San 
Antonio.40,41 All samples were measured in a 50 mM potassium phosphate buffer, pH 6.5 
containing 50 mM NaCl and 1 mM TCEP. All data were collected at 20°C and spun at 50 krpm. 
All data were first analyzed by two-dimensional spectrum analysis with simultaneous removal of 
time-invariant noise42,43 and then by enhanced van Holde-Weischet analysis and genetic 
algorithm refinement44,45 where applicable, followed by Monte Carlo analysis.41 
Pull-down experiments 
U2OS cells were transfected with BirA, myc-PHC2 and Avi-BMI1ΔRing constructs using 
Fugene 6 (Roche) transfection agent. Cells were harvested by centrifugation 48 hours after 
transfection and lysed through sonication in lysis buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 
1 mM EDTA, 2.5 mM EGTA, 1 mM NEM, 1 mM NaF,  0.1 M Na3VO4, 10% glycerol, 0.1 mM 
β-glycerophospate, 0.01% NP-40) with protease inhibitor cocktail (Sigma). Lysate was clarified 
by centrifugation and 10% total volume of whole cell lysate was taken as input. Streptavidin 
magnetic beads (Pierce) were added to each sample and incubated at 4°C with rotation for 16 
hours. Beads were washed 4 times with wash buffer (20 mM Tris, pH 8.0, 300 mM KCl, 1 mM 
EDTA, 10% glycerol, 0.1% NP-40) with protease inhibitor cocktail (Sigma) and proteins were 
eluted with SDS in wash buffer. Samples were analyzed by SDS-Page and Western blotting 
probed with either myc antibody (Cell Signaling) or BMI1 antibody (Millipore).  
Cellular proliferation  
50,000 U2OS cells were transfected with 50nM of Control or BMI1 siRNA (Dharmacon) 
using lipofectamine RNAiMax (Life Technologies) and incubated for 48 hours. After incubation, 
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the medium was replaced with incomplete medium and BMI1 siRNA transfected cells were 
transfected with BMI1 WT and mutant constructs were transfected using Lipofectamine 2000 
(Life Technologies). To count cell numbers at 24, 48, 96 and 120 hours after transfection, cells 
were washed, trypsinized and live cells were counted at different time intervals using Tryphan 
Blue staining. At the end of the each time point whole cell lysates were harvested and protein 
levels visualized by Western blot. 
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Chapter 3: High-throughput Screening to Identify Inhibitors of the 
BMI1-PHC2 Protein-Protein Interaction 
 
This chapter contains proprietary data 
A. Abstract 
BMI1 has been identified as an oncogenic factor in many solid and blood cancers and is 
suggested to be a novel target for small molecule inhibitor development. BMI1 is best 
characterized as a member of the canonical polycomb repressive complex 1 where it serves as a 
scaffolding protein mediating multiple protein-protein interactions. Thus a challenge in 
inhibiting BMI1 is identifying an appropriate approach to target this protein. One opportunity is 
through disruption of the BMI1-PHC2 protein-protein interaction characterized in Chapter 2. 
Here we present the development of two biochemical assays monitoring this interaction that are 
suitable for high-throughput screening (HTS). These assays were employed in a HTS campaign 
with the University of Michigan Center for Chemical Genomics screening ~ 150,000 diverse 
small molecules. From these screening efforts we identified three classes of small molecules that 
bind directly to BMI1, paving the way towards development of inhibitors of the BMI1-PHC2 
protein-protein interaction.  
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B. Background 
B.1. Rationale for developing small molecule inhibitors of BMI1-PHC2 protein-protein 
interaction 
 As discussed in Chapter 1, polycomb proteins are important oncogenic factors in many 
cancers and as such have been identified as potential targets for therapy development.1 BMI1 in 
particular represents a novel therapeutic target in many diseases. Previous studies using genetic 
inhibition demonstrated that knockdown of BMI1 reduces proliferation of many cancer cells 
including ex vivo models of gastric carcinoma,2 hepatocellular carcinoma,3-5 breast cancer,6 
colorectal cancer,7 multiple myeloma8 and acute myeloid leukemia.9,10 Further, loss of BMI1 
reduces the tumorigenic potential of cancer initiating cells in models for acute myeloid 
leukemia9,10 and colorectal cancer7 demonstrating that targeting BMI1 may be a strategy to 
inhibit cancer cell populations that are resistant to current chemotherapeutics and that drive 
tumor relapse.11  
While these studies using BMI1 knockdown demonstrate the potential therapeutic benefit 
of inhibiting BMI1 they do not suggest the best strategy for targeting this protein. Indeed, the 
hematopoietic and skeletal abnormalities of BMI1 knockout mice demonstrate a critical role of 
BMI1 in regulating normal cellular processes,12-16 including normal hematopoiesis,9 demonstrate 
that targeted approaches to disrupt select BMI1 function are needed.  As described in Chapter 2 
BMI1 mediates multiple protein-protein interactions within the PRC1 complex providing 
multiple opportunities to selectively modulate BMI1 function. We further demonstrated in 
Chapter 2 that disruption of the BMI1-PHC2 interaction decreases cellular proliferation of U2OS 
cells. These data support a campaign to develop small molecule inhibitors of the BMI1 ULD by 
disrupting the BMI1-PHC2 protein-protein interaction as an approach to regulate BMI1 function.  
B.2. Is the BMI1-PHC2 interaction a good target for disruption with small molecules? 
We have provided a detailed structural and functional characterization of the BMI1-
PHC2 interaction in Chapter 2. These studies provide valuable insight into the molecular basis 
for this interaction and suggest that this interaction is promising for inhibitor development for a 
number of reasons. First, the BMI1-PHC2 PPI is between the globular BMI1 ULD domain and a 
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peptide fragment of PHC2 which buries 1,338 Å2 of accessible surface area (Figure 3.1). This 
category of PPI is recognized as amenable to orthosteric small molecule inhibition as there is one 
protein-protein interface and there may be potential small molecule binding pockets at the 
interface.17  
 
Figure 3.1. BMI1-PHC2 interface is an attractive target for small molecule inhibitors. 
Surface representation of BMI1-PHC2 complex. 
Second, the BMI1-PHC2 interface is quite hydrophobic, a feature which generally 
supports high affinity small molecule ligand binding. The PHC2 β-hairpin encloses the 
hydrophobic core of BMI1 which forms a groove that may be amenable to small molecule 
binding (Figure 3.2). Third, with the exception of the BMI1 Arg165 and His174 residues which 
form critical polar interactions, the BMI1-PHC2 interface lacks charged residues (Figure 3.2). 
However, an intriguing aspect of the BMI1-PHC2 interaction is the presence of a buried 
glutamate in PHC2 (Glu45) which extends into a slightly basic surface formed by BMI1 Lys182. 
This feature suggests that molecules with acidic groups may appropriately mimic this interaction 
for potent inhibition. Finally, our solution NMR studies suggest that the apo BMI1 structure is 
perturbed upon binding of PHC2, indicating the presence of conformational dynamics for this 
domain. This is encouraging for inhibitor development as there may be protein conformations 
amenable to ligand binding that are not apparent in the crystal structure of the domain.  
75 
 
Together, this analysis suggests that the BMI1-PHC2 interaction is a favorable target for 
small molecule inhibitor development. 
B.3. Biochemical assays and high-throughput screening strategy 
Many recent reviews have highlighted the role of robust, solution phase biochemical 
assays as screening platforms for protein-protein interactions.18-20 In a high-throughput screening 
(HTS) campaign these assays serve to quantify the protein-protein interaction in the presence of 
small molecules cataloged in compound libraries. PPI inhibitors are thus identified through 
change of assay signal compared to positive and negative control samples. To identify inhibitors 
of the BMI1-PHC2 interaction we designed two biochemical assays for the BMI1-PHC2 
interaction that are amenable for HTS: fluorescence polarization and AlphaLISA. 
Fluorescence polarization (FP) is a common bioassay for binary interactions.21,22 In this 
system one binding partner (protein, peptide, nucleotide or tracer molecule) is labeled with a 
 
Figure 3.2. Features of BMI1-PHC2 interaction with relevance for drug discovery.  
Surface electrostatic potential representation of BMI1 with PHC2 shown as cyan cartoon and 
buried Glu45 labeled. The hydrophobic core of BMI1 is shown in white. 
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fluorophore which when free in solution tumbles rapidly and emission light is depolarized. 
Addition of a larger molecular weight binding partner slows this tumbling and emission light is 
polarized. The degree of light polarization is thus a direct readout of the interaction. This system 
has many advantages in a high-throughput screening setting: 1) the assay is not sensitive to 
environmental changes such as temperature and pH; 2) the degree of polarization is independent 
of dye concentration thus allowing good sensitivity with low concentrations of material; 3) 
modern instruments have very precise measurement of polarization thus FP assays tend to have 
good assay reproducibility and sensitivity and; 4) modern fluorophore labeling methods make 
development of the assay relatively straightforward and cost effective to develop and utilize. 
To eliminate false-positive compounds that are potentially interfering with the primary 
screen we developed a secondary screening assay using an independent technology; the 
PerkinElmer AlphaLISA chemiluminescent assay.23 In this assay tagged proteins of interest are 
mixed with antibody conjugated AlphaLISA beads that are themselves conjugated to light 
sensitive dyes. Excitation of the donor bead at 680 nm results in release of singlet oxygen and if 
the acceptor bead is within ~1,000 Å the singlet oxygen is transferred to the acceptor bead 
resulting in AlphaLISA signal at 615 nm. Thus, AlphaLISA signal is a function of the proximity 
of the protein binding partners and disruption of this interaction results in signal decrease. While 
more sensitive to environmental conditions and assay interference by fluorescent compounds 
than the FP assay, positive aspects of the AlphaLISA system for high-throughput screening 
include: 1) homogeneous, no-wash set up which minimizes the number of assay steps leading to 
robust reproducibility; 2) large dynamic range from low bead concentrations therefore resulting 
in low background signal and; 3) applicability to low or moderate affinity interactions due to the 
conjugation of multiple antibodies to each donor or acceptor bead thus amplifying the signal.24  
Prior to investing in a HTS campaign it is necessary to evaluate the statistical robustness 
of proposed screening assays. To assess the quality of our assays we relied on three metrics: 
signal-to-noise (S/N), the coefficient of variance (CV)25 and the Z-factor.26 The S/N is calculated 
as the ratio of the raw signal of positive controls with all assay components to the signal of 
negative controls without protein targets. CV is a percentage measurement calculated by the ratio 
of the standard deviation to the mean and is interpreted as variation between measurements. 
Lower CVs thus signify lower variability. The final statistic reporting on assay robustness is the 
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Z-factor. This parameter is calculated from the S/N between positive and negative controls and 
the standard deviation of both controls (Equation 3.1). This term is reported from 0-1 and assays 
with Z-factors greater than 0.5 are considered acceptable for high-throughput screening.  
Z-factor = 1 − ()



 
Equation 3.1. Z-factor calculation 
Through application of these assays in an HTS campaign we aim to identify lead 
compounds that inhibit the BMI1-PHC2 interaction and can be optimized through medicinal 
chemistry to develop a quality chemical probe or clinical candidate. 
C. Results 
C.1. BMI1 -PHC2 Biochemical Assay Development  
C.1.1 Fluorescence Polarization Assay 
We developed a fluorescence-polarization assay to monitor the direct interaction between 
the BMI1 and PHC2 proteins in solution. A scheme of this assay is illustrated in Figure 3.3. In 
this system, recombinant BMI1 ULD was expressed with a thioredoxin (trx) tag. The trx tag was 
retained, essentially doubling the molecular weight of the protein, in order to achieve the greatest 
assay dynamic range.  
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 First, we performed titration of BMI1 ULD constructs with the fluorescein-labelled 
PHC231-62 (FITC-PHC2) to determine the affinity of the interaction in this platform (Figure 
3.4.A). The binding affinity of BMI1 ULD to PHC2 interaction in this assay is 216 nM, 
comparable to ITC measurements (Chapter 2). We also confirmed that the trx tag does not 
contribute to the affinity of the BMI1-PHC2 interaction but does increase the assay dynamic 
range by ~30% (Figure 3.4.A). For assay validation we performed a competition experiment 
titrating with untagged PHC232-61 competitor. The dose-dependent decrease in polarization 
following addition of the competitor (IC50 of 684 ± 106 nM), indicates that this assay is sensitive 
to disruption of the BMI1-PHC2 complex and is applicable for inhibitor screening (Figure 
3.4.B). 
 
Figure 3.3. Scheme of fluorescence polarization assay for BMI1-PHC2 interaction. 
In the absence of trx-BMI1 binding partner, FITC-PHC2 tumbles freely and emitted light is 
depolarized. Addition of trx-BMI1 causes dose-dependent increase in polarization. 
Competition of this interaction with small molecules subsequently decreases polarization.  
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Figure 3.4. Development of fluorescence polarization assay for HTS. 
A. Representative fluorescence polarization experiments titrating FITC-PHC2 with trx-tagged 
or untagged BMI1 ULD constructs or with trx-tag. B. Fluorescence polarization experiment 
titrating PHC232-61 competitor. In both graphs, error bars are standard deviation of two 
technical replicates. KD and IC50 are reported as average and standard deviation from three 
independent experiments. 
This assay was optimized in a low volume (15 µL) format appropriate for high-
throughput screening. We tested the performance and reproducibility of the assay using a multi-
drop liquid dispenser and 384-well plate with multiple replicates of the positive control (100% 
inhibition- FITC-PHC2 alone) and of the negative control (no inhibition, trx- BMI1 ULD with 
FITC-PHC2). All controls contained a final DMSO concentration of 1.7%. This data were used 
to calculate the Z-factor (equation 3.1). Under optimized pre-HTS conditions the Z-factor was 
0.83, indicative of a high quality assay. Compared to buffer controls, the assay had a 3-fold 
signal-to-noise, which is acceptable for fluorescence polarization assays. Statistics for this assay 
are summarized in Figure 3.5.A. Thus this fluorescence polarization assay is appropriate for 
high-throughput screening and we employed this as the primary assay in our HTS campaign 
(Figure 3.5.B). 
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A. 
 
B.  
 
Figure 3.5. FP Assay Performance. 
A. Pre-screening quality statistics for BMI1-PHC2 FP Assay. B.  Scatter plot of FP assay data 
from one day of screening at the University of Michigan CCG (plates 37801-37815) showing 
positive controls (red), negative controls (blue) and compound wells (green). Z’ is indicated in 
purple on the right axis. 
Signal-to-
noise 3.2 
Coefficient of 
variance (%) 1.7 
 Z-factor 0.83 
C.1.2. AlphaLISA Assay Development 
The AlphaLISA assay developed for the BMI1-PHC2 PPI was designed with N-
terminally tagged His6-trx-PHC21-79 (His-PHC2) and N-terminal FLAG tagged BMI1 ULD 
(FLAG-BMI1).  When FLAG-BMI1 and His-PHC2
 
are in complex the Ni-chelate donor and 
anti-FLAG acceptor beads are in close proximity and maximum signal is achieved. However, 
inhibition of the FLAG-BMI1- His-PHC2 interaction by small molecules or protein competitors 
causes a dose-dependent decrease in Alpha signal. This assay is illustrated in Figure 3.6.  
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Figure 3.6. Scheme of AlphaLISA assay for BMI1-PHC2 interaction. 
To validate this assay we tested competition with both untagged BMI1 ULD and with 
PHC232-61 peptide. Addition of these competitors to mixtures reduced Alpha signal in a dose-
dependent manner where IC50= 354 ± 77 nM and 404 ± 132 nM for BMI1 ULD and PHC2 
peptide respectively (Figure 3.7). This assay was optimized in a miniaturized 384-well format 
and the Z’ for the assay was determined to be 0.87 (positive control: FLAG-BMI1 + anti-FLAG 
acceptor beads; negative control: all protein and bead components). All controls contained 1.7% 
DMSO. Compared to buffer controls, the assay had a signal-to-noise of 16. Statistics for this 
assay are summarized in Figure 3.8.A. 
82 
 
 
Figure 3.7. Competition experiments of AlphaLISA assay. 
Representative AlphaLISA experiment titrating untagged PHC232-61 (left) or BMI1 (right) 
competitor. Error bars are standard deviation of two technical replicates and IC50 is reported 
as average and standard deviation from two independent experiments performed in duplicate.  
Figure 3.8. Quality assessment of BMI1-PHC2 AlphaLISA Assay 
A. Pre-screening quality statistics for BMI1-PHC2 AlphaLISA Assay. B.  Scatter plot of FP 
assay data from control plate showing positive controls (red) and negative controls (blue). 
Based on the assays and metrics described we performed high-throughput screening to 
identify small molecule inhibitors of the BMI1-PHC2 interaction. HTS had three stages: primary 
screening with single point measurements, confirmation screening retesting active compounds in 
triplicate and dose-response screening with compound titration performed in two orthogonal 
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assays. Subsequently, active compounds were evaluated for direct protein binding, compound 
mechanism of action was assessed by NMR spectroscopy and mass spectrometry and limited 
SAR-by-catalog was performed. 
C.2. Primary Screening 
We performed HTS at the Center for Chemical Genomics (CCG) at the University of 
Michigan. For screening we selected commercial libraries from Chembridge, ChemDiv and 
Maybridge with most compounds meeting standard molecular weight, solubility and hydrogen 
bonding requirements for lead-like compounds. Some small libraries within the collection 
contained known pharmacologically active or FDA approved drugs. In total, 147,943 compounds 
were screened in the primary screen. Compounds were screened at an approximate concentration 
of 33 µM with 1.7% DMSO delivered by pintool.  
We defined hits as those with activity greater than 2.5 standard deviations from the mean 
of the negative control or had at least 12.5% inhibition. This selection criteria allowed us to 
identify even weak inhibitors of the interaction which could be used as scaffolds for future 
medicinal chemistry efforts to design more potent inhibitors. From this selection we removed 
compounds with molecular weight greater than 700 Da, with evident fluorescence interference 
and promiscuous activity in other biochemical screens performed at the CCG. Applying this 
criteria we identified 1,500 active compounds giving a ~1% overall hit ratio for the primary 
screen. These active compounds were then subjected to confirmation screening. 
C.3. Confirmation Screening 
To validate activity of hits identified in primary screening we tested the 1,500 active 
compounds in triplicate at 33 µM with the FP assay. Active compounds were selected based on 
activity in both the primary and confirmation screen and we defined hits as those with greater 
than 12.5% inhibition or 2.5 times the standard deviation of the negative controls for at least 3 
points. Applying this criteria and filtering out compounds with undesirable reactive groups a 
total of 360 compounds were selected for dose response, a 24% confirmation rate. Figure 3.9 
shows activity correlation between the primary and confirmation screens.  
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Figure 3.9. Comparing compound activity in confirmation screening. 
Correlation plot of compound activity in primary screen vs. confirmation screen. Compounds 
selected for dose-response screening are boxed in red box. 
C.4. Dose Response Measurements 
To test dose-dependent activity of the 360 selected compounds and determine IC50 values 
titration experiments were performed in an 8-point, 2-fold dilution series starting at 100 µM 
concentration, followed by sigmoidal curve fitting analysis. Active compounds were defined as 
those with IC50 less than 100 µM, minimal evidence of compound aggregation, precipitation or 
other assay interference. Applying these criteria, 180 compounds were selected for dose-
dependent screening using the secondary AlphaLISA assay described above. In a similar titration 
experiment, 154 compounds (85%) showed dose-dependent activity. Active compounds were 
manually inspected and 60 compounds were selected for in-lab follow-up using fresh powder 
ordered directly from the vendor. A breakdown of the overall HTS screening campaign is shown 
in Figure 3.10. 
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Figure 3.10. Summary of HTS. 
D.R. = dose response. 
C.5. Characterization of active compounds 
Following the HTS campaign we selected 60 active compounds for follow up in in-lab 
experiments including testing freshly ordered powder in biochemical assays and validating direct 
binding to BMI1 by NMR spectroscopy. Through these efforts, we identified three classes of 
compounds (BI-1; BI-2 and BI-3) that inhibit the BMI1-PHC2 interaction (Figure 3.11, Table 
3.1). These fresh compounds exhibited low to high micromolar inhibition in the FP assay. 
Generally, the activity of fresh compounds did not correlate well with activity in the HTS 
campaign, suggesting that the compound age affected the potency of the inhibitors. However, 
these molecules are promising starting points for the development of optimized inhibitors.  
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Figure 3.11. Validation of HTS hits from fresh powder. 
Fluorescence polarization assay with trx-BMI1 and FITC-PHC2 titrated with active 
compounds from HTS that were reordered from commercial sources. Representative 
experiments are shown and error bars are the standard deviation of two technical replicates; 
IC50 is reported as average and standard deviation from at least two independent experiments.  
Table 3.1. Confirmed hits from HTS campaign that bind directly to BMI1 ULD. 
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C5.1. Class 1 BMI1-PHC2 inhibitors 
C.5.1.1. Structure Activity Relationship 
Class 1 inhibitors feature an amino-thiazole core. The parent compound (BI-1-1) has high 
micromolar activity in the FP assay (IC50 = 765 ± 83 µM) and structure-activity relationship 
studies were pursued through commercially available analogs. All analogs were tested for 
activity in the fluorescence polarization assay (Table 3.2).  
The weak inhibition of BI-1-2 and BI-1-8 in the fluorescence polarization assay 
demonstrates the criticality of the 1,3-dichloro substitution on the phenyl ring. BI-1-2 lacks 
chloro substitution at the 1 position and BI-1-8 is mono-substituted at the 3 position with a 
methoxy group. From the greater than 2-fold reduced activity for these compounds we concluded 
that the hydrophobic chloro groups contribute greatly to compound activity and substitution with 
other similar groups may help drive potency. Compounds lacking the acidic moiety, BI-1-3 and 
BI-1-9, were not soluble in buffer even at moderate concentrations (as determined by NMR). 
Therefore the role of this functionality in the activity of these compounds cannot be empirically 
determined.  
Compounds BI-1-4, BI-1-5, BI-1-6 and BI-1-7 test the role of the rigid bicyclic group. 
BI-1-4 which features a cyclohexyl group, and therefore has considerably greater conformational 
flexibility, does not have significantly different activity than the parent compound (IC50 = 765 
µM vs 734 µM). BI-1-5 has an unsaturated cyclohexene moiety which improves potency 
compared to a saturated cyclohexyl in BI-1-1, suggesting that ring conformation is not critical 
for potency. Interestingly, BI-1-6 and BI-1-7 which also have greater conformational flexibility 
than BI-1-1 due to the addition of the extra carbon in the bicyclic ring (BI-1-6) or the five-
membered ring with exocyclic aliphatic chain (BI-1-7), both have significantly improved 
activities (IC50 = 37 and 219 µM, respectively) relative to the parent compound. The SAR 
reported here suggests that increased hydrophobicity in this region of the molecule improves 
potency and that ring conformation is not the most important considerations for this motif. The 
most potent compound, BI-1-6 is 20-times more potent than the parent, demonstrating that future 
SAR studies may further improve these inhibitors.  
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Table 3.2. Structure-activity-relationship for BI-1 series of inhibitors. 
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C.5.1.2. Compound mechanism of action by NMR 
To test direct binding of active compounds from HTS to BMI1 ULD we turned to NMR 
spectroscopy. Through the structural studies in Chapter 2, 82% of visible resonances for 
backbone amides of BMI1 ULD were assigned using triple resonance experiments. Many 
residues with missing backbone amide assignment are in the PHC2 binding site; in particular the 
β1 strand which forms one side of the binding site is unassigned. However, there are 5 methyl-
containing amino acids in the PHC2 binding site thus methyl groups can serve as probes for this 
site in the absence of complete backbone amide assignment. We used 1H-15N and 1H-13C-HSQC 
binding experiments to rapidly assess of direct binding of compounds to BMI1 ULD as well as to 
localize the compound binding site on the protein. 
 
Figure 3.12. BI-1-1 binds directly to BMI1 ULD. 
Selections of 1H-15N HSQC spectra of apo BMI1 ULD (black) or with 100 µM BI-1-1 
(magenta). Resonance assignments are labeled and directions of chemical shift perturbation are 
shown with arrows.  
The 1H-15N HSQC spectrum of BMI1 in the presence of BI-1-1 showed a distinct set of 
chemical shift perturbations as illustrated in Figure 3.12. All active analogs in the BI-1 series 
showed similar chemical shift perturbations regardless of their activity in the fluorescence 
polarization assay. This led us to speculate that backbone amides in the protein may not be very 
90 
 
sensitive to compound binding in this case and that methyl groups might be more informative. 
Therefore 1H-13C HSQC spectra were recorded for BMI1 in complex with BI-1-7. In this spectra, 
two leucine and methionine resonances are affected with compound binding (Figure 3.13.A).  
 
Figure 3.13. BI-1-7 binding site mapping by NMR spectroscopy. 
A: Selection of 1H-13C HSQC spectrum of apo BMI1 ULD (red/green) or with 200 µM BI-1-7 
(dark blue/cyan). Resonances in the leucine and methionine regions of the spectrum that are 
affected are circled and direction of chemical shift perturbation are shown with aarows. B: 
Magnitude of chemical shift perturbations from 1H-15N HSQC binding experiment with 0.5 
mM equivalents of BI-1-7 are mapped onto the BMI1 ULD structure. The PHC2 binding site 
is between the β1 and α1 structural elements. Methionine and leucine residues in the PHC2 
binding site are labeled. The 1H-13C NMR experiments were performed by Jon Pollock.  
Using the amide backbone assignment of the BMI1 ULD we mapped the 1H-15N HSQC 
chemical shift perturbations from BI-1-7 onto the BMI1 ULD structure. This demonstrates that 
the BI-1 series compounds bind to the PHC2 binding site, as illustrated in Figure 3.13.B. 
Additionally, there are two methionines and three leucine residues in the PHC2 binding site, 
which may correspond to the resonances perturbed in 1H-13C HSQC binding experiments. 
Together the data from two NMR methods demonstrates direct binding of this class of inhibitors 
to BMI1 ULD and suggests an orthostatic mechanism of inhibition through binding to the PHC2 
binding site in BMI1.   
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C.5.2. Class 2 BMI1-PHC2 inhibitors 
The BI-2 class of BMI1 inhibitors features a benzamide core with a methylsulfone-
substituted pyrimidine tail group. BI-2 has low micromolar activity in the fluorescence 
polarization assay (IC50 = 8.2 ± 6.7 µM). Eighteen BI-2 analogs were purchased from 
commercial sources and most had similar low to mid micromolar IC50 (experiments performed 
by Jon Pollock, data not shown). NMR binding experiments with BI-2 show significant chemical 
shift perturbations in slow exchange regime (Figure 3.14.A). Mapping of these perturbations 
onto the BMI1 ULD structure show the significant changes at the C-terminus of the protein 
(Figure 3.14.B). The strong effects of these compounds on BMI1 ULD spectra hinted that these 
compounds may be covalently modifying the protein. 
 
Figure 3.14. BI-2 binding site mapping by NMR spectroscopy. 
A: Selection of 1H-15N HSQC spectrum of apo BMI1 ULD (black) or with 100 µM BI-2 (red). 
Perturbed residues are labeled and directions of chemical shift perturbation are shown with 
arrows. B: Magnitude of chemical shift perturbations from the experiment on the left are 
mapped onto the BMI1 ULD structure. Residues that are broadened with compound addition 
are shown as spheres. The covalently modified cysteine residue is labelled.  
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Mass spectrometry studies by my colleague Jon Pollock indeed showed covalent 
modification of BMI1 by this class of molecules with the addition of 394 Da in molecular weight 
corresponding to single site modification. We suspected that this molecule may be covalently 
modifying the protein at a cysteine residue.  BMI1 has two cysteines, one is solvent-exposed at 
the C-terminus of the protein (Cys231) and the other is in the BMI1 binding site (Cys166). To 
identify which site was being modified we generated Cys231 to alanine mutant protein. By mass 
spectrometry and NMR there was little to no modification of the mutant protein suggesting that 
the C-terminal cysteine was the primary target (data not shown). Investigation into the 
mechanism of action for these compounds indicates that this reaction proceeds via nucleophilic 
aromatic substitution with the cysteine substituting for the methylsulfone leaving group in a 
reaction recently characterized by Guan et al.27 Indeed, analogs lacking the methylsulfone 
pyrimidine did not show any inhibition in the FP assay (data not shown).   
C.5.3. Class 3 BMI1-PHC2 inhibitors 
The class 3 BMI1-PHC2 inhibitor is a cyclopentaquinoline fragment and compound has 
mid-micromolar activity (IC50 = 229 ± 133 µM; Table 3.1). 1H-15N HSQC NMR binding 
experiments suggest that this compound weakly interacts with the BMI1 ULD (Figure 3.15.A). 
Chemical shift mapping onto the BMI1 structure illustrates only very weak chemical shift 
perturbations with no localized cluster of perturbed resonances (Figure 3.15.B).  
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Figure 3.15. BI-3 binding site mapping by NMR spectroscopy. 
A: Selections of 1H-15N HSQC spectrum of apo BMI1 ULD (black) or with 0.5 mM or 2 mM 
equivalents of BI-3 (magenta or dark blue, respectively). Perturbed residues are labeled and 
directions of chemical shift perturbation are shown with arrows. B: Magnitude of chemical 
shift perturbations with 0.5 mM of BI-3 are mapped onto the BMI1 ULD structure. The PHC2 
binding site is between the β1 and α1 structural elements. 
While the BI-3 molecule had only weak activity, we are encouraged by the structural 
features of this molecule which may mimic the contacts between BMI1 and PHC2. The 
hydrophobic ring system may bind in the hydrophobic core of BMI1 ULD and similar to the BI-
1 series, the tail carboxylic acid may replace the buried PHC2 Glu45. Further, the direct 
interaction of BI-3 with BMI1 observed in NMR experiments and inhibitory activity in the FP 
assay is promising as it suggests that BMI1 can bind low-molecular weight fragment-like 
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ligands. This supports future directions for the identification of BMI1 inhibitors using fragment-
based approaches. 
D.   Discussion and Conclusions 
In this Chapter we present our efforts to identify small molecule inhibitors of the BMI1-
PHC2 interaction through high-throughput screening. We developed two orthogonal screening 
assays using the fluorescence polarization and AlphaLISA platforms, each of which showed 
good performance in pre-HTS testing with Z-factors greater than 0.8. Using the fluorescence 
polarization assay we screened almost 150,000 compounds from chemically diverse libraries. 
This assay had a hit rate of 1% which allowed follow up of even weak inhibitors in an effort to 
obtain chemical scaffolds that could be improved through medicinal chemistry. Use of the 
AlphaLISA assay in dose-response screening allowed the elimination of many false positives and 
the identification of the most promising compounds for follow up with fresh powder. 
Through these efforts we identified three classes of small molecules that disrupt the 
BMI1-PHC2 PPI with micromolar activity and bind directly to BMI1 ULD. These compounds 
represent three different approaches to inhibiting this interaction. Structure-activity-relationship 
studies of the BI-1 class of compounds identified BI-1-6 which inhibits the BMI1-PHC2 in vitro 
interaction with an IC50 of 37 µM, the most potent orthosteric inhibitor of the BMI1-PHC2 PPI 
identified thus far. NMR-based mapping studies suggest that this class of compounds bind to the 
BMI1 ULD domain at the PHC2 interface, demonstrating that this interface is amenable to small 
molecule binding. This series has a promising scaffold and future SAR studies may develop this 
series into potent inhibitors. Proposed modifications could test alkyl substitution of the phenyl 
ring, introduction of other bicyclic groups or replacement of the acid with different polar 
moieties such as sulfonamide or ester. Additionally, substantial scaffold modifications could be 
tested to determine the minimal pharmacophore and optimize the next set of ligands. Either 
crystallographic or solution structural studies with BMI1 ULD in complex with BI-1 inhibitors 
could greatly enhance these SAR efforts. 
The BI-2 class disrupts the BMI1-PHC2 interaction through covalent modification of a 
C-terminal cysteine suggesting the presence of an allosteric regulatory network between distal 
sites of the protein and the PHC2 binding site. The BI-3 class is a fragment-like ligand and direct 
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binding of this molecule to BMI1 ULD indicates that a fragment-based drug discovery approach 
yield other promising inhibitors for BMI1.  
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E. Experimental methods 
Plasmid construction. 
cDNA encoding full-length BMI1 and full-length PHC2_B was obtained from the Raul Lab 
(Department of Pathology, University of Michigan) and the desired constructs were subcloned 
into the pET32p bacterial expression vector using standard molecular biology techniques. The 
pET32p vector is a modified pET32a vector (Novagen) that contains a Precision Protease 
recognition sequence between a thioredoxin (trx) solubility tag and the target protein.  
Protein expression and purification 
BMI1 constructs:  All BMI1 proteins were expressed in Codon+ BL21 (DE3) E. coli cells 
(Sigma) with an N-terminal His6- thioredoxin tag (trx). Cells subjected to ampicillin (100 
µg/mL) selection were grown in Luria broth (Fisher) or labeled M9 medium (Marley 2001) at 
37°C (220 rpm) until OD600 reached 0.6-0.8. Incubation temperature was lowered to 18°C for 1 
hour then protein over-expression was induced with 0.5 mM (final concentration) Isopropyl β-D-
1-thiogalactopyranoside (IPTG; Gold Bio) for 16-18 hours at 18°C. Cells were lysed in a buffer 
containing 50 mM tris, pH 7.5 at 25°C, 250 mM NaCl, 20 mM Imidazole, 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM β-mercaptoethanol (β-ME) using a French Press. 
Clarified lysate was applied to a HisTrap HP (GE Healthcare) column using Äkta Prime FPLC 
and eluted with lysis buffer containing 0.5 M imidazole. To remove the His6- trx tag, the protein 
was cleaved with Precision protease and BMI1 ULD constructs were further purified using 
cation exchange chromatography. Purified protein solution was buffer exchanged into storage 
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buffer (100 mM bis tris, pH 6.5, 50 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine 
hydrocholoride (TCEP-HCl)) using HiPrep Desalting Column (GE Healthcare). Protein 
concentration was measured using absorbance at 280 nm. Protein identity and purity was verified 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein was flash 
frozen and stored at -80°C.   
15N-labeled BMI1 for NMR Spectroscopy: Protein was expressed as above with the exception 
of the use of the M9 minimal media supplemented with 15N ammonium sulfate (Cambridge 
Isotopes) and 15N Bioexpress (Cambridge Isotopes).28  
Table 3.3. Recipe for M9 minimal media for expression of 15N-labeled BMI1 ULD. 
Reagent Final 
Concentration 
Sodium phosphate (dibasic) 28 mM 
Potassium phosphate (monobasic) 14.7 mM 
Sodium chloride 8.5 mM 
Sodium sulfate 3 mM 
Biotin 1 mg/L 
Thiamin 1 mg/L 
Magnesium sulfate 1 mM 
Calcium chloride 3 mM 
15N ammonium sulfate 7.5 mM (1 g/L) 
Glucose 10 g/L 
PHC21-79. PHC21-79 protein was expressed in BL21 (DE3) E. coli cells (Sigma) with an N-
terminal His6- thioredoxin tag. Cells were subjected to ampicillin (100 µg/mL) selection and 
grown in Luria broth (Fisher) at 37°C (220 rpm) until OD600 reached 0.6-0.8. Incubation 
temperature was lowered to 18°C for 1 hour then protein over expression was induced with 0.5 
mM (final concentration) Isopropyl β-D-1-thiogalactopyranoside (IPTG; Gold Bio) for 16-18 
hours at 18°C. Cells were lysed in a buffer containing 50 mM tris, pH 7.5 at 25°C, 250 mM 
NaCl, 20 mM imidazole, 0.5mM PMSF, 1 mM β-ME using a French Press. Clarified lysate was 
applied to a HisTrap HP (GE Healthcare) column using Äkta Prime FPLC and eluted with lysis 
buffer containing 0.5 mM imidazole.  Trx-PHC21-79 protein was further purified by gel filtration 
on a Superdex S-75 column in buffer 50 mM phosphate, pH 6.5, 50 mM NaCl, 1 mM TCEP-
HCl. PHC2 was further purified by Superdex S75 gel filtration (GE Healthcare) pre-equilibrated 
with storage buffer (50 mM phosphate, pH 6.5, 50 mM NaCl, 1 mM TCEP). Protein 
concentration was measured using absorbance at 280 nm. Protein identity and purity was verified 
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by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein was flash 
frozen and stored at -80°C.  
Table 3.4. Summary of high-throughput screening campaign. 
Category 
Parameter Description 
Primary 
Assay 
Type of Assay 
In vitro fluorescence polarization (FP) 
competition assay 
Target 
BMI1
 
ULD (inhibition of the BMI1-PHC2 
interaction) 
Primary measurement Detection of fluorescence polarization signal 
Key reagents 
His-trx-BMI1, FITC-PHC2 (PHC2
 32-61) 
peptide, FP buffer: 100mM bis tris, 50mM 
NaCl, 1mM TCEP, 0.01% BSA, 0.025% 
tween-20, pH 7.25 
Assay protocol Described in methods section 
Library 
Library size 147,943 
Library composition 
Maybridge HitFinder, Chembridge custom 
collection of small molecules, ChemDiv 
custom collection of small molecules, Library 
of Pharmacologically Active Compounds 
(LOPAC- Sigma Aldrich), Prestwick 
Chemical Library, BioFocus NIH Clinical 
Collection, MicroSource Spectrum Collection 
Source 
Center for Chemical Genomics (CCG), 
University of Michigan 
Screen 
Format 384-well, Corning 3676 
Concentration tested 33 µM, 1.7% DMSO 
Plate controls 
NC: His-trx BMI1, FITC-PHC2; PC: FITC-
PHC2 
Reagent/compound 
dispensing system 
Biomek FX, Beckman 
Detection instrument and 
software 
PHERAstar, BMG 
Assay validation/QZ Z’=0.83; Mean FP for NC=129 mP, SD=8 mP; Mean FP for PC=35 mP, SD=5 mP 
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Normalization 
% inhibition= 100 x (average of FP for 
negative control – FP for sample)/(average of 
FP for negative control- average of FP for 
positive control) 
Post-HTS 
analysis 
Hit criteria 
 
Change in FP signal ≥ 2.5 standard deviations 
from mean of negative control OR 12.5% 
active 
Hit rate 1% 
Additional assay(s) 
AlphaLISA with FLAG-BMI1 and His6-trx-
PHC21-79, NMR 1H-15N HSQC to validate 
direct binding of compounds to BMI1 ULD 
Confirmation of hit purity 
and structure 
Compounds were repurchased from 
Maybridge, Chembridge and ChemDiv and 
verified analytically 
Fluorescence Polarization Assay: Development and High-Throughput Screening 
Fluorescence Polarization Assay Development 
Fluorescence Polarization Assay to Determine BMI1-PHC2 Affinity: The fluorescein-labeled 
peptide probe (FITC-PHC2) (FITC-PQILTHVIEGFVIQEGAEPFPVGRSSLLVGN- NH2) was 
purchased from Genscript. The probe was dissolved in storage buffer (100 mM bis tris, pH 6.5, 
50 mM NaCl, 1 mM TCEP) to a concentration of 1 mM and stored at -20°C. For the assay, the 
probe was diluted to 80 nM in FP assay buffer (100 mM bis tris, pH 7.25, 50 mM NaCl, 1 mM 
TCEP, 0.01% bovine serum albumin, 0.025% (v/v) Tween-20). Then 10 μL of probe solution 
was added to a series of 30 μL solutions of varying concentrations of His6-trx BMI1 in FP assay 
buffer (100 mM bis tris, pH 7.25, 50 mM NaCl, 1 mM TCEP, 0.01% bovine serum albumin, 
0.025% (v/v) Tween-20) to obtain a final concentration of up to 25 μM. Samples were incubated 
for 1 hour at room temperature in the dark before 15 μL samples were plated onto assay plate 
(Corning #3676).  Changes in fluorescence polarization and anisotropy were measured at 525 nm 
after excitation at 495 nm using PHERAstar microplate reader (BMG). Data fit with a sigmoidal 
dose-response equation were used to assess BMI1 ULD construct binding with the Prism 4.0 
(GraphPad) program. 
Fluorescence Polarization Competition Assay with PHC2 peptide or compound: FITC-
PHC2 was mixed with trx-BMI1 at 40 nM and 1 μM, respectively, in FP assay buffer (100 mM 
bis tris, pH 7.25, 50 mM NaCl, 1 mM TCEP, 0.01% bovine serum albumin, 0.025% (v/v) 
Tween-20). This protein-probe mix was then mixed 1:1 with competitor stocks of varying 
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concentrations for a final probe concentration of 20 nM and final protein concentration of 0.5 
μM and 5% DMSO in all reactions. Samples were incubated for 1 hour at room temperature in 
the dark before 15 μL samples in duplicate were plated onto assay plate (Corning #3676). 
Fluorescence polarization data was recorded and analyzed as above. Data fit with a one-site 
competition equation were used to assess inhibition with the Prism 4.0 (GraphPad) program. 
Fluorescence Polarization Assay in High-Throughput Screening 
Fluorescence polarization high-throughput primary and confirmation screening assay: 10 
μL of 0.75 μM His6-trx BMI1 in FP assay buffer (100 mM bis tris, pH 7.25, 50 mM NaCl, 1 mM 
TCEP, 0.01% bovine serum albumin, 0.025% (v/v) Tween-20) was dispensed to columns 1-22 of 
384-well assay plate (Corning 3676). Reagents were dispensed with a multidrop liquid dispenser 
(Thermo Scientific). 10 μL FP assay buffer was dispensed to columns 23, 24 of the plate. 
Compounds were added to columns 3-22 and DMSO was added to columns 1, 2, 23 and 24 of 
the plate using Biomek FX dual head (Beckman) robot equipped with a pintool. 5 μL of 60 nM 
FITC-PHC2 in FP assay buffer was added to all wells of the plate giving a final probe 
concentration of 20 nM and final protein concentration of 500 nM in a 15 μL reaction. Plates 
were incubated for 1 hour at room temperature in the dark. The degree of fluorescence 
polarization was measured by a PHERAstar microplate reader (BMG).  
Dose-response assay:  200 nL of compound with variable concentrations were pre-plated onto 
assay plates using a Mosquito X1 robot (TTP Labtech). His6-trx BMI1 and FITC-PHC2 were 
diluted into FP assay buffer to a final concentration of 500 nM and 20 nM respectively. 15 μL of 
the protein-probe mixture was dispensed to columns 1-22 of the assay plate. 15 μL of 20 nM 
FITC-PHC2 in assay buffer was dispensed to columns 23-24 of the assay plate. Incubation and 
measurement was performed as described above. 
AlphaLISA Assay: Development and High-Throughput Screening 
AlphaLISA Assay Development 
AlphaLISA Assay Development: FLAG-BMI1 and His6-PHC2 were mixed varying ratios and 
concentrations up to 1.5μM in AlphaLISA assay buffer (100 mM bis tris, pH 7.25, 50 mM NaCl, 
1 mM TCEP, 0.01% bovine serum albumin, 0.025% (v/v) Tween-20). AlphaLISA Ni-chelate 
donor beads and anti-FLAG acceptor beads (PerkinElmer) were each diluted 1:1,000 (v/v) in 
AlphaLISA buffer. 7.5 μL of protein mixture was mixed with 7.5 μL bead mixture in duplicates 
on PerkinElmer 384-well ProxiPlate PLUS for final protein concentrations up to 0.75 μM and 
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final bead concentrations of 1:2,000 (v/v). All pipetting with beads was done in the dark. 
Reactions were incubated for 1 hour at room temperature in the dark. Alpha signal (europium 
emission at 607-623nm) was measured as with the PHERAStar plate reader (BMG). Data fit 
with a sigmoidal dose-response equation were used to quantify the PPI by the Prism 4.0 
(GraphPad) program. 
AlphaLISA Assay with BMI1 protein or PHC232-61 Peptide Competition: FLAG-BMI1 and 
His6-PHC2 were mixed 1:1 at 1 μM final concentration in AlphaLISA assay buffer (100 mM bis 
tris, pH 7.25, 50 mM NaCl, 1 mM TCEP, 0.01% bovine serum albumin, 0.025% (v/v) Tween-
20). Protein mixture was incubated at room temperature for 30 minutes.  AlphaLISA Ni-chelate 
donor beads and anti-FLAG acceptor beads (PerkinElmer) were each diluted 1:1,000 (v/v) in 
protein mixture. 40 μL of protein-bead mixture was incubated with 40 μL of varying 
concentrations of the PHC232-61 peptide or BMI1 protein to obtain concentrations of up to 20 
μM. Reactions were incubated for 1 hour at room temperature in the dark. Duplicates of 15 μL 
per reaction were plated onto PerkinElmer 384-well ProxiPlate PLUS plate. Assay plates were 
quantified using excitation at 680 nm and europium emission at 615 nm as measured by 
Pherastar plate reader (BMG). Data were fit with a one-site competition equation were used to 
assess protein or peptide competition with the Prism 4.0 (GraphPad) program. 
AlphaLISA High-Throughput Screening 
High-throughput dose-response assay: 200 nL of compound with variable concentrations were 
pre-plated onto assay plates with a Mosquito X1 robot (TTP Labtech). FLAG- BMI1 and His-
PHC2
 
were diluted into AlphaLISA buffer (100 mM bis tris, pH 7.25, 50 mM NaCl, 1 mM 
TCEP, 0.01% bovine serum albumin, 0.025% (v/v) Tween-20) to a final concentration of 500 
nM each. Proteins were incubated on ice for 30 minutes. AlphaLISA Ni-chelate donor beads and 
anti-FLAG acceptor beads (PerkinElmer) were each diluted 1:2,000 (v/v) final concentration into 
protein mixture, protein-bead mixture was incubated on ice for 15 minutes. 15 μL of the protein-
bead mixture was dispensed to columns 1-22 of the assay plate (PerkinElmer 384-well 
ProxiPlate PLUS) using multidrop liquid dispenser (Thermo Scientific). 15 μL of 500 nM 
FLAG-BMI1 with 1:2,000 (v/v) anti-FLAG AlphaLISA acceptor beads in assay buffer was 
dispensed to columns 23-24 of the assay plate. Plates were incubated for 1 hour at room 
temperature in the dark. Alpha signal (europium emission at 607-623 nm) was measured as by 
Envision plate reader (Perkin Elmer).  
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NMR experiments 
All NMR experiments were performed on a Bruker Advance III 600-MHz spectrometer 
equipped with a 5 mM TCI cryogenic probe. All spectra were acquired at 30°C. Spectra were 
processed with NMRPipe29 and analyzed with Sparky.30  
Small molecule binding experiments. To test direct binding of compounds to BMI1 ULD, 
samples were prepared with 50 µM final  15N BMI1 concentration in NMR buffer (100 mM bis 
tris, 50 mM NaCl at pH 6.5, 1 mM TCEP) with 50, 100, or 500 µM final compound 
concentration in 5% final DMSO. All samples contained 7% D2O.   
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Chapter 4: Development of Small Molecule Inhibitors of 
Ring1B/BMI1 E3 Ubiquitin Ligase 
 
This chapter contains proprietary data 
A.  Abstract 
The polycomb proteins BMI1 and Ring1B have been identified as important oncogenic 
factors in many cancers. Genetic studies demonstrate that knockdown of these proteins slows or 
abolishes cancer cell proliferation and tumor growth in a number of tumor types indicating that 
they may be promising targets for small molecule therapeutic development. BMI1 and Ring1B 
function as a heterodimeric E3 ubiquitin ligase for nucleosomal histone H2A, 
monoubiquitinating lysine 119- a chromatin modification associated with repressed gene 
transcription. Here we present a strategy to modulate the enzymatic activity of this complex 
through the development of small molecules inhibitors of the Ring1B/BMI1 E3 ubiquitin ligase. 
To identify ligands directly binding to the Ring1B/BMI1 RING domain heterodimer we 
performed a NMR-based fragment screen. The most potent hit from this screen showed specific 
binding to the complex and weak (mM) inhibition of E3 ligase activity. Through an extensive 
medicinal chemistry campaign we optimized the small molecule fragment ligand into to a potent 
inhibitor with low micromolar affinity and in vitro inhibitory activity of nucleosome 
ubiquitination by Ring1B/BMI1. Based on NMR chemical shift mapping and mutagenesis 
studies we identified the ligand binding site as the nucleosome binding interface of the Ring1B 
protein. Binding of the inhibitors results in significant conformational change in Ring1B. As a 
consequence, the ligand-bound conformation is incompatible with nucleosome substrate binding 
preventing H2A ubiquitination. In cellular studies potent Ring1B/BMI1 inhibitors decrease 
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global ubiquitinated H2A levels. Overall, we have developed a highly novel inhibitor for the 
polycomb E3 ubiquitin ligase complex which can be used as a chemical tool to explore the role 
of these proteins in normal and cancer biology. 
B. Background 
Chapter 1 details the role of BMI1 in cancer and describes studies linking Ring1B/BMI1-
mediated H2A ubiquitination with transcriptional repression of key tumor suppressor genes.1-3 It 
has been shown that increased levels of ubiquitinated H2A is correlated with poor prognosis for 
patients with pancreatic cancer.4 Further, genetic knockdown studies demonstrate that loss of 
BMI1 leads to reduced tumor growth in mouse models of many solid and hematologic 
malignancies.5-15 Inhibiting the ubiquitin ligase activity of Ring1B/BMI1 E3 ligase activity may 
therefore be a promising approach for therapeutic intervention.  
B.2. Mechanism of protein ubiquitination 
Protein ubiquitination is a signaling mechanism in many cellular pathways including 
protein degradation, nuclear transport, endocytosis, gene expression and DNA repair.16 Ubiquitin 
is a small, 8.5 kilo Dalton, protein that can be post-translationally attached to substrate proteins 
through the formation of an isopeptide bond between the C-terminus of ubiquitin and a target 
lysine. Mechanistically, the ubiquitination cascade begins with ubiquitin activation by the E1 
enzyme which becomes covalently attached to ubiquitin at a catalytic cysteine through an ATP-
dependent step (Figure 4.1). Ubiquitin is transferred from the E1 to a receptor cysteine on the E2 
ubiquitin conjugating enzyme via a transthioesterification reaction.17 Ubiquitin is further 
transferred to substrate through interaction of E2 enzymes with E3 proteins which mediate 
substrate recognition. In the human genome there are only 9 E1 enzymes and 35 E2 enzymes, 
whereas there are hundreds of E3 enzymes;18 thus substrate specificity is achieved at the level of 
the E3. 19,20 
There are two structural families of E3 enzymes, the HECT domain family and the RING 
domain family which have unique mechanisms of transferring ubiquitin to substrate. The smaller 
class of E3s, the HECT family, accepts the ubiquitin molecule from the E2 and then transfers the 
ubiquitin to substrate.21,22 The larger class of E3s, the RING family has hundreds of family 
members. This class of E3s does not have ubiquitin transferred directly to them. Instead these 
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proteins serve as scaffolding proteins mediating the interaction between E2 and substrate. 
Structural studies have revealed that through distal contacts with the substrate RING E3s help to 
position the E2 catalytic cysteine above the substrate lysine facilitating formation of the 
isopeptide bond.23-25 Mechanistic studies suggest that RING E3s may also allosterically activate 
the E2 enzyme26,27  through contacts with the ubiquitin molecule to rearrange the E2 active site 
for activation of the substrate lysine.28,29  
The overall ubiquitin ligase cascade is shown in Figure 4.1.  
 
Figure 4.1. Overview of ubiquitination cascade.   
Potential sites for small molecule inhibition are shown in red. Adapted from Di Fiore, P.P. et 
al Nat. Rev. Mol. Cell Biol. 2003, 4, 491-497. 
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B.3. Ring1B/BMI1 E3 ligase structure and substrate specificity  
Within the PRC1 complex the Ring1B and BMI1 proteins each have N-terminal zinc-
finger RING domains.30,31 Each domain coordinates two zinc molecules through C3HC4 
coordination. The Ring1B RING domain is an active E3 ligase by itself, however the activity is 
enhanced through interaction with the BMI1 RING domain.31 The reverse is not true; the BMI1 
RING domain has no intrinsic E3 ligase activity31 and the role of this domain is likely to stabilize 
Ring1B, maintain ubiquitin in a transfer-ready conformation28,29 and facilitate substrate 
recognition.  
The Ring1B/BMI1 E3 ligase has a very narrow substrate profile; the canonical substrate 
is histone H2A lysine 119 in the context of the nucleosome. Ring1B/BMI1 lacks activity towards 
isolated histone octamer or H2A protein or peptide.32 The structural basis for this selectivity was 
revealed by McGinty and coworkers in a recently published crystal structure by of the 
Ring1B/BMI1-E2 “polycomb ubiquitination module” in complex with the nucleosome.23 These 
studies identified the major E3-substrate interface as localized to a highly basic region on 
Ring1B and the H2A/H2B acidic patch. The “nucleosome binding loop” in Ring1B, from 
residues 86-98, features 8 arginine or lysine residues. Key to nucleosome binding is the “arginine 
anchor,” Arg98, which extends into an acidic pocket formed by H2A residues Glu61, Asp90 and 
Glu92. Additionally, Ring1B Lys97 interacts with H2A residues Glu61 and Glu64. These two 
Ring1B residues contribute significantly to nucleosome binding as single alanine mutations at 
either position reduces nucleosome binding affinity by at least 50 fold.  Additional interactions 
between BMI1 and H3 and H4 histones and between the E2 (UbcH5c) and nucleosomal DNA 
further contribute to substrate binding. Through these structural studies it becomes clear that 
Ring1B/BMI1 would be unable to catalyze ubiquitination of histone octamer, isolated histone 
protein or peptide. 
There is suggestion in the literature that the topoisomerase Topα,33 p5310,34,35 and the 
ribonucleotide reductase M136 may also be Ring1B/BMI1 substrates, however these are not well 
validated and direct binding between the E3 complex and these substrates has not been 
demonstrated. 
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B.4. E3 ligases as targets for small molecule inhibitors  
B.4.1. Strategies to identify inhibitors of E3 ubiquitin ligases 
Given the large number of cellular processes regulated by protein ubiquitination there has 
been significant interest in developing small molecule inhibitors of this pathway as potential 
therapeutics for a wide range of diseases. The ubiquitin cascade provides many avenues for 
inhibitor development targeting either enzymatic activity or protein-protein interactions (Figure 
4.1).37,38 As there are very few E1 and E2 isozymes in the human genome E1 and E2 family 
members participate in many different ubiquitin pathways including the ubiquitin proteasome 
system.39 Therefore, small molecule inhibitors of these enzymes have non-specific cellular 
activity and can be considered general proteasome inhibitors. Thus, from a drug discovery 
standpoint targeting the E3 enzyme represents the most promising avenue for inhibiting 
ubiquitination in a specific cellular pathway.  
A challenge to identifying inhibitors of E3 ligases is the complexity of the biochemical 
process outlined above. Due to the multitude of enzymes, cofactors and protein-protein 
interactions required for this system, an activity-based screening campaign detecting 
ubiquitinylated substrate would likely identify inhibitors of other steps in the cascade. 
Deconvolution of such hits to identify specific E3 inhibitors would be lengthy and likely 
unfruitful.  
As RING domain E3s are not true enzymes and serve as scaffolding proteins, the tactic to 
inhibit these factors is through disruption of protein-protein interactions. Thus screening assays 
quantifying protein-protein interactions are required to identify inhibitors of these proteins in a 
high-throughput fashion. Förster resonance energy transfer (FRET) and fluorescence polarization 
(FP) assays have both been developed for E3 ubiquitin ligases.40,41 FRET-based assays sensitive 
to E3-ubiquitin, E3-substrate and ubiquitin-substrate interactions or the formation of poly-
ubiquitin chains are representative approaches for these systems.42-45 These assays have been 
applied as screening platforms for inhibitors of p53 ubiquitination by MDM2,46 and TRAF6 
catalyzed poly-ubiquitin chain formation.47 Similarly, a fluorescence polarization assay was used 
to screen inhibitors of the interaction between the SCF complex protein (Skp1-Cdc53/Cullin-F-
box, E3 ligase complex) Cdc4 and a fluorescently-labeled peptide substrate.48  
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B.4.2. Challenges identifying inhibitors of Ring1B/BMI1 
While the technologies discussed above represent unique approaches to identify E3 ligase 
inhibitors, these assays are not fully applicable to the Ring1B/BMI1 system as: i) nucleosomal 
substrate is required for ligase activity, production of which may be limiting for HTS; ii) the 
interaction between Ring1B/BMI1 – isolated H2A protein is weak and has not been detected in 
direct binding experiments precluding adaption of substrate peptide-based assays such as FP 
(Cierpicki lab, unpublished); iii) given that the Ring1B/BMI1 heterodimer only catalyzes mono-
ubiquitination assays detecting the creation of poly-ubiquitin chains are not applicable. In order 
to overcome these limitations of high-throughput screening systems and identify specific 
inhibitors of the Ring1B/BMI1 E3 ligase we turned to a fragment-based drug discovery 
approach.  
B.4.3. Fragment-based drug discovery 
The goal of fragment-based drug discovery is to identify small molecule ligands of a 
target protein with the aim of developing them into potent inhibitors through a medicinal 
chemistry campaign.49,50 In these screens, small libraries of compounds sampling diverse 
chemical space are screened using a biophysical method capable of detecting weak (mM) hits 
such as NMR spectroscopy, X-ray crystallography or isothermal titration calorimetry. Such 
libraries typically follow the “rule-of-three”51-guidelines defining promising fragments as those 
with molecular weights less than 300 Da, good solubility for screening at high concentration 
(clogP ≤ 3), and limited chemical complexity with fewer than 3 hydrogen bond donors/acceptors 
and  fewer than 3 rotatable bonds. Fragment-based screens typically have moderate hit rates 
often identifying multiple ligands which have high-quality interactions with the target protein. 
Based on the small size of fragment ligands these molecules generally have good ligand 
efficiency; a metric calculated as the ratio of the free energy of binding to the number of 
heteroatoms in the ligand.50 Additionally, it has been demonstrated that the identification of 
protein ligands through a fragment screen is correlated with the success of lead discovery 
programs therefore fragment screening has been suggested indicate the “druggability” of a 
particular target.52,53 Through intensive medicinal chemistry campaigns these fragments can be 
developed into lead-like molecules with potent activity.  
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C. Results 
C.1. Identification of small molecule fragment ligands of Ring1B/BMI1 fusion protein  
In order to identify small molecule ligands of Ring1B/BMI1 we performed an NMR-
based fragment screen of 1,000 compounds from a “rule of three” library. Compounds were 
screened in mixtures of 20 compounds at 0.25 mM final concentration and we analyzed binding 
of fragment compounds to Ring1B/BMI1 using NMR. Sixteen mixtures showed specific binding 
and deconvolution identified the active compounds, representing a 1.6% hit rate. The most 
promising compound from a potency and medicinal chemistry standpoint was compound 1, 5-
phenyltiophene-2-carboxylic acid (Figure 4.2.A). Compound 1 showed specific chemical shift 
perturbations clustering in a region of the Ring1B protein (binding site discussed below; Figure 
4.2.B) and showed weak yet promising inhibitory activity in an in vitro ubiquitination assay, 
 
Figure 4.2. Characterization of Compound 1. 
A. Structure of Compound 1. B. Binding of compound 1 to Ring1B/BMI1. Selection of 1H-15N 
HSQC spectra for Ring1B/BMI1 in the absence (black) or presence (magenta) of 0.5 mM 
compound 1. C. Activity of compound 1 in ubiquitination assay. Western blot (α-FLAG 
detection) for Ring1B/BMI1 in vitro ubiquitin ligase assay with compound 1 or DMSO 
control. 
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inhibiting nucleosome H2A K119 ubiquitination by Ring1B/BMI1 (Figure 4.2.C). Through 
titration in NMR experiments the binding affinity of compound 1 for Ring1B/BMI1 was 
estimated as 7 mM.  
C.2. NMR-guided SAR of Ring1B/BMI1 ligands 
Using compound 1 as a scaffold we pursued a structure-activity-relationship study to 
grow the fragment into a more potent ligands. In the absence of structural information we 
proceeded with rationally exploring diverse chemical space and building on step-by-step 
improvements.   
All medicinal chemistry efforts were performed in the Drs. Cierpicki and Grembecka labs. 
C.2.1. Measuring affinity of compounds by NMR 
To assess analog potency we used NMR spectroscopy. For the bulk of analogs tested, 
chemical exchange in the 1H-15N HSQC spectra is in the fast exchange regime. To compare 
affinities of selected ligands we performed NMR titration experiments. Plots of the magnitude of 
the chemical shift perturbation (Equation 4.1- See Experimental Methods) vs. ligand 
concentration were fit with a saturation binding isotherm to calculate KD and Bmax (saturation 
chemical shift) (Figure 4.3.A). We observed in titration studies that many residues in the ligand 
binding site have approximately the same Bmax (Figure 4.3.A). Thus we rationalized that the 
Bmax obtained from titration studies could be used in equation 4.2 (see Experimental Methods) 
to fit chemical shift perturbations from experiments recorded at only a single concentrations. 
This is a rapid approach to quantify relative affinities of analogs based on just one binding 
experiment (Figure 4.3.B). This method has limitations due to the small number of data points 
analyzed, however it can be used to generally compare analog potency. Overall, this is an 
efficient approach to compare potency of ligands with millimolar to mid-micromolar affinity. 
We applied this method to estimate KD for over one hundred analogs tested at a single 
concentration. For ease of protein production we expressed the Ring1B-BMI1 complex as a 
fusion protein (Ring1B/BMI1) with the C-terminus of Ring1B fused directly to the N-terminus 
of BMI1. This protein retains the biological activity of the non-covalent complex and therefore 
likely has a very similar structure.  
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Figure 4.3. NMR estimation of binding affinity to guide SAR. 
A. Example analysis of the chemical shift perturbation for a residue that shows saturation at 
the same chemical shift for ligands of different affinity. Left: curve fit for the Cys67 resonance 
with different ligands. Right: table with KD and Bmax determined by the titration shown on 
the left. B. Analysis of Gly83 chemical shift perturbation for either titration or single point 
experiments for a selection of compound 1 analogs showing major improvements in affinity 
throughout the SAR studies.  
For the majority of analogs tested the same set of Ring1B residues are perturbed and 
improved ligand potency did not cause more residues to be affected. Interestingly, for the most 
potent analogs (KD < 10 µM) we observed appearance of new peaks likely due to ordering of 
several residues in the binding site. Additionally, for these more potent ligands we observed 
intermediate exchange phenomenon on NMR spectra which precluded quantitative chemical 
shift analysis using the method described above. Therefore, for the most potent compounds we 
determined binding affinity using ITC. All affinities reported in tables 4.1-4.6 are based on 
single point the NMR analysis protocol unless otherwise noted, (ie. NMR titration or ITC).  
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C2.1. Fragment growth approach with hydrophobic/hydrophilic group scanning 
The first major improvement to the compound 1 was replacement of the thiophene core 
moiety with a pyrrole (compound 2), which improved the affinity by approximately two-fold (KD 
~ 3.6 mM). All subsequent modifications were thus performed in the context of this scaffold 
which are detailed in Table 4.1. We tested replacement of the acidic group with an ester 
(compound 3). This modification significantly reduced binding potency suggesting that the 
acidic group participates in critical interactions with the protein (KD ~ 20 mM). Next we 
explored SAR around the phenyl ring. Compounds 4-9 explore substituents at the R3 position. 
Substitution with hydrophobic methyl, chloro, trifluoromethyl or methoxy groups significantly 
reduced binding and substitution with polar sulfamide or amide group completely abolished 
binding.  
In contrast to substitutions at the R3 position which decreased binding affinity, 
substitutions at the R2 position did not have a dramatic effect on affinity (compounds 10-20). 
Alkyl or alkoxy groups of various size such as methyl, ethyl, methoxy, ethoxy, phenoxy and 
isopropoxy were well tolerated at R2 (compounds 10-18), neither enhancing nor diminishing 
binding. Interestingly, substitution with a hydroxyl group at this position (compound 19) 
significantly decreased binding affinity whereas substitution with a primary amine (compound 
20; KD ~ 2.9 mM) did not affect binding. 
We tested substitutions at the R1 position (compounds 21-27) which followed a similar 
pattern where bulky hydrophobic groups such as phenoxy and ethyoxy are well tolerated but do 
not improve binding affinity. Interestingly, addition of a hydroxyl group at R1 slightly improved 
binding affinity whereas addition of a primary amine significantly reduced affinity (KD ~ 1.9 and 
8.9 mM, respectively), suggesting that the R1 and R2 occupy sites in the protein with different 
potential as hydrogen bond donors or acceptors. Together this scanning of R1 and R2 SAR 
suggests that careful arrangement of hydrogen bond donors and acceptors is critical at these 
positions.  
Our studies with di-substitutions also did not significantly improve binding potency 
(compounds 28-30). 2,4-dimethoxy (compound 28) and 1-methoxy-4-methyl (compound 29) 
substituted phenyl had similar affinity to the unsubstituted parent compound. The 1,4-dimethoxy 
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substituted compound (compound 30) had ~4 fold reduced affinity relative to the parent 
compound. These studies indicate that careful orientation of substituents is required as two larger 
groups are not tolerated at the R1 and R2’ positions yet can be tolerated at the R2 and R2’ 
positions. 
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Table 4.1. SAR for 5-phenylpyrrole scaffold. 
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The biggest gain in affinity was through the addition of an indole group (compound 31) 
which improved the potency by about two fold (KD ~2 mM). Given the lack of other 
improvements thus far we designed all subsequent modifications in the context the indole ring, 
as detailed in Table 4.2.  
 
Table 4.2. SAR of 5-indol-4-yl-pyrrole scaffold. 
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C.2.2 Optimization of 5-indol-4-yl-pyrrole scaffold 
In an effort to determine the role of the R4 acid in the context of the indole-pyrrole 
scaffold we synthesized compound 32 with an R4 amide. This modification reduced potency by 
~3 fold, leading us to conclude that a negative charge is required at this position. All further 
analogs were made in the context of the acidic moiety. 
We designed compounds 33-38 to explore the role of the indole proton through 
substitution at the R1 position with both hydrophobic and polar groups. Substitution with methyl 
(compound 33) may slightly improve potency, although the improvement is likely within error of 
the analytical method (KD ~ 1.3 mM). Substitution with larger groups such as ethyl and 
cyclopropyl reduced potency. Substitution with hydroxyethyl or aminoethyl reduced the affinity 
by 3.5 or 8 fold, respectively (compounds 37, 38). Overall, from these studies we concluded that 
substitution of the indole nitrogen is not favorable.  
Next we explored substitution of the pyrrole ring in the context of either a methylated or 
unsubstituted indole nitrogen (compounds 39-48). Regardless of indole nitrogen substituent, 
methyl substitution at either the R2 or R3 positions improved the potency by up to 2 fold (KD ~ 
1.5-1.0 mM) (compounds 39-42). Significant improvement was attained through di-ethyl 
substitution, compounds 43 and 44, with compound 44 having a 10-fold gain in affinity (KD ~ 
190 μM) over unsubstituted pyrrole. We also introducing a fused cyclohexane ring in this 
position (compounds 45-46) and found that these modification improved potency over the 
unsubstituted parent compound by ~4-fold (KD ~ 430 μM, compound 46) but had reduced 
potency relative to diethyl substituted compounds (43-44). This indicated that these two 
positions likely occupy different sites in the protein and independent hydrophobic groups at these 
positions are beneficial.  
We were encouraged by the large gain in affinity through ethyl and phenyl substitution at 
the R2 and R3 positions of the core pyrrole ring, respectively (compounds 47-48). Table 4.3 
describes SAR of hydrophobic groups at these positions. Compound 47 with 3-ethyl and 4-
phenyl substituents on pyrrole had a measured of 30 μM by NMR, a 200-fold improvement over 
the initial fragment hit. Importantly, switching the phenyl to the R2 positions significantly 
reduced affinity (compounds 49-50), with compound 50 having an affinity of 4.7 mM. Based on 
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the structural similarities yet significant differences in potency between the relatively low 
affinity compound 50 and high affinity compounds (such as compound 47) we used compound 
50 as a negative control in future studies. Additionally, from these studies we concluded that 
unsubstituted indole compounds have slightly improved potency compared to 1-methyl 
substituted indoles and for this reason, along with better solubility and ease of synthesis future 
analogs were generated with unsubstituted indole.  
Based on the significant improvement of the phenyl substitution at R3 we tested different 
six membered rings at this position (compounds 51-54; Table 4.3). Replacement of phenyl with 
benzyl did not affect potency (compound 51 vs. 47), however extending the group with a one 
carbon linker reduced the potency by ~ 3 fold (compound 52). Changing phenyl to cyclohexyl 
 
Table 4.3. SAR of 5-indol-4-yl-pyrrole-2-carboxylic acid scaffold. 
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reduced the affinity by ~ 5-fold (compound 53), however compound 54 with methylcyclohexyl 
has similar affinity as phenyl and benzyl substituents. Overall, these studies indicated that alkyl 
chain length and conformational flexibility are important for substituents at this position. Based 
on these results as well as the greater potential for chemical modification, we designed future 
compounds using the phenyl-substituted scaffold.  
C.2.3 Further optimization of 5-indol-4-yl-pyrrole scaffold 
 In the next step we explored substitutions in the phenyl ring at R2 in the context of 4-
ethyl. These analogs were compared to the unsubstituted phenyl compound 47, KD ~ 30 μM. 
These studies are summarized in Table 4.4.  
Substitution at the para position with either hydrophobic or polar groups resulted in a 2-5 
fold loss of affinity (compounds 55-58). The meta position is less sensitive to substitution as 
fluoro, methyl, or benzoxy substitution resulted in only ~ 2 fold reduction in affinity (KD ~ 40, 
73 or 67 μM, compounds 59, 60 and 62, respectively). Interestingly, meta-methoxyphenyl 
(compound 61) had approximately the same affinity as unsubstituted phenyl suggesting 
prospects for improving potency through this substitution. 3-methyl-4-fluorophenyl (compound 
63) had only 2-fold reduction in affinity (KD ~ 72 μM) indicating that there is likely room in the 
binding pocket for multiple substituents on the phenyl ring and future exploration is needed to 
identify the optimal moieties to maximize hydrophobic or polar interactions.  
We designed compounds 64-69 to explore ortho-substituents. In general substitutions at 
this position are well tolerated. Small hydrophobic groups such as methyl and trifluoromethyl do 
not improve or reduce binding affinity, while methoxy substitution reduces the affinity by ~ 2-
fold (compounds 64, 65 and 66). 2-phenyl substitution (compound 67) similarly reduced potency 
by ~ 2-fold suggesting that there is some room for small alkyl groups but not for larger groups. 
Importantly, compound 69, featuring 2-chlorophenyl, had ~2-fold improved potency (KD = 18 
μM calculated through NMR titration).  
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Table 4.4. SAR of monosubstituted 5-indol-4-yl-pyrrole-2-carboxylic acid. 
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Encouraged by the improved potency of compound 69, we tested analogs with di-
substitutions in the context of 2-chloro. This series is summarized in table 4.5.  
2,3- dichlorophenyl (compound 70) had slightly reduced affinity, but 2-chloro-4-
methoxyphenyl (compound 71) significantly improved affinity (KD = 5 μM calculated through 
NMR titration). 2-chloro-4-ethoxyphenyl (compound 72) had reduced affinity relative to 
compound 71 supporting the observations from mono substituted phenyl analogs that addition of 
a smaller alkyl group is tolerated but not a larger group. We designed compounds 73 and 74 to 
explore the addition of polar nitro or amine groups, neither of which improves nor reduces 
potency (KD ~ 20 and 22 μM, respectively). Based on the improved potency of compound 71, we 
tested hydroxyethyl substitution at R1 in an effort to retain potency while improving solubility 
for biochemical and cellular studies, however the binding affinity was decreased by ~70 fold 
(compound 75). Finally, replacement of the chloro group with a larger bromo atom did not 
improve potency (compound 76; KD ~ 7 μM).  
Following these studies, we explored substitution of alkyl groups at the R2 position to 
gain affinity with the improved chloro substituted phenyl scaffold. Replacement of the ethyl 
group with methyl or propyl decreased activity (compounds 77, 78, KD ~ 67 and 86 μM, 
respectively). The butyl substituted compound 79 could not be tested due to solubility 
limitations. We were encouraged by significantly improved potency by isopropyl substitution 
(compound 80; KD = 8.9 μM determined by ITC).  
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Table 4.5. SAR of disubstituted 3-phenyl5-indol-4-yl-pyrrole-2-carboxylic acid. 
*Affinity of compound 79 was not determined (N.D.) due to limited compound solubility. 
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Table 4.6. SAR of heterocycle substituents of 5-indol-4-yl-pyrrole scaffold.  
 
C.2.4. SAR of 5-indol-4-yl-pyrrole-2-carboxylic acid 
Next, we tested different heterocycles at R2; Table 4.6.  
In the context of the ethyl at R1 the addition of 4-chloropyridine at R2 (compound 81) 
reduced potency ~ 2 fold relative to 2-chlorophenyl (compound 69). Substitution with either 6- 
or 4- indolyl (compounds 82, 83, respectively) significantly improved the potency, with 
compound 83 having an estimated affinity of 9 μM (NMR titration). Combining the gain in 
potency from indole and chloro modifications compound 84, 5-chloro-4-indolyl, was constructed 
which had a slight gain in affinity (KD =6.9 μM by ITC). Ultimately, to maximize the effects of 
R1 isopropyl compound 85 was designed with 5-chloro-4-indolyl at R2,  which had a two-fold 
gain in affinity (KD = 3.5 μM as determined by ITC, Figure 4.4.A).  
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Figure 4.4. Characterization of most potent compound by ITC. 
A. Isothermal titration calorimetry experiment of Ring1/BMI1 titrated with compound 85. B. 
Structures of most potent Ring1B/BMI1 inhibitor to date (compound 85) and negative control 
compound (compound 50).   
Overall, through the extensive medicinal chemistry campaign a very weak fragment 
ligand of Ring1B/BMI1 was optimized into a potent ligand, improving the potency by three 
orders of magnitude. Compound 85 thus represents a novel chemical probe for Ring1B/BMI1 
ubiquitin ligase activity with compound 50 serving as a structurally related negative control 
(Figure 4.4.B).  
C.3. Ring1B/BMI1 ligands are potent and specific inhibitors of in vitro ubiquitin ligase assay 
activity 
To test the inhibitory activity of Ring1B/BMI1 ligands we developed an in vitro ubiquitin 
ligase assay. In this assay the E1, UbcH5a (E2) enzymes and Ring1B/BMI1 fusion protein are 
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incubated with ATP, flag-ubiquitin and recombinant or commercial nucleosomes at 30° C. 
Ubiquitin ligase activity is visualized through western blot.  
Throughout the medicinal chemistry campaign we observed a good correlation between 
improved binding affinity and in vitro inhibitory activity of Ring1B/BMI1 compounds (data not 
shown). The most potent ligand, compound 85, has an IC50 ~ 1.3 µM in the in vitro 
ubiquitination assay while no inhibitory activity was observed for compound 50 (negative 
control) (Figure 4.5).  Significantly, this demonstrates that potent ligands of Ring1B/BMI1 are 
also inhibitors of ubiquitin ligase activity. 
 
Figure 4.5. Optimized Ring1B/BMI1 ligand is inhibitor of in vitro ubiquitin ligase 
activity. 
Western blots probed with antibody for UbH2A or H3 for in vitro ubiquitin ligase assay with 
Ring1B/BMI1 incubated with either negative control compound 50 (left) or the most potent 
ligand compound 85 (right).  
To assess the potential of Ring1B/BMI1 inhibitors as chemical tools for biological 
experiments we wanted to determine their specificity against other RING E3 ubiquitin ligases.  
Recently two other E3 ligases, Brca1/Bard1 and Trim37 have been identified as mediating 
H2A ubiquitination in breast cancer.54,55 While these proteins have similar function they have 
low sequence identity to Ring1B (30% and 37% identity to Trim37 and Brca1, respectively) 
and thus Ring1B/BMI1 inhibitors are expected to have good selectivity over these other E3 
ligases. To test this we performed ubiquitin ligase assays with these E3s. As expected 
compound 69 showed no inhibition of either Trim37 or Brca1 up to 500 µM, whereas the 
estimated IC50 for this compound against Ring1B/BMI1 is 16 µM, showing at least 30-fold 
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selectivity (Figure 4.6). Additionally, no binding to the Brca1/Bard1 or Trim37 proteins was 
observed by NMR experiments with various Ring1B/BMI1 ligands we developed (data not 
shown). This demonstrates that we have developed potent and specific Ring1B/BMI1 
inhibitors and supports their application as chemical tools. 
 
Figure 4.6. Inhibitors are specific for Ring1B/BMI1 E3 ubiquitin ligase. 
Western blots probed with FLAG antibody for in vitro nucleosome ubiquitination assay with 
various E3 ligases incubated with compound 69 for Ring1B/BMI1 (top), Brca1/Bard1 (center) 
or Trim37 (bottom). Bands are labeled on right. 
C.4. Ligand binding site and orientation probed by mutagenesis and NMR studies   
To identify the ligand binding site on the Ring1B/BMI1 fusion protein, we mapped NMR 
chemical shift perturbations from compound 71 onto the crystal structure of the heterodimer 
complex (PDB: 2H0D).30 This analysis shows that the ligand binds primarily to the Ring1B 
protein and that there are no interactions between BMI1 and the small molecule. Additionally, 
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chemical shift perturbations are localized to a region of Ring1B between the αβ helix and the 
zinc binding loop (Figure 4.7.A). Inspection of the surface composition of the complex shows 
that there is a small hydrophobic cavity in this region but access to this pocket is occluded by the 
sidechain of Ring1B Lys97 (Figure 4.7.B).   
 
Figure 4.7. Mapping of NMR chemical shift perturbations onto Ring1B/BMI1 structure 
identifies ligand binding site. 
A. Structure of Ring1B/BMI1 (PDB: 2H0D)30 with magnitude of backbone NH chemical shift 
perturbations for binding of 500 µM compound 71 colored as indicated. Ring1B protein is 
colored dark gray and BMI1 protein is colored light gray. Unassigned residues are colored 
black. Zinc molecules are shown as silver spheres. B. Surface representation of Ring1B/BMI1 
structure colored by hydrophobicity of sidechains. Ligand binding site is indicated by dashed 
circle. Lys97 sidechain occluding binding site.  
To validate this binding site, we designed mutants to perturb the conformation of this 
loop through charge repulsion and introduction of hydrophobic residues in the solvent exposed 
loop (Figure 4.8.A). We purified four mutant proteins and confirmed that the overall protein fold 
was not disrupted by NMR (data not shown). We tested ligand binding to these mutants by 1H-
15N NMR HSQC experiments (Figure 4.8.B). As expected, Ring1B Ile77Glu or Lys85GLu 
mutants had decreased affinity for the ligands. More significantly, the Leu94Ala mutation very 
dramatically reduced compound binding. Further, we designed Lys92Met mutant suspecting that 
replacement of the polar lysine with a larger hydrophobic methionine residue would cause 
significant structural perturbations of this loop. Unexpectedly, this mutation did not have an 
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effect on compound binding. We assayed these Ring1B mutants in the in vitro ubiquitin ligase 
assay and observed a strong correlation between reduced compound binding and reduced 
ubiquitin ligase activity (Figure 4.8.C). 
 
Figure 4.8. Probing compound binding site by mutagenesis. 
A. Compound binding site with mutated residues indicated in red. B. Table of relative affinity 
of ligands for mutant Ring1B protein as assessed by NMR. C. Western blot probed with FLAG 
antibody for in vitro ubiquitin ligase activity for Ring1B mutants. Bands are labeled on right.  
The reduced activity of the Lys85Glu and Ile77Glu mutants can be explained by the 
introduction of negative charges into this region of the protein that requires positively charged 
residues for interaction with the nucleosome. Inspection of the crystal structure suggests that the 
introduced methionine for Lys92 may be buried in the core of the loop region and thereby not 
affect protein activity. Leu94 mutation to alanine may disrupt the hydrophobic core of this region 
of the protein, and while the protein is still folded the decreased stability of this region may be 
enough to disrupt activity. Ring1B-nucleosome interface contacts are illustrated in Figure 4.10.  
To gain insight into the ligand binding mode we turned to a paramagnetic relaxation 
enhancement (PRE). PRE is a NMR method used in structural biology to determine protein or 
protein complex structures and can be used to map the ligand binding.56,57 In this system a spin 
label with unpaired electrons is introduced into the protein or ligand of interest and magnetic 
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dipolar interactions between a physically close nuclei and the unpaired electrons in the spin label 
result in an increase in relaxation rate of the nucleus and thus loss of NMR signal.58 This effect is 
visualized through the broadening of resonance signals for nuclei that are within a defined 
distance range of the spin label. The magnitude of the PRE is dependent on the electron-nucleus 
distance (r), with a proportionality of r-6 allowing both qualitative and quantitative assessment of 
the distances between the spin label and an observed nucleus.58 It is estimated that PRE effects 
can be observed for nuclei within 15-25 Å of the spin label.59 
For PRE studies we designed compound 86, which features the same basic chemical 
scaffold as compound 69 but is substituted with a pyrroline nitroxide at the 4 position connected 
to the core of the molecule by a short PEG linker (Figure 4.9.A). The SAR studies above suggest 
that this site is amenable to modification by large groups while still maintaining affinity for the 
protein. 1H-15N HSQC experiments with compound 86 titration show that the compound still 
binds to the protein with KD~ 250 µM. In these experiments three effects are observed that allow 
estimation of the binding orientation of this ligand (Figure 4.9.B).  
First, a number of resonances are completely broadened (eg. Asp74) upon addition of 
even low concentrations of compound suggesting they are within close proximity of the spin 
label. Second, some resonances show both fast exchange perturbations as well as dose-dependent 
peak broadening due to PRE (eg. Glu66) and these nuclei are likely close to the outer edge of the 
spin label effects (15-25 Å). Finally, a number resonances show fast exchange perturbations 
upon ligand binding indicating that they are further from the spin label yet still experience some 
change in chemical environment following ligand binding (eg. Thr64 and Thr89). 
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Figure 4.9. Paramagnetic relaxation enhancement (PRE) studies orient Ring1B/BMI1 
ligands in binding site.  
A. Structure of compound 86 with nitroxide spin label for PRE studies. B. Selection of 1H-15N 
HSQC spectra for Ring1B/BMI1 titrated with compound 86; DMSO= black, red= 0.5 
equivalents, cyan= 1 equivalent, purple= 2 equivalents. C. Ring1B/BMI1 colored for the 
effects of compound 86 with residues that experience broadening effect indicated in red and 
residues that undergo chemical shift perturbations shown in yellow. Compound 86 is modeled 
into a previously published structure (PDB: 3RPG)32 with the nitroxide spin label shown as an 
orange sphere. 
While multiple spin-labeled ligands would be required for the generation of a robust set 
of distance restraints from PRE studies and thus accurate positioning of the ligand in the binding 
site, the data from these experiments allow the determination of the orientation of the molecule 
with the protein. Figure 4.9.C illustrates the estimated orientation of compound 86 based on the 
analysis of ligand titration described above. The broadened residues in helix αβ and at the base of 
the pocket suggest that the spin label is oriented towards these features. Residues that show 
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chemical shift perturbations but not PRE broadening are at the back of the ligand binding pocket 
indicating that the hydrophobic side of the ligand is likely orientated towards this region of the 
protein. Additionally, the residues that experience chemical shift perturbations but not PRE could 
be a result of protein conformational change as a result of ligand binding rather than interactions 
with the ligand.  
C.5. Inhibitor binding results in conformational change in Ring1B  
Analysis of the surface topology of the Ring1B/BMI1 complex does not suggest an 
obvious pocket for small molecule binding (Figure 4.7.A). However, robust ITC, mutagenesis 
and NMR binding data demonstrate that Ring1B/BMI1 inhibitors do bind directly to this protein 
at the nucleosome binding surface. This suggests that protein conformational change is required 
for ligand binding. Analysis of chemical shift perturbations, which are sensitive to both ligand 
binding and protein conformational change, validates this conjecture. For example, the 
magnitude of chemical shift perturbations, greater than 0.5 ppm for some resonances, suggesting 
these effects may be due to protein conformational change. Additionally, in binding studies with 
the most potent ligands we observed the appearance of new resonances in the 1H-15N HSQC 
spectrum which we assigned to residues in the substrate binding site indicating that ligand 
binding results in stabilization of protein conformation in this region. Finally, the PRE studies 
detailed above demonstrate that there is a region of the ligand binding site that is further from the 
spin label but experiences a change in chemical environment following ligand binding, likely 
through protein conformational change.  
The structural and biochemical characterization of the Ring1B/BMI1-nucleosome 
interaction by McGinty et al23 demonstrated that several basic residues in the nucleosome 
binding site of Ring1B contribute to direct protein-nucleosome interaction and thus E3 ligase 
activity (Figure 4.10). On the basis of the observed conformational change in Ring1B with 
compound binding we suspected that the ligand-bound conformation of Ring1B/BMI1 is 
incompatible with nucleosome binding.  
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Figure 4.10. Ring1B-nucleosome interface. 
Details of the Ring1B-nucleosome interface from PDB 4R8P23 showing the requirement for 
careful orientation of basic sidechains in Ring1B (dark gray) to interact with acidic residues on 
the H2A (magenta) surface. Key basic residues are labeled. Other histones are colored in pale 
blue. 
C.6. Ring1B/BMI1 inhibitors disrupt protein-nucleosome interaction 
To experimentally validate that the ligand-bound conformation of Ring1B/BMI1 
precludes binding to nucleosome substrate we developed a gel based EMSA assay 
(electrophoretic mobility shift assay) using nucleosomes reconstituted with Oregon Green-
labeled H2B. Gel visualization by Typhoon imager allows detection of the mobility of 
nucleosomes in the presence of Ring1B/BMI1 protein. Experiments with pre-incubation of 
Ring1B/BMI1 with compounds allows analysis of the effect of compound binding on this 
interaction. We observed a clear change in mobility of nucleosomes following the addition of 
Ring1B/BMI1 (Figure 4.11.A). The potent E3 ligase inhibitors prevent this interaction as 
demonstrated by a dose dependent decrease in the bound nucleosome fraction with compound 
titration (Figure 4.11.B). The most potent inhibitor, compound 85, has an IC50 ~ 3 µM in this 
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assay, whereas the inactive compound 50 has no effect on nucleosome binding. Together these 
studies confirm that the inhibitor-bound conformation of Ring1B/BMI1 is incompatible with 
direct nucleosome binding thereby blocking its ubiquitination activity.  
 
Figure 4.11. Ring1B/BMI1 ligand binding prevents interaction with nucleosome. 
A. EMSA assay for OregonGreen488 labeled nucleosomes titrated with Ring1B/BMI1. B. 
Competition EMSA experiments with Ring1B/BMI1 incubated with decreasing concentrations 
of either negative control compound 50 (left) or compound 85 (right). Shift positions of free 
and bound nucleosomes are labeled. 
C.7. Preliminary cellular studies demonstrate utility of inhibitors as chemical probes 
We next wanted to determine if the potent in vitro Ring1B/BMI1 inhibitors we developed 
have potential as novel chemical tools to address biological questions in a cellular context. To do 
this we assessed cell permeability and on-target activity by treating MCF10A cells with ligands 
with different in vitro potency. We selected MCF10A breast epithelial cells, a cell line in which 
Ring1B/BMI1 is the major H2A ubiquitin ligase.54 Treatment of cells with compounds 69 and 85 
showed dose-dependent decrease of global H2AK119Ub levels (Figure 4.12.A). Additionally, 
the activity of these compounds in cells correlates with their in vitro activity as the more potent 
compound, compound 85, has IC50 < 6.25 µM whereas the weaker compound 69 has IC50 ~12.5 
µM in these cellular studies. Together this data indicate that Ring1B/BMI1 inhibitors are cell 
permeable and have good on-target activity.  
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Figure 4.12. Ring1B/BMI1 inhibitors are cell permeable with on-target activity. 
Western blots of MCF10A cell lysate probed with antibodies for UbH2A and GAPDH as 
indicated. Cells were treated with compounds for 6 days.  
D. Discussion and Conclusion 
The work presented here describes the development of highly novel small molecule 
inhibitors of the Ring1B/BMI1 E3 ubiquitin ligase. This work employed fragment-based 
screening to identify small molecule ligands directly binding to the Ring1B/BMI1 E3 ubiquitin 
ligase. Optimized ligands are also potent and specific inhibitors of Ring1B/BMI1 E3 ligase 
activity both in vitro and in cells. Supporting mechanistic studies demonstrate that ligand binding 
causes significant structural perturbation in the substrate binding site of Ring1B preventing 
nucleosome binding and thus H2A ubiquitination. Therefore the optimized small molecule 
inhibitors of Ring1B/BMI1 presented here represent novel inhibitors of direct protein-
nucleosome interaction. And finally, these molecules represent the first cell-permeable 
compounds that bind directly to Ring1B/BMI1 to block its E3 ligase activity setting the stage for 
use as chemical tools in polycomb biology and cancer biology.  
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The SAR studies detailed in this chapter allow a comprehensive analysis of the chemical 
basis for potent inhibition of Ring1B/BMI1 through disruption of protein-nucleosome 
interaction. To design more potent compounds we have developed a structural model of Ring1B 
in complex with compound 69 based on computational docking studies supported by NMR-
derived distance restraints (Figure 4.13.B). This model was generated by my colleague Dr. 
George Lund. Compound 69 features the pyrrole core substituted with 2-carboxylic acid, 3-
chlorophenyl, 4-ethyl and 5-indole (Figure 4.13.A).  
This model illustrates that the small molecule inhibitors insert between the αβ helix and 
the zinc binding loop of Ring1B, pushing these elements apart and forming critical contacts with 
residues on both sides of this pocket. Key hydrophobic interactions between the indole and 
pyrrole ring systems and the hydrophobic core of the protein likely drive the affinity of this 
interaction. Critically, the 5-indole is bracketed by Leu80 and Leu94 providing a structure-based 
explanation for the loss of binding affinity to the Leu94A mutant. The sidechain of Ser96 is also 
 
Figure 4.13. Docking model of Ring1B in complex with compound 69. 
A. Structure of compound 69 with key features highlighted. B. Computational docking model 
of compound 69 in complex with Ring1B generated by Dr. George Lund. Hydrophobic residues 
in the binding site are colored magenta and key basic residues in the site are colored green. Zinc 
atoms are shown as gray spheres.  
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positioned in the ligand binding site and may contribute to some polar interactions. The 4-ethyl is 
positioned between Ile76 and Leu100, and while there is room in the structure to accommodate 
the larger isopropyl group featured in compound 85, there is no room for a phenyl ring at this 
position supporting the observation that compound 50 has significantly reduced binding affinity. 
In the model, the 3-chlorophenyl is situated at the base of the binding site which is capped by 
Met62 and there may be hydrophobic interactions between these moieties. Additionally, the 
chloro group is oriented towards the αβ helix and form a halogen bond with backbone carbonyl 
of Ile77. Finally, the 2-carboxylic acid is in close proximity to Lys97 and may form electrostatic 
interactions with this residue further contributing to compound activity. In summary, this 
structural model helps rationalize the steep SAR observed throughout the studies detailed in this 
chapter and provides a basis to design more potent compounds.  
One such opportunity may be through exploiting the high density of basic residues in the 
ligand binding site. The structural model suggests that the sidechain of Lys85 is positioned near 
the 5-indole and future molecules designed with carbonyl or sulfonyl substituents on the indole 
could participate in polar interactions with this residue further contributing to binding affinity. 
Similarly, the sidechain of Lys97 may be in position to interact with the other side of this indole 
group. While the conformational flexibility of this region of the protein has thus far hindered 
structural studies of the protein-ligand complex by X-ray crystallography. Current efforts are 
focused on detailed structural characterization to drive structure-based design of more potent 
inhibitors.   
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E. Experimental methods 
Plasmid construction 
Ring1B/BMI1 fusion protein. A synthetic gene encoding Ring1B (res. 10-116) fused to BMI1 
(res. 1-104) was ordered from Genscript and subcloned into the pET32a vector (Novagen). 
Histone proteins. Ampicillin- resistant plasmids encoding Xenopus histones H2A, H2B, H3 and 
H4 in the pET3d vector were a kind gift from Dr. Yali Dou’s lab (Department of Pathology, 
University of Michigan). 601 DNA sequence. Ampicillin- resistant plasmid encoding the 147 
base pair Widom 601 sequence was a kind gift from Dr. Yali Dou’s lab (Department of 
Pathology, University of Michigan). Plasmids for mutant constructs were made using standard 
QuikChange mutagenesis protocol (Stratagene) and verified by Sanger sequencing.  
Protein expression and purification 
Unlabeled Ring1B/Bmi1 wild type and mutants. Plasmids encoding RingBmi1 wild type or 
mutants were transformed into BL21 (DE3) E. coli cells T1R (Sigma) and selected with 
ampicillin (100 µg/mL). Seed cultures, 5 mL Luria broth (Fisher Scientific) cultures 
supplemented with ampicillin (100 µg/mL), were inoculated with a single colony and grown for 
4 hours at 37°C (220 rpm). Seed cultures were diluted (200-fold) into 1 L cultures of Luria broth 
supplemented with ampicillin (100 µg/mL). Cultures were grown at 37°C (220 rpm) until OD600 
reached 0.6-0.8. Incubation temperature was lowered to 25°C and protein over expression was 
induced with 0.5 mM (final concentration) isopropyl β-D-1-thiogalactopyranoside (IPTG; Gold 
Bio) for 16-18 hours at 25°C. Cultures were harvested by centrifugation, resuspended in 30 mL 
lysis buffer (50 mM Tris, pH 7.5 at 25°C, 150 mM NaCl, 2 mM DTT, 100 µM ZnCl2, 0.5 mM 
PMSF) and lysed using French press cell disrupter. Inclusion bodies were pelleted by 
centrifugation and washed three times in wash buffer A (lysis buffer A +  1% (v/v) triton-x100), 
washed once with lysis buffer and once with wash buffer B (50 mM Tris, pH 7.5 at 25°C, 150 
mM NaCl, 100 μM ZnCl2, 0.5 mM PMSF, 2 mM DTT, 1 M Guanidine HCl). Protein was 
solubilized in 6 M Guanadine HCl in lysis buffer by rocking at room temperature for 1 hour. 
Protein was refolded through serial dialysis into 100-fold excess refolding buffer (50 mM Tris, 
pH 7.5 at 25°C, 150 mM NaCl, 2 mM DTT, 100 μM ZnCl2). To remove the His6-thioredoxin 
tag, the protein was cleaved with Tobacco Etch Virus (TEV) protease. The His6-thioredoxin 
protein was separated from RingBmi1 protein using cation exchange chromatography. The 
purified protein solution was buffer exchanged into storage buffer (50 mM HEPES, pH 7.2, 100 
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mM NaCl, 10 mM MgCl2, 10 μM ZnCl2, 1 mM DTT) through dialysis. Protein concentration 
was measured using absorbance at 280 nm. Protein identity and purity was verified by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein was flash frozen and 
stored at -80°C.  
15N-labeled Ring1B/Bmi1 for NMR Spectroscopy. Protein was expressed as above with the 
exception of the use of the M9 minimal media supplemented with 15N ammonium sulfate 
(Cambridge Isotopes) and 15N Bioexpress (Cambridge Isotopes).60 Upon IPTG induction, media 
was supplemented with 100 μM ZnCl2 (final concentration). Following protein refolding and tag 
cleavage, protein was dialyzed into 100-fold excess NMR buffer: 50 mM sodium phosphate, pH 
6.8, 150 mM NaCl, 1 mM TCEP, 10 µM ZnCl2.  
Histone proteins. Plasmids encoding genes for the four histones were transformed into 
CodonPLUS BL21 (DE3) E. coli cells (SOURCE) and selected with ampicillin (100 µg/mL). 
Seed cultures, 5 mL Luria broth (Fisher Scientific) supplemented with ampicillin (100 µg/mL), 
were inoculated with a single colony and grown for 4 hours at 37°C (220 rpm). Seed cultures 
were diluted (200-fold) into 1 L cultures of Luria broth supplemented with ampicillin (100 
µg/mL). Cultures were grown at 37°C (220 rpm) until OD600 reached 0.5-0.7. Protein over 
expression was induced with 0.4 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG; Gold Bio) 
(final concentration) for 4 hours at 37°C. Cultures were harvested by centrifugation. Cells were 
resuspended in 30 mL lysis buffer A (50 mM Tris, pH 7.5 at 25°C, 100 mM NaCl, 1 mM Na-
EDTA, 1 mM PMSF, 1 mM β-ME) and lysed using French press cell disrupter. Inclusion bodies 
were pelleted by centrifugation and washed three times in wash buffer A (lysis buffer + 1% (v/v) 
triton-x100). Proteins were solubilized by mincing pellet in 0.5 mL DMSO and incubated at 
room temperature for 30 minutes. 5 mL unfolding buffer A (7 M Guanadine HCl, 20 mM sodium 
acetate, 10 mM DTT) was slowly added to pellet and solution was gently pipetted to facilitate 
resuspension. Protein solution was incubated with gentle stirring at room temperature for 4 hours 
before clarifying by centrifugation. Clarified, solubilized protein was dialyzed at room 
temperature into three changes of 100-fold excess dialysis buffer (7 M urea, 100 mM sodium 
acetate, 20 mM Tris, pH 7.5 at 25°C, 100 mM NaCl, 2 mM β-ME). Proteins were further 
purified using anion and cation exchange. Briefly, 4 mL gravity Q Sepharose (GE Healthcare) 
was equilibrated with dialysis buffer. Clarified protein sample was applied to the column and 
incubated for 10 minutes. Protein was eluted in 3 steps with Q elution buffer: Q100 (7 M urea, 
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20 mM sodium acetate, pH 5.2, 100 mM NaCl, 2 mM β-ME), Q150 (7 M urea, 20 mM sodium 
acetate, pH 5.2, 100 mM NaCl, 2 mM β-ME), Q200 (7 M urea, 20 mM sodium acetate, pH 5.2, 
100 mM NaCl, 2 mM β-ME). Fractions containing protein were pooled and applied to 2 mL 
gravity SP Sepharose (GE Healthcare). Protein was eluted in 3 steps with S elution buffer: S300 
(20 mM sodium acetate, pH 5.2, 300 mM NaCl, 7 M urea, 2 mM β-ME), SAU500 (100 mM 
sodium acetate, 20 mM Tris, pH 7.5 at 25°C, 500 mM NaCl, 7 M urea, 3 mM β-ME), SAU1000 
(100 mM sodium acetate, 20 mM Tris, pH 7.5 at 25°C, 1 M NaCl, 7 M urea, 3 mM β-ME). 
Fractions containing purified protein was pooled and dialyzed against 3 changes of 4 L of MilliQ 
water with 2 mM β-ME at 4°C. Samples were clarified and lyophilized. Purified protein was 
stored at -80°C. 
UbcH5c, Trim37 and Brca1/Bard1 were expressed and purified by other members of the 
Cierpicki lab. 
NMR Spectroscopy 
All NMR experiments were performed on a Bruker Advance III 600-MHz spectrometer 
equipped with a 5 mm TCI cryogenic probe. All spectra was acquired at 30°C. Spectra were 
processed with NMRPipe61 and analyzed with Sparky.62 
Compound stock preparation and concentration verification. Powdered compounds were 
resuspended in the appropriate amount of DMSO to make 100 mM stocks. Compound stock 
concentration was verified through 1H NMR experiments compared to internal standard (BD-10). 
If necessary, stock concentrations were adjusted and re-verified though the same methodology. 
SAR-by-NMR Experiments. For screening analogs, samples were prepared with 60 µM final 
concentration 15N RingBMI1 in NMR buffer (50 mM sodium phosphate, pH 6.8, 150 mM NaCl, 
1 mM TCEP, 10 µM ZnCl2) with compounds in 5% final DMSO. All samples contained 7% 
D2O.   
Chemical shift perturbation quantification. The magnitude of perturbation for fast-exchanging 
chemical shifts was calculated as the magnitude of change of both the 1H and 15N chemical shifts 
in hertz.63  
 
Equation 4.1. Calculation of chemical shift perturbations ∆ =	√((	
 − 		
) +	(	 − 		)) 
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Determination of KD using chemical shift perturbations of small molecule titration. 
Chemical shift perturbations for small molecule titrations were fit in Prism GraphPad (reference) 
using a binding isotherm described by the equation 2. [RingBmi1]= 60 µM for all titrations; 
[Lig]= concentration of ligand. Bmax is determined through fitting ligand titrations with a 
saturating binding isotherm. 
 
Equation 4.2. Calculation of KD and Bmax for ligand titration. 
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Estimation of small molecule KD using single point chemical shift perturbation. For rapid 
comparison of compound 1 analogs, KDs were estimated in Prism GraphPad using equation 4.2 
where [RingBmi1] = 60 µM. For each compound, equation 4.2 was solved using the magnitude 
of chemical shift perturbation for glycine 83 resonance at a single concentration and an estimated 
saturation chemical shift (Bmax) of 360 Hz at 1 M ligand. Equation adapted from Ref. 63.  
Nucleosome reconstitution (adapted from64,65) 
Octamer reconstitution. Lyophilized histone proteins were resuspended in histone unfolding 
buffer (8 M guanidine HCl, 20 mM Tris pH, 7.5, 5 mM DTT). Proteins were rocked at room 
temperature for 1 hour. Proteins were mixed in a 1:1:1:1 molar ratio for a final protein 
concentration of 2 mg/mL. Histone mixture was dialyzed overnight into 2,000-fold excess 
octamer reconstitution buffer (2 M NaCl, 10 mM Tris, pH 7.5, 1 mM ETDA, 5 mM β-ME). 
Homogeneous octamer was purified via size exclusion chromatography using a Sephacryl S200 
column (GE Healthcare) with octamer reconstitution buffer (2 M NaCl, 10 mM Tris, pH 7.5, 1 
mM ETDA, 5 mM β-ME). Octamer quality was verified by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) using 18% Tris-glycine-SDS gel (BioRad) and 
purified samples were flash frozen and stored at -80°C. Concentration was measured using 
absorbance at 276 nm. 
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H2BOG488 Octamer Assembly. Reconstitution of labeled nucleosomes was performed as above 
with the exception that H2B S112C was labeled with OregonGreen 488 prior to assembly. 
Labeling was achieved by incubated H2B S112C with two equivalents of OregonGreen 
maleiminde (Invitrogen) for 4 hours at 4°C with rotation in unfolding/labeling buffer (7 M 
guanidine HCl, 20 mM Tris, pH 7.5, 25 mM NaCl, 30 mM TCEP) before the reaction was spiked 
with an additional equivalent of dye. Excess dye was removed by dialyzing into two changes of 
100-fold excess histone unfolding buffer. Labeling was verified by mass spectrometry.  
601 DNA purification. The plasmid encoding the 23 copies of the 147 base pair Widom 601 
sequence was amplified in DH5α E. Coli cells and purified in milligram quantities with the 
GigaPrep kit (Qiagen). Purified DNA was digested at a concentration of 1 mg/mL with EcoRV 
(New England Bioscience) at a concentration of 30 units of EcoRV per nanomole EcoRV site in 
1x Buffer #3 (New England Bioscience). Reactions were incubated at 37°C for 16 hours. 
Digestion progress was verified on a 10% agarose gel. If reaction was incomplete, reactions were 
supplemented with 50% more enzyme and incubated at 37°C for another 15 hours. The Widom 
601 insert was separated from vector backbone by the addition of 0.192 volume equivalents of 4 
M NaCl and 0.346 volume equivalents of 40% PEG 6000. Samples were incubated on ice for 1 
hour before the vector was pelleted by centrifugation. The Widom 601 insert in the supernatant 
was further precipitated by the addition of 2.5 volume equivalents of cold 100% ethanol and 
incubated at -80°C for 1 hour. DNA was pelleted by centrifugation and air dried. Purified DNA 
was resuspended in 10:0.1 TE (10 mM Tris, 0.1 mM EDTA sodium salt, pH 8.5 at 25°C). 601 
DNA purity was verified by 10% agarose gel stained in ethidum bromide and the concentration 
was measured by using absorbance at 260 nm. 
Nucleosome reconstitution. Briefly, 601 DNA and histone octamer were mixed in varying 
molar ratios at 0.7 mg/mL final DNA concentration in high salt nucleosome reconstitution buffer 
(2 M NaCl, 20 mM Tris, pH 7.5, 1 mM ETDA, 1 mM DTT). Reactions were incubated on ice for 
30 minutes before serially diluting the salt concentration (2 M NaCl, 0.85 M NaCl, 0.65 M NaCl, 
0.2 M NaCl) in 1000-fold excess dialysis buffer (20 mM Tris, pH 7.5, 1 mM ETDA, 1 mM 
DTT) for a total of 20 hours at 4°C. Reconstituted nucleosomes were dialyzed into the final 
assay buffer (50 mM HEPES, pH 7.2, 100 mM NaCl, 10 mM MgCl2, 1 μM ZnCl2, 1 mM DTT). 
Nucleosome quality was assessed by native-PAGE (polyacrylamide gel electrophoresis) using 
7.5% Tris-glycine gel (BioRad) run under native conditions at 4°C and visualized with ethidium 
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bromide staining (20 µg/mL). Concentration was measured by absorbance at 260nm (DNA) and 
converted to total nucleosome concentration.  
In vitro ubiquitin ligase assay 
Reactions. ATP, E1, E2 and E3 enzymes were diluted in ubiquitination assay buffer 
(Ring1B/BMI1: 50 mM HEPES, pH 7.2, 100 mM NaCl, 10 mM MgCl2, 1 μM ZnCl2, 1 mM 
DTT; Brca1/Bard1: 50 mM Tris, pH 7.5, 5 mM MgCl2, 15 mM KCl, 0.7 mM DTT, 2 mM NaF; 
Trim37: 50 mM Tris, pH 7.9, 5 mM MgCl2, 2 mM NaF, 10 mM DTT) and incubated with 
varying concentrations of compound for 30 minutes at room temperatures. 30 μL final volume 
reactions were initiated with the addition of flag-ubiquitin and mono-nucleosomes (see table 
4.7). Reactions were incubated at 30°C for 1.5 hours before being quenched with 10 μL 4xSDS 
buffer. Samples were boiled for 5 minutes.  
Reactant Amount per reaction Source 
E1 41 ng BostonBioChem 
E2 (UbcH5c) 876 ng In house 
E3 (RingBmi1 fusion wild 
type or mutant) 
42 ng (50 nM) In house 
E3 (Brca1/Bard1) 55 ng (60 nM) In house 
E3 (Trim37) 1 μg (2.5 μM) In house 
ATP 3 μM Calbiochem 
FLAG-ubiquitin 8 μg BostonBioChem 
Mono-nucleosomes 250 ng In house 
Hela nucleosomes 250 ng Reaction 
Biology 
Table 4.7. Reaction conditions for ubiquitin-ligase assay. 
Western blot. Samples were loaded onto 20 well 4-12% bis-Tris-glycine gel (Novex) and ran in 
1x MES SDS running buffer (Invitrogen) at room temperature. Western transfer was completed 
using semi-try transfer apparatus (BioRad) to Immobilon-P PVDF membrane (Millipore). 
Membranes were blocked with either 5% milk or 5% BSA for 2 hours at room temperature. 
Membranes were probed with 1:8,000 anti-FLAG (Cell Signaling) or 1:3,000 anti-H2A (Abcam) 
overnight at 4°C. Membranes were washed for 1 hour with 5 changes in TBST (50 mM Tris-
base, 150 mM sodium chloride, pH 7.6 at 25°C, 1% tween-20) at room temperature before being 
probed with 1:10,000 anti-rabbit IgG-HRP antibody (Cell Signaling) for 1 hour at room 
temperature. Blots were visualized with Amersham ECL Prime (GE Healthcare).  
EMSA Assay 
143 
 
Ring1B/BMI1 was diluted to 1 µM final concentration in EMSA buffer (50 mM HEPES, pH 7.2, 
100 mM NaCl, 10 mM MgCl2, 1 μM ZnCl2, 1 mM DTT, 5% glycerol, 0.01% BSA) and 
incubated with varying concentrations of compound at room temperature for 90 minutes. 
H2BOG488 Nucleosomes were added to a 10 ng/µL final concentration in 10 µL reaction and 
reactions were incubated at room temperature for 30 minutes. 1 µL DNA loading dye was added 
to each reaction (Life Technologies). Reaction species were separated by electrophoresis at 4° C 
under native conditions using 7.5% Tris-glycine acrylamide gel (BioRad) that was pre-run to 
equilibrate current and buffer. Gels were imaged with Typhoon Trio+ 9410 Variable Mode 
Imager (GE Healthcare) with the following parameters: power set to 600 PMT with Blue laser 
(488 nm) excitation and 520 nm bandpass filter and the focal plane at the platen surface. Images 
were analyzed with ImageQuant TL 7.0 (GE Healthcare). 
ITC 
Ring1B/BMI1 was exchanged into ITC buffer (50 mM phosphate, pH 6.8, 100 mM NaCl, 1 µM 
ZnCl2, 1 mM TCEP) by gel filtration and degassed prior to measurement. The titrations were 
performed using a VP-ITC titration calorimetric system (MicroCal) at 25°C. The calorimetric 
cell, containing Ring1B/BMI1 (26.6 µM) with 5% DMSO, was titrated with compound 85 (270 
µM in 5% DMSO) injected in 10 µL aliquots. Reference cell contained buffer with 5% DMSO. 
Data were analyzed using Origin 7.0 (OriginLab) to obtain KD and stoichiometry.  
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Chapter 5. Discussion 
 
A. Conclusions 
As outlined in Chapter 1, we were motivated to undertake the work in this dissertation to 
obtain a more complete understanding of BMI1’s role in cancer and to develop strategies to 
inhibit BMI1 with small molecule inhibitors. The results presented here have expanded our 
knowledge of the molecular details of BMI1’s protein-protein interactions and demonstrated that 
distinct interactions are important for BMI1 function in regulating cellular proliferation. Further, 
we hypothesized that targeted disruption of BMI1’s protein-protein interactions is an attractive 
approach to inhibit this protein. Through pursuit of complementary approaches to inhibit BMI1 
either through disruption of protein-protein interactions within the PRC1 complex or targeting 
the E3 ligase we established a number of chemical approaches to advance the understanding of 
BMI1 function in cancer. 
A.1. Structural insights into BMI1 function in PRC1 complex 
In Chapter 2 we characterized the BMI1-PHC2 interaction using biophysical methods 
and determined the 3D structure of the BMI1-PHC2 complex. Through this characterization we 
identified that BMI1 ULD is also involved in oligomerization through self-association. The 
structural insights suggest a number of hypotheses about the function of the canonical PRC1 
complex. Although a complete understanding of polycomb gene targeting and silencing 
mechanisms remains elusive1,2 it has been demonstrated that vertebrate polycomb PcG proteins 
are capable of condensing chromatin in vitro and in cells suggesting that chromatin compaction 
is a polycomb transcriptional repression mechanism.3,4,5 In this mechanism chromatin 
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compaction is believed to be a result of polycomb complexes bridging neighboring or distant 
nucleosome via inter-complex subunit interactions.3 With this in mind we propose that BMI1 
self-association may contribute to polycomb complex spreading via direct interactions between 
PRC1 complexes leading to chromatin compaction and robust gene silencing (Figure 5.1.). 
Bioinformatics analysis of the published ULD-domain containing polycomb structures by the 
PISA (Proteins, Interfaces, Surfaces and Assemblies)6 server and examination of the sequences 
of other PCGF orthologs suggests that self-association may be limited to BMI1 and its close 
ortholog MEL-18/PCGF2. Therefore chromatin compaction may be restricted to the canonical 
PRC1 complex.  
 
Figure 5.1. Model for role of BMI1-PHC2 oligomerization in PRC1 spreading. 
Model for PRC1 spreading over either local (left) or distal (right) chromatin domains through 
the BMI1-PHC2 oligomerization unit. Subunits are colored as in Figure 5.2.   
Recent studies have highlighted the relevance of PRC1 subunit diversity in PcG gene 
targeting and silencing mechanisms.7-10 We speculate that BMI1 and PHC oligomerization could 
serve to incorporate a variety of PcG proteins into a larger assembly. The so-called variant-PRC1 
complexes are defined by the incorporation of other PcG orthologs such as the Ring1B ortholog 
Ring1A or the BMI1/PCGF4 orhologs, PCGF1-6, with conserved ULD domains.11 Further, 
PCGF proteins form direct interactions with distint binding partners, including BCOR, E2F6, 
KDM2B and L3MBPL2, thereby contributing to complex heterogenity.7,12-14 Interestingly, mass 
spectrometry studies indicate that all PRC1-like complexes contain both Ring1A and Ring1B 
orthologs although the functional significance and molecular mechanisms behind this subunit 
redundancy have not been established. 4,9,15,16 4,9,15,16 BMI1 multimerization could facilitate 
150 
 
integration of multiple RING orthologs in the same complex where BMI1-Ring1A and BMI1-
Ring1B heterodimers are linked by the BMI1-PHC oligomeric unit (Figure 5.2.).  
Similarly, recent mass spectrometry studies using BMI1 as bait identified both the 
Ring1B binding partners RYBP and CBX as associated proteins.8,9 Structural studies 
demonstrated that RYBP and CBX interactions with Ring1B are physically mutually exclusive.17 
It is therefore puzzling that in functional studies it was observed that RYBP and CBX can co-
localize on the same loci.7,10 These observations could be explained by the contribution of 
homodimerized BMI1 molecules in complex with Ring1B (or Ring1A) molecules that are 
themselves bound by different binding partners thereby amplifying subunit heterogeneity within 
a larger complex (Figure 5.2). This analysis supports the hypothesis that the ULD-containing 
PCGF proteins define the subunit diversity of PRC1 complexes through protein-protein 
interactions with distinct binding partners.7,12  
 
Figure 5.2. Model for role of BMI1-PHC2 oligomerization in PRC1 subunit 
heterogeneity. 
Model for the contribution of BMI1 self-association to PRC1 heterogeneity where complexes 
incorporating different Ring orthologs and various binding partners are linked through the 
BMI1-PHC2 oligomerization unit. 
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A.2. Multiple approaches to inhibit BMI1 with small molecules  
In Chapters 3 and 4 we demonstrate two approaches to inhibit BMI1 with small 
molecules: inhibition of BMI1 ULD protein-protein interactions and blocking the E3 ligase 
activity of the RING domains of Ring1B/BMI1 (Figure 5.3). The small molecules described in 
these chapters therefore represent chemical tools that can be used to address specific questions 
about BMI1 function.   
In Chapter 3 through high-throughput screening we identified three classes of compounds 
that bind directly to the BMI1 ULD. The BI-1 class of compounds binds to BMI1 at the BMI1-
PHC2 interface to orthosterically disrupt this interaction. The BI-2 class covalently modifies the 
C-terminal Cys231 of BMI1 ULD. Cys231 is distant from the PHC2 binding site and this 
suggests an allosteric mechanism to inhibit this interaction. Finally, the BI-3 fragment 
demonstrates that smaller ligands can disrupt BMI1 ULD- PHC2 protein-protein interaction. 
Overall, these results demonstrate the feasibility of identifying small molecules by high-
throughput screening to block the BMI1-PHC2 PPI. In cells disruption of this interaction would 
likely perturb the overall architecture of the PRC1 complex; it remains to be determined if this is 
an appropriate strategy to inhibit BMI1.   
 
Figure 5.3. Two approaches to inhibit BMI1 with small molecules. 
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As an alternative approach to inhibit BMI1, in Chapter 4 we focused on developing small 
molecule inhibitors of the Ring1B/BMI1 E3 ubiquitin ligase. We identified a fragment ligand 
and optimized it into low micromolar inhibitors of both in vitro and cellular Ring1B/BMI1 E3 
ligase activity. To our knowledge these molecules represent the first directly binding inhibitors 
of this complex. We demonstrated a novel mechanism of action where ligands insert into the 
core of the protein by opening the nucleosome binding loop in Ring1B and thus preventing 
substrate recognition. These novel molecules demonstrates the feasibility of direct disruption of 
protein-nucleosome interactions with small molecules. Further, this work supports the 
development of small molecule modulators of other RING E3 ligases through fragment 
screening as an opportunity to develop inhibitors of select ubiquitination pathways and thus 
specific cellular processes.  
B. Future Directions 
B.1. BMI1 function in protein complexes 
B.1.1. BMI1 function within the PRC1 complex  
The structural characterization of the BMI1 ULD in Chapter 2 clarifies the role of BMI1 
in mediating the interaction between PHC2 and the Ring1B and CBX subunits of the canonical 
PRC1 complex. A remaining question about BMI1 function is what effect BMI1-PHC2 or 
BMI1-BMI1 interactions have on the E3 ligase capacity of the complex. It was previously 
observed that while the close BMI1 ortholog, MEL-18 (PCGF2), can be incorporated into the 
canonical PRC1 complex, this protein does not contribute to E3 ligase activity of the PRC1 
complex.18 Further, mice deficient in Mel-18 have a different phenotype than those lacking 
Bmi119,20 and in contrast to BMI1, MEL-18 is suggested to be a tumor suppressor.21-23 It remains 
to be determined if MEL-18 can self-associate in a similar manner as BMI1, although we 
hypothesize that this may be a unique characteristic of BMI1 and may explain its particular 
function within the PRC1 complex. Future biochemical or cellular experiments with BMI1 
protein-protein interaction mutants or small molecule inhibitors could be used to address this 
question. Additional work dissecting the spatial arrangements of the PRC1 subunits by electron 
microscopy (EM), small angle X-ray scattering (SAXS) or mass spectrometry can provide 
insights into the mechanisms and allostery of intra-complex regulation. Additionally, BMI1 self-
association characterized in this work suggests a role for BMI1 in chromatin compaction or 
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contributing to PRC1 subunit heterogeneity. Future work clarifying the functional role of this 
interaction by in vitro24 or in cell25 chromatin compaction assays will further illuminate BMI1 
function within the PRC1 complex.   
B.1.2. BMI1 beyond the PRC1 complex   
It is tempting to speculate that BMI1 may have other protein binding partners outside the 
PRC1 complex which contribute to its oncogenic function. While there is evidence from 
coimmunoprecipitation (Co-IP) and yeast-two-hybrid experiments that BMI1 interacts with the 
transcription factors E4F1,26 PLZF27 and Zfp27728 there has been no demonstrated direct binding 
between these proteins by biophysical methods. Therefore, it remains to be robustly evaluated if 
BMI1 has non-PRC1 binding partners. The 20 amino acid BMI1-interaction motif in PHC 
proteins identified in Chapter 2 can be used in a bioinformatics search to identify such partners 
based on sequence identity or similarity. A challenge to this tactic is that the structural 
characterization other polycomb ULD-binding partner complexes demonstrated that the 
intermolecular β sheet in these interactions can be formed by disparate parts of the binding 
partner protein which are not necessarily contiguous in primary sequence. For example, in the 
structure of PCGF1 and BCOR, BCOR interacts with PCGF1 through an intermolecular β sheet 
formed by two strands of non-contiguous residues; one strand is from residues 1594 to 1601 and 
the other strand from 1703 –1707.12 Therefore, a BLAST search to identify potential BMI1 
binding partners is complicated by the requirement for two potential motifs that may not be 
linear in sequence yet in the tertiary fold can form interactions at the same site.  
Alternatively, an experimental proteomics approach could be used to identify BMI1 
binding partners in cells. However, a challenge of this method is that due to multiple protein-
protein interactions within the PRC1 complex, the majority of BMI1 molecules are likely buried 
within this complex and pulldown studies may not identify new binding partners. An alternative 
approach to identify BMI1 protein binding partners is through covalent crosslinking coupled 
with downstream mass-spectrometry experiments. 29,30 These techniques are particularly well 
suited to capture transient interactions, which may be advantageous in identifying non-PRC1 
BMI1 binding partners.  
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B.2. Future efforts to inhibit BMI1’s protein-protein interactions with small molecules  
The compounds identified by HTS in Chapter 3 demonstrate that the BMI1-PHC2 
interaction is amenable to inhibition by small molecules. Going forward we are interested in 
developing more potent small molecule inhibitors of this interaction by exploring new strategies. 
First, the covalent modification of Cys231 by the BI-2 class opens the door for covalent 
approaches to disrupt this PPI. In addition to the C-terminal cysteine, BMI1 ULD has only one 
other cysteine which is in the PHC2 binding site (Cys166). As such, screening alkylating agents 
against the C231A mutant protein may allow identification of covalent ligands that bind in the 
PHC2 binding site. My colleague Jon Pollock has confirmed by mass spectrometry that Cys166 
can be modified by a maleimide-containing compound (data not shown). This proof-of principle 
experiment demonstrates the viability of this approach and supports future efforts screening 
covalent ligands targeting this site.  
Second, the low hit rate from HTS may be due to the general unsuitability of many 
current commercial high-throughput screening libraries for identification of protein-protein 
interaction inhibitors.31,32 Applying the robust biochemical assays developed in Chapter 3 to 
screen natural product or more diverse libraries may yield more promising lead compounds. 
Finally, as demonstrated by the direct binding of the fragment-like compound BI-3 to BMI1 
ULD a fragment-based drug discovery approach may represent a promising avenue to develop 
inhibitors of this target. 
B.3. Use of BMI1 inhibitors as chemical tools 
The molecules developed in Chapter 4 have exciting prospects as chemical tools and 
future generations of ligands with sub-micromolar activity can be applied to address important 
biological questions.  
B.3.1. Chemical tool for polycomb silencing mechanisms  
We have demonstrated in vitro that the Ring1B/BMI1 inhibitors developed through this 
work disrupt nucleosome binding by this E3 ubiquitin ligase. However, in a cellular context 
Ring1B and BMI1 associate with other proteins that contribute to chromatin targeting, such as 
CBX7. Thus, in the complex cellular environment it is unlikely that Ring1B would be displaced 
from chromatin following treatment with these inhibitors. This presents an excellent opportunity 
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to use these novel chemical probes to address important questions about polycomb gene 
silencing.  
Of particular interest is clarifying the role of H2A monoubiquitination in transcriptional 
repression and to dissect the molecular mechanisms of different PRC1 complexes. It has been 
demonstrated that in embryonic stem cells only some polycomb target genes are regulated by 
histone ubiquitination expression of other genes is repressed by the association of PcG proteins 
on chromatin.5,33 Other recent studies have suggested that some PRC1 complexes do not 
stimulate H2A ubiquitination,9 suggesting that distinct Ring1B binding partners determine the 
silencing mechanisms at different target loci. The inhibitors developed in this work could be 
used to explore these heterogeneous systems.  
First, chem-seq experiments could be used to clarify precisely which genes or pathways 
are sensitive to H2A ubiquitination as opposed to Ring1B chromatin association and other 
protein-protein interactions.34,35 These experiments would require the development of a 
biotinylated inhibitor which can be used as an affinity tag for Ring1B preceding sequencing of 
cross-linked genes and qRT-PCR analysis of gene transcription. Based on the modeling studies 
described in Chapter 4 the biotin group could be attached at either the 1 or the 2-position on the 
unsubstituted indole which are likely solvent exposed.  
Second, a biotinylated inhibitor enables proteomics studies by streptavidin pull-down of 
Ring1B/BMI1- inhibitor complexes to identify Ring1B binding partners. Combined with ChIP-
seq methodologies this may allow identification of distinct PRC1 complexes responsible for 
repression of individual genes through H2Aub-dependent and independent mechanisms. 
Performing these experiments in multiple cell lines or developmental states could shed light into 
various transcriptional repression programs in different contexts.  
B.3.2. Chemical tool in cancer biology 
As discussed in Chapter 1 the polycomb proteins Ring1B and BMI1 are attractive 
therapeutic targets in many tumor types based on the reduced in vitro proliferative capacity and 
reduced tumor growth observed with BMI1 knockdown.27,36-45 However, BMI1 knockout mice 
have hematopoietic and skeletal abnormalities demonstrating that complete loss of BMI1 
through genetic ablation may have toxic effects.20,37-39 However, inhibiting BMI1’s protein-
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protein interaction may provide good opportunities for targeted therapeutic intervention. Further 
it remains to be determined to what extent BMI1’s oncogenic function is dependent on its E3 
ligase activity. The inhibitors generated in Chapter 4 could therefore be used as tool compounds 
to establish if inhibition of the polycomb E3 ligase complex provides a therapeutic window to 
reduce tumor burden without generating adverse effects.  
Additionally, targeting so-called cancer initiating cells has emerged as an exciting area 
for therapy development to treat treatment-resistant tumors.40-43 BMI1 has been identified as an 
important factor in regulating self-renewal and maintenance of these cells in a number of tumor 
types 36-39,44 and has thus been proposed as a therapeutic target to inhibit these cancer initiating 
cell populations.45 The compounds reported in Chapter 4 could therefore be used as tools to test 
the hypothesis that small molecule inhibitors of the Ring1B/BMI1 E3 ubiquitin ligase represent a 
valid strategy to prevent tumor growth or metastasis by blocking cancer initiating cells.  
B.4. Investigation into RING E3 ligase mechanisms 
Through the biophysical and biochemical studies in Chapter 4 we demonstrated that 
potent inhibitors of the Ring1B/BMI1 complex induce significant conformational change in 
Ring1B to prevent nucleosome binding. This suggests that Ring1B is capable of adopting 
multiple conformations with different functional consequences; a closed “active” conformation 
and an “open” inactive conformation. What is not clear is if this conformational change is a 
consequence of inhibitor binding (induced-fit) or the trapping of an inactive conformation that is 
natively sampled (conformational selection).46 NMR dynamics studies could provide insight into 
these questions. Our group has obtained robust assignment of NMR spectra of Ring1B and 
preliminary relaxation dispersion and R1/R2 relaxation data from our lab suggests that the 
nucleosome binding loop is dynamic with motions on the micro to nanosecond timescale, 
suggesting that conformational flexibility might contribute to protein regulation. Future studies 
sorting protein dynamics associated with ligand binding from intrinsic protein motion could 
provide novel insight into a potential auto-regulatory mechanism for RING E3 ligases. 
B.5. Inhibitors of RING E3 ligases 
As discussed in Chapter 4, RING E3 ubiquitin ligases represent attractive, yet 
challenging, targets for inhibitor development to block many cellular pathways. Given the 
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complicated biochemical assay for ubiquitination, the fragment-based approach used in Chapter 
4 to identify ligands of the Ring1B/BMI1 complex likely represents one of the most promising 
avenues to identify ligands of specific RING domains. Further, as the core of RING domain 
proteins featuring zinc-coordinating motifs is highly conserved,47 targeting the substrate-binding 
site is the most promising avenue to block activity of specific E3s. It is attractive to speculate 
that the conformational flexibility observed in the Ring1B protein to regulate substrate binding 
and prevent E3 ligase activity may be a conserved feature of RING domain E3s. If indeed this is 
a conserved mechanism, it may be possible to develop small molecule ligands that modulate 
these conformations to inhibit protein function in a similar manner as the inhibitors developed 
for Ring1B. Such inhibitors would therefore be specific inhibitors of different cellular 
ubiquitination pathways and provide novel approaches to regulate cellular processes.  
In summary, the work presented here provides insight into BMI1 protein-protein 
interactions and describes various strategies to inhibit these interactions with small molecules. 
Together this supports future efforts deploying these chemical tools to study BMI1 in cancer and 
their development into new potential therapeutics.  
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Appendix A 
*The text and data presented here are adapted from the following manuscript: Gray, 
F.L.V.; Murai, M.; Grembecka, J.; Cierpicki, T. “Detection of Disordered Regions in Globular 
Proteins Using 13C-Detected NMR.” Protein Science, 2012, 21, 1954-60. 
______________________________________________________________________________ 
A. Abstract 
Characterization of disordered regions in globular proteins constitutes a significant 
challenge. Here, we report development of an approach based on 13C-detected NMR experiments 
for the identification and assignment of disordered regions in large proteins. Using this method 
we show that disordered fragments can be accurately identified in menin, a globular protein with 
a molecular weight over 50 kDa. Our work demonstrates an efficient way to characterize 
disordered fragments in globular proteins for structural biology applications. 
B. Introduction 
B.1. Function of disordered regions in proteins 
Disordered regions in proteins can play important roles in protein function. These regions 
are frequently involved in cell signal transduction, transcriptional regulation, molecular 
recognition and protein regulation through post-translational modification.1,2 In particular, 
unstructured regions in proteins have become recognized as a feature facilitating promiscuous 
interactions with many protein binding partners through the adoption of different secondary 
conformations through coupled binding-and-folding.3,4 For example, the disordered N and C-
termini of p53 have been identified as having over 40 different protein binding partners and 
structural studies have shown that these sequences can attain varying structures when in complex 
with different binding partners.5 Conversely, some proteins have multiple binding motifs within 
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a larger disordered region that form interactions with different sites in a globular protein. This is 
illustrated by the MLL-menin interaction where a natively unstructured region of MLL interacts 
with the menin protein through two short motifs connected by a flexible linker.6,7 Methods to 
rapidly define the boundaries of regions involved in molecular recognition and to analyze their 
structural transitions are valuable to advance functional characterization by disordered proteins 
of these interactions and to facilitate protein-protein interaction inhibitor development.  
Additionally, the identification and characterization of disordered regions in proteins has 
become an important task for computational protein structure prediction and for structural 
biology.8-11 Disordered fragments can be predicted using various bioinformatics methods,8,11,12 
however high resolution experimental validation and biophysical characterization of these 
regions remains challenging. Accurate methods of identifying disordered fragments in globular 
proteins is of significant interest to the structural biology community as the presence of flexible 
protein segments may interfere with production of diffraction quality crystals. Consequently, 
extensive protein engineering can be required to remove these flexible regions to enable 
crystallization or improve the quality of protein crystals. For example, the recent X-ray structure 
of the Drosophila effector caspase drICE required the deletion of a highly flexible internal 
fragment.13 Additionally, deletion of internal flexible regions in the GluR2 receptor ligand 
binding domain resulted in improved diffraction of protein crystals from 2.5 Å to 1.5 Å.14,15 
Experimental identification of internal disordered regions is commonly based on rapid hydrogen-
deuterium exchange rates for solvent exposed amide protons which can be detected using mass 
spectrometry.16,17 Nevertheless, accurate identification of disordered residues remains difficult 
and an efficient strategy to experimentally detect such fragments in globular proteins would 
significantly facilitate the design of protein constructs suitable for crystallization.  
B.2. 13C-detected NMR  
NMR is a valuable experimental technique uniquely suited for high resolution studies of 
disorder in proteins.18 However, amide proton-detected NMR experiments commonly used for 
protein studies are hindered in the characterization of intrinsically disordered proteins due to 
poor resonance dispersion and fast exchange of amides with water limiting the observation of 
complete set of resonances. To the contrary, NMR experiments directly detecting 13C overcome 
these limitations as random coil carbon chemical shifts have greater dispersion than proton 
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chemical shifts and observation of 13C is not affected by exchange of amide protons with water.19 
Additional advantages of carbon detected experiments include the observation of resonances 
corresponding to the backbone Cα and C’ carbons allowing for detection of all amino acids, 
including proline, which is frequently found in disordered regions.20 Finally, carbon detected 
experiments are less sensitive to environmental conditions such as pH and temperature which 
can limit the experimental applications of proton detected experiments.21 
B.3. Model system: the menin protein 
As a model system to test a 13C-detected NMR approach to identify both short and long 
disordered regions that inhibit structural studies we used the menin protein. Menin is a tumor 
suppressor protein which controls cellular growth in endocrine tissues22 and also functions as an 
oncogenic cofactor required for leukemogenesis.23 Structural studies were recently undertaken 
and while full length menin proved recalcitrant to crystallization experiments, successful 
crystallization of the protein was achieved through deletion of internal disordered fragments.24,25 
The first menin to be crystallized was the homolog from Nematostella vectensis and 
crystallization required truncation of the C-terminus and deletion of one internal disordered 
fragment.24 In this study we evaluated whether this internal disordered fragment could be 
identified through 13C-detected NMR experiments. As a model protein we chose C-terminally 
truncated constructs of Nematostella menin (N_menin∆C corresponding to residues 1-468). 
C. Results   
Sequence analysis using the DISOPRED2 server8 revealed that all menin homologs have 
multiple internal regions predicted to be disordered. We first tested whether 13C NMR 
experiments could be used to identify these internal disordered fragments in Nematostella menin. 
The CACO spectrum of 13C,15N labeled N_menin∆C revealed the presence of approximately 27 
resonances (Figure A.1.A). Given the significant molecular weight of the protein (55 kDa), we 
expect that all observable signals correspond to the most disordered residues. Slow tumbling of 
the protein molecule leads to very strong broadening of resonances for structured fragments and 
acts as an efficient filter leaving observable signals only for highly mobile residues. To assign 
these observed resonances we also collected CBCACO and CANCO experiments.26,27 A feature 
of the 13C-detected experiments employed here is the acquisition of 2D spectra which facilitates 
complete backbone carbon assignment through the straightforward analysis of the 2D CANCO 
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and CACO experiments. In each spectra Cα chemical shifts are on the y-axis and C’ chemical 
shifts are on the x-axis. In the CANCO spectrum resonances are seen for correlations between 
the C’i-1-Cαi+1 chemical shifts and connecting the resonance daisy chain allows for facile 
assignment by even novice spectroscopists. An overview of this simple assignment strategy is 
illustrated in Figure A.1.A. The CBCACO experiment was employed as analysis of Cβ-C’ 
correlations was essential for unambiguous assignment due to significantly less peak overlap in 
this region and because the Cβ chemical shifts allow for the identification of the amino acid type.  
Through the sequential assignment procedure outlined above we found that the majority 
of CACO signals correspond to an internal fragment (residues 423-440), 5 N-terminal residues 
and 2 C-terminal residues (Figure A.1.A). Several remaining peaks were unassigned due to 
 
Figure A.1. Assignment of disordered residues in Nematostella menin. 
A. 2D 13C CACO (blue), CBCACO (red) and CANCO (green/cyan) spectra for N_menin∆C. 
Arrows illustrate process of sequential assignment for a selection of residues. Residues retained 
from the vector following TEV cleavage are labeled in red. B. Disorder prediction for 
N_menin∆C as predicted by DISOPRED2 server.8 Dashed line shows the threshold for 
predicted disordered regions (highlighted in yellow). Red box indicates the experimentally 
observed disordered fragment of the protein.  
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reduced intensities. Most likely these peaks correspond to the shorter and less disordered loops. 
The assigned residues 423-440 yield strong resonances, clearly indicating that this fragment is 
disordered in solution. Consistently, deletion of residues 426-442 in Nematostella menin was 
necessary to obtain diffraction quality crystals and to determine the X-ray structure of the 
protein.24 
The internal disordered fragment in Nematostella menin is fairly short and its assignment 
based on 13C-detected experiments was relatively straightforward. However, unambiguous 
assignment for more complex proteins with multiple disordered fragments would be more 
difficult due to increased peak overlap and complexity of 2D spectra. Therefore, we assessed 
whether assignment of disordered regions based on 13C experiments could be facilitated by 
combining bioinformatics methods for disorder prediction and chemical shift calculation. To test 
this, we first employed the program DISOPRED28 for the prediction of internal regions of 
increased disorder in N_menin∆C. Based on this method, three possible internal disordered 
regions were identified: residues 177-187, 356-367 and 418-456 (Figure A.1.B). We next 
assumed that these disordered fragments would have chemical shifts consistent with random-coil 
values, which can be predicted with high accuracy.28-30 Thus, we used the ncIDP program28 to 
generate predicted chemical shifts for these regions. These predicted chemical shifts were used to 
simulate spectra with Cβ-C’, Cα-C’ and C’i-Cαi+1 correlations and compared to experimental 
data for N_menin∆C. Using this approach we found that observed resonances correspond to 
residues 423-440, consistent with the manual assignment. Overall, this analysis validated the use 
of chemical shift prediction as a very efficient strategy to aid in completing the assignment of 
disordered regions in large proteins.  
D.  Discussion 
In summary, we have developed a simple method for the identification and assignment of 
disordered regions in large proteins based on carbon-detected NMR experiments. We have 
demonstrated that this approach allows for identification of disordered residues in the 50 kDa 
menin protein. The assignment of relatively complex spectra can be rapidly achieved through the 
combination of experimental data with chemical shift calculation. Importantly, the NMR 
experiments allowed for highly accurate identification of even relatively short disordered 
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fragments (~10 amino acid long), which are more difficult to predict using bioinformatics 
methods.11  
We applied this method in Chapter 2 to optimize BMI1 ULD constructs for structural 
biology studies. Further, we used this method to map the protein-protein interaction motif of the 
intrinsically disordered protein PHC2 which undergoes disorder-to-order transitions when in 
complex with BMI1. Thus, we demonstrated that the highly sensitive 13C-detected experiments 
are valuable tools to study protein mechanisms.  
The overall approach of this method and its applications is summarized in Figure A.2. 
 
Figure A.2. Applications of 13C-detected NMR approach for rapid characterization of 
disordered regions of proteins. 
 
E.  Materials and Methods: 
Protein purification: The synthetic construct encoding Nematostella menin was ordered from 
Genscript and cloned into the pET32a vector. The truncation after residue 487 led to generation 
of the N_menin∆C which was used for NMR experiments. The 13C,15N labeled N_menin∆C 
protein was expressed by growing bacterial cells in isotopically enriched M9 minimal media. 
The purification was carried out following previously described protocol.24  
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NMR Spectroscopy: For NMR experiments the 13C,15N-labeled N_menin∆C sample was 
prepared at a final concentration of 100 μM in 50 mM Tris buffer, pH 7.5, 150 mM NaCl, 1 mM 
TCEP with 10% D2O. NMR measurements were performed using a Bruker Advance III 600-
MHz spectrometer equipped with 5 mm TCI cryogenic probe. The following parameters were 
used for 13C-detected experiments: 2D CACO26  data size: 64 (t1) x 512 (t2) complex points, t1max 
(13C) = 16 ms, t2max (13C) = 85.2 ms; 2D CBCACO26 data size: 70 (t1) x 512 (t2) complex points, 
t1max (13C) = 7.8 ms, t2max (13C) = 85.2 ms; 2D CANCO27 data size 50 (t1) x 512 (t2) complex 
points, t1max (13C) = 7.4 ms, t2max (13C) = 85.2 ms. All 13C detected experiments were recorded 
with 1H excitation in order to increase the sensitivity and processed with the IPAP scheme for 
decoupling. These experiments were recorded with 1 second relaxation delay and 32, 64, 448 
scans per increment, respectively. This lead to total acquisition times of 2.5, 6 and 31 hours. All 
experiments were collected at 25° C. Spectra were processed with NMRPipe31 and analyzed with 
Sparky.32  
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